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Studying and Improving Lambda Red Recombination for 
 Genome Engineering in Escherichia coli 
 
Abstract 
 
 The phage-derived Lambda Red recombination system utilizes exogenous DNA in order 
to generate precise insertion, deletion, and point mutations in Escherichia coli and other bacteria.  
Due to its convenience, it is a frequently-used tool in genetics and molecular biology, as well as 
in larger-scale genome engineering projects.  However, limited recombination frequency 
constrains the usefulness of Lambda Red for several important applications.  In this work, I 
utilize a mechanism-guided approach in order to improve the power and utility of Lambda Red 
recombination. 
 In Chapter 1, I discuss the capabilities of Lambda Red recombination, and introduce its 
notable past uses, particularly in genome engineering.  I also summarize the current mechanistic 
understanding of Lambda Red, describe several past improvements of the recombination process, 
and discuss our motivation for improving Lambda Red recombination further. 
 In Chapter 2, I advance and support a novel mechanism for the Lambda Red 
recombination of dsDNA, in which Lambda Exonuclease entirely degrades one strand, leaving 
the other strand intact as ssDNA.  This single-stranded intermediate then anneals at the lagging 
strand of the replication fork and is incorporated into the newly synthesized strand.  In Chapter 3, 
I use this mechanistic insight to investigate new methods for improving dsDNA recombination 
frequency, finding that recombination frequency can significantly be enhanced by using 
phosphorothioate bonds to protect the 5ʹ end of the lagging-targeting strand, and by removing the 
endogenous nuclease ExoVII. 
 iv  
 
 Chapters 4 and 5 detail my efforts to improve the multiplex recombination of short 
oligonucleotides.  In collaboration with Marc Lajoie and Christopher Gregg, I find that removing 
a set of five exonucleases results in significantly higher multiplex oligonucleotide recombination 
frequencies, as well as the improved inheritance of mutations carried on the 3′ ends of 
oligonucleotides.  Additionally, multiplex recombination frequencies were further improved by 
modifying DnaG primase so as to increase the amount of accessible ssDNA at the lagging strand 
of the replication fork.   
 Finally, in Chapter 6, I suggest additional ways in which Lambda Red recombination 
may be improved in the future, and discuss a recent project that illustrates how the developments 
described in this thesis have enabled exciting new applications. 
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Chapter One  
 
 
Introduction: Improving Lambda Red Recombination to Create 
a Powerful Tool for Genome Engineering 
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 Synthetic biology – broadly defined by a European Commission expert working group as 
“the engineering of biology: the synthesis of complex, biologically based (or inspired) systems, 
which display functions that do not exist in nature” – has recently emerged as an important and 
rapidly evolving scientific field.
1
  While a detailed review of synthetic biology is well beyond the 
scope of this thesis, recent accomplishments representative of the diversity of the field include 
the engineering of a strain of yeast to produce the antimalarial drug precursor artemisinic acid,
2
 
the use of DNA origami
3-5
 to generate a “nanorobot” capable of selectively delivering a 
molecular payload (e.g., an antibody) to specific cell types,
6
 the de novo design of enzymes with 
novel catalytic activities,
7-9
 and the engineering of programmed genetic circuits within 
bacterial
10,11
 and mammalian
11,12
 cells.  
 While synthetic biology has benefited from advancements in a number of different 
technologies and capabilities – such as DNA sequencing, computational modeling, and a variety 
of analytical techniques – the development of the field is perhaps most directly a result of 
breakthroughs in DNA synthesis and editing.  Specifically, advancements in the ability to 
“write” DNA have enabled the emergence of genome engineering as an important subfield of 
synthetic biology.  Indeed, the past three years have seen two particularly notable 
accomplishments in bacterial genome engineering.  First, in 2010, scientists from the J. Craig 
Venter Institute reported the creation of a self-replicating bacterial cell with an entirely synthetic 
genome, generated by transplantation of an in vitro synthesized Mycoplasma mycoides genome 
into a Mycoplasma capricolum cell.
13
  This achievement built upon a large body of prior 
methodology development,
14-20
 and stands as the crowning achievement of de novo genome 
synthesis and transplantation reported to date. 
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 A second major achievement in bacterial genome engineering was recently reported by 
George Church and colleagues.  In this work, our group generated a strain of Escherichia coli in 
which all instances of the UAG stop codon were changed to the UAA stop codon, and the 
function of the UAG codon was subsequently reassigned.
21,22
  This strain demonstrated steps 
toward genetic isolation and virus resistance, and enabled the dedicated use of the UAG codon 
for the incorporation of non-standard amino acids.
22
  Rather than generating this strain by de 
novo genome synthesis as above, we utilized an approach in which we started with a wild type E. 
coli bacterium and edited its genome in vivo until it had the desired sequence. 
 While these two projects both leveraged recent advancements in DNA writing to achieve 
impressive ends, they embody two starkly different approaches to synthetic biology and genome 
engineering.  In Venter’s work, a genome was designed de novo, synthesized with the desired 
sequence, and then transplanted into a suitable recipient cell.
13
  While this approach has 
considerable promise and will likely enable powerful applications in the future, it comes with 
several drawbacks.  For one, synthesizing entire genomes remains a substantial technical 
challenge.  The M. mycoides genome synthesized at the Venter Institute has a size of 1.08 
million base pairs (1.08 Mb), and represented the culmination of many years of intense labor and 
methodology development.  However, this genome is considerably smaller than those of E. coli 
(4.64 Mb)
23
 and most other bacterial species commonly used for research and biotechnological 
applications.  Synthesizing a larger bacterial genome such as that of E. coli appears to be beyond 
current capabilities, and will likely require additional technological development.   
 A second drawback to this approach is its requirement for designing and synthesizing a 
viable genome sequence de novo.  Because the genome must be synthesized in its entirety prior 
to transplantation, any errors or changes that result in a non-viable genome are not likely to be 
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discovered until the final transplantation step.  Indeed, a 1 bp deletion in essential gene dnaA 
resulted in the initial inability to generate a viable transplanted M. mycoides genome, as “one 
wrong base out of more than 1 million in an essential gene rendered the genome inactive.”
13
  
Thus, copying a genome with perfect fidelity (or generating a genome with only non-functional 
“watermark” changes, as in the described work
13
) remains a significant technical challenge.  
However, a far greater challenge arises if one is trying to synthesize a genome with functional 
alterations, as in our work reassigning the UAG codon.
21,22
  Because de novo genome synthesis 
does not provide for a straightforward way to troubleshoot non-viable genomes, this method 
therefore necessitates designing a viable genome a priori.  Given that even minor genetic 
changes can have significant and unpredictable effects,
24
 this constitutes a significant challenge, 
and limits the degree to which de novo genome synthesis can be used for ambitious genome 
engineering projects. 
 Rather than synthesizing genomes de novo, our group is pioneering methods for editing 
existing genomes in vivo to generate desired sequences and functions.  This approach has several 
advantages.  For one, it circumvents the need to undertake a laborious and expensive whole 
genome synthesis project in order to make a limited number of changes to a genome.  
Additionally, because our approach involves making genetic changes in vivo, it provides a 
straightforward means of identifying and troubleshooting lethal or deleterious design elements.  
Changes that result in a non-viable genotype will fail to be generated in vivo, and can therefore 
be identified and redesigned.  Similarly, otherwise serious deleterious changes will have an 
immediately detectable phenotype, and can be altered or reverted if necessary.  Furthermore, this 
approach has the additional advantage of enabling the simultaneous testing of multiple different 
genome designs.  Because our designed genetic changes are encoded as discrete units, they can 
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be generated combinatorially, thereby allowing billions of genome designs to be created at 
once.
25
  Desired clones can subsequently be isolated by screening or selection; this approach 
therefore also enables the use of directed evolution to generate and identify genomes which 
confer a targeted phenotype.  Thus, editing genomes in vivo is a powerful, versatile, and practical 
alternative to de novo genome synthesis.  As such, it is likely to be a cornerstone strategy for 
future efforts in synthetic biology and genome engineering. 
 Our in vivo genome engineering approach was enabled by the development and 
advancement of Lambda Red recombination (“recombineering”).  This recombination system 
utilizes components derived from the Lambda phage in order to carry out efficient genetic 
modification in Escherichia coli
26
 and a variety of other bacteria.
27-32
  The Lambda Red 
recombination system is RecA-independent,
26
 and can precisely recombine exogenous 
oligonucleotides
33
 or double-stranded DNA (dsDNA) cassettes
26
 at genomic loci specified by 
flanking homology regions of as little as 35 bp.
34
  Lambda Red recombination can be used to 
create insertion, deletion, and mismatch mutations.
25
  To generate an insertion or mismatch 
mutation, a heterologous or mismatched sequence is placed in between the two homology 
regions of the recombinogenic DNA; in contrast, a deletion can be generated by using a 
recombineering oligonucleotide or cassette with homology regions that flank the sequence to be 
deleted.
25
  A combination of these approaches can be used to simultaneously delete a genomic 
region and replace it with a heterologous sequence (e.g., a selectable marker).
35
 
 Three phage-derived proteins – Gam, Exo, and Beta – are required in order to mediate the 
efficient Lambda Red recombination of exogenous dsDNA cassettes.  The first protein, Gam, 
prevents the degradation of linear dsDNA by the endogenous nucleases RecBCD and SbcCD.
36
  
Exo then degrades the recombinogenic dsDNA in a 5′ to 3′ manner, leaving single-stranded 
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DNA (ssDNA) in the recessed regions.  Finally, Beta binds to the single-stranded regions 
produced by Exo, and facilitates recombination by promoting annealing to the homologous 
genomic target sites.
37,38
  For the Red-mediated recombination of exogenous ssDNA 
oligonucleotides, only the Beta protein is required, and it is well-accepted that Beta mediates the 
annealing of the recombinogenic oligonucleotide to its homology targets on the lagging strand of 
the replication fork.
33,37
  Once annealed at the replication fork, the oligo is subsequently 
incorporated into the newly synthesized strand as an Okazaki Fragment.
37
  In contrast, the 
precise mechanism by which Lambda Red recombines dsDNA was largely uncharacterized prior 
to the work described in this thesis; this topic is covered in detail in Chapter 2. 
 In addition to its more recent uses in large-scale genome engineering projects, Lambda 
Red recombineering has been a broadly used tool in genetics and molecular biology since its 
development about 15 years ago.
39,40
  Lambda Red recombination is frequently used to make 
precise genetic changes on a number of different targets, such as bacterial chromosomes,
33,41,42
 
plasmids,
43
 phages,
44
 and BACs,
45,46
 including those used for downstream applications in 
eukaryotes.
47,48
  Both ssDNA oligonucleotides
33
 and dsDNA cassettes
26
 are commonly used for 
recombineering, and both strategies have been used for a broad array of powerful applications.  
Recombineering with dsDNA is frequently used to insert exogenous genes onto a recombination 
target; this is facilitated by the fact that insertion cassettes can easily be generated by PCR.  
Homology regions can be encoded on the 5′ end of PCR primers, and subsequent use of such 
primers for amplification of the desired insertion sequence will yield a dsDNA cassette ready for 
Lambda Red recombineering.  Thus, this strategy is commonly applied to insert heterologous 
genes
42
 and pathways
49
 onto the E. coli chromosome for use in metabolic engineering and other 
efforts.  A similar dsDNA recombineering strategy is also frequently used to replace endogenous 
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genes with selectable markers, thereby facilitating the one-step generation of knockout 
mutants.
35
  Beyond its use as a standard molecular biology technique, this one-step knockout 
method has also been employed in larger-scale projects such as the creation of a complete library 
of single-gene knockout E. coli strains,
50
 as well as a strain of E. coli with 15% of its genome 
removed.
51
  Additionally, dsDNA recombineering has been applied as a cloning tool, facilitating 
the incorporation of large regions of BAC or chromosomal DNA onto plasmids,
45,52
 as well as 
the development of entirely new cloning strategies.
53
    
 Similar to dsDNA recombineering, Lambda Red recombination with ssDNA has also 
found a variety of applications.  Like dsDNA recombineering, ssDNA recombineering has been 
used to make precise genetic changes on a number of different targets, including the 
chromosomes of E. coli
33,54
 and other bacteria,
54,55
 as well as plasmids,
43
 BACs,
56,57
 and 
phages.
44,58
  Moreover, the power and versatility of ssDNA recombineering has recently been 
bolstered by the discovery that Lambda Red is capable of simultaneously recombining multiple 
oligonucleotides at once.
25
  This technique – called Multiplex Automatable Genome Engineering 
(“MAGE”), due to its ability to be automated and applied in iterative cycles – can be used for 
both generating genetic diversity and creating a single strain with a desired genotype.  For the 
first category of applications, a pool of several oligonucleotides is introduced into cells in one or 
multiple cycles; different cells recombine different combinations of oligos, thereby giving rise to 
a highly diverse population.  The resulting population of cells can then be selected or screened 
for a desired property.  This technique has been applied to rapidly optimize the pathway coding 
for the biosynthesis of the small molecule lycopene,
25
 and to improve the production of indigo by 
combinatorially modifying promoters in the aromatic amino acid biosynthesis pathway.
59
  
Alternatively, similar methodology can be used to generate a single strain with a desired 
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genotype.  In this case, cycling can be continued until an isogenic fully converted population is 
attained; more practically, the desired strain can also be identified by screening after the 
appropriate number of recombination cycles.  This strategy was used to generate the UAG-
recoded E. coli strain described above,
21,22
 and to create strains of E. coli with multiple 
components of the protein translation machinery His-tagged for convenient co-purification.
60
  
 The broad utility of Lambda Red recombineering – particularly the ability to use MAGE 
for genome engineering, as described above – is largely a result of a great deal of work that has 
gone into improving the process.  While the RecA-independent recombination capabilities of the 
Lambda phage have been known for almost 50 years,
61,62
 it was not until 1998 that the Lambda 
Red proteins (and the similar phage-derived RecET system) were utilized for targeted bacterial 
genetic engineering.
39,40
  The potential usefulness of these phage-derived recombination systems 
was quickly recognized, initiating effort to improve their power, versatility, and convenience.  In 
2000, researchers from Donald Court’s group isolated a portion of the Lambda genome 
containing the Lambda Red genes.  They then placed this Lambda fragment on the E. coli 
chromosome, under the control of the temperature-inducible cI857 repressor.
26
  This system – 
also used in the work described in this thesis – allows for the heat-controlled induction of the 
Lambda Red proteins, and prevents toxicity due to undesired expression of Lambda genes kil
63
 
and gam.
26
  The researchers also optimized several parameters – including induction time, 
dsDNA concentration, and flanking homology lengths – in order to maximize dsDNA 
recombination frequency.
26
  However, given that most dsDNA recombineering applications have 
involved the use of selectable markers, recombination frequency was generally not considered to 
be of critical importance.  Thus, little additional work was done to improve the performance of 
dsDNA recombineering. 
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 In contrast to the work with dsDNA recombineering, several discoveries have resulted in 
significant improvement of the recombination frequency of ssDNA oligonucleotides.  Initial 
work by the Court group achieved a rough optimization of oligo length, and provided anecdotal 
evidence that mutations encoded near the ends of an oligonucleotide are inherited less frequently 
than those encoded nearer to the center – a result that has been confirmed in subsequent 
studies.
33,64,65
   However, most of the recombineering oligonucleotides tested in this study 
demonstrated low recombination frequencies – typically well under 1%.
33
  Oligo recombination 
frequency was subsequently improved by way of a number of different strategies. 
First, it was observed that recombineering oligos that anneal at the lagging strand of the 
replication fork have significantly higher recombination frequencies than their leading-targeting 
counterparts.
66
  This reinforces the ssDNA recombination model involving annealing at the 
lagging strand and subsequent incorporation as an Okazaki fragment;
37
 moreover, targeting the 
lagging strand represents a simple and predictable way to ensure improved recombination 
frequencies.  It was also observed that the magnitude of this lagging strand bias was quite 
variable.
66
  Subsequent experiments showed that this was largely due to differences in the ability 
of mismatch repair proteins to recognize and revert the respective mismatches conferred by the 
lagging- and leading-targeting oligos.
41,66
  By removing the cell’s ability to carry out mismatch 
repair entirely (e.g., by knocking out mutS), recombination frequencies can reliably be 
improved.
41
  If wholesale removal of the mismatch repair system is contraindicated – for 
example, in genome engineering applications where off-target mutations are highly undesired – 
recombination frequency can alternatively be improved by evading mismatch repair through the 
use of C-C mismatches,
41
 stretches of six or more mismatched bases,
67
 or chemically modified 
10 
 
oligo bases such as 2′-fluorouridine, 5-methyldeoxycytidine, 2,6-diaminopurine, and iso-
deoxyguanosine.
64
 
 Subsequent work from the Church lab has achieved further improvement of single-
stranded oligonucleotide recombineering.  First, an optimization of oligo concentration found 
that singleplex recombination frequency is maximal at roughly 1 µM, and a more rigorous 
optimization of oligonucleotide length determined that 90 bp oligos – rather than the 70 bp 
oligos previously used by the Court group – yield the highest recombination frequencies.
25
  
Additionally, it was discovered that recombination frequency can further be improved by 
protecting oligos from nuclease degradation through the use of phosphorothioate bonds, 
particularly on the 5′ end of oligonucleotides.
25
  A correlation was also observed between 
internal oligonucleotide secondary structure and recombination frequency.  Secondary structure 
of ∆G < -12.5 kcal/mol was found to be markedly detrimental to recombination frequency, 
presumably as a result of intramolecular interactions interfering with the ability of an oligo to 
anneal to its recombination target.
25
  Finally, our group found that oligos with a high degree of 
off-target genomic homology typically have depressed recombination frequencies.
21
  Thus, by 
minimizing internal secondary structure and off-target genomic homology, recombination 
frequency can be augmented further.  Through the combined use of these strategies, we are 
routinely able to attain singleplex oligo recombination frequencies of around 30%
25
 – a stark 
improvement from the initial reported frequency of 0.2% obtained by the Court group.
33
   
 These enhanced singleplex recombination frequencies paved the way for the development 
of MAGE.  Our group’s discovery that Lambda Red is capable of simultaneously recombining 
multiple oligonucleotides would not have had practical implications if singleplex recombination 
frequencies had remained below 1%, as very few cells would be expected to recombine more 
11 
 
than one oligo.  However, given singleplex recombination frequencies of about 30%, 
recombination with a pool of multiple oligonucleotides should result in a population of cells with 
a broad distribution of mutations.  The frequency of desired mutations can further be increased 
by performing iterative cycles of recombination – i.e., Lambda Red induction, cell washing, 
introduction of oligos by electroporation, and subsequent cell regrowth.
25
  Nevertheless, even a 
single cycle of MAGE facilitates significant recombination; for a cycle of MAGE using ten 
oligonucleotides, we found that cells recombined an average of 0.4 oligos, and that several 
clones recombined as many as 5 of the 10 oligonucleotides.
68
  
 Further improvement of MAGE was enabled by the recent discovery that multiplex 
recombination frequencies can be enhanced by directing an oligo to repair a defective selectable 
marker near the loci targeted by the other recombineering oligonucleotides.
69
  Subsequent 
selection for the repaired marker results in roughly fourfold higher recombination frequencies at 
the other targeted loci, due to enrichment for cells with high levels of recombination in the 
vicinity of the selectable marker.
69
  This technique, called co-selection MAGE (CoS-MAGE), 
substantially improves the power of MAGE, yielding an average of 1.4 non-selectable oligos 
recombined per cycle with the 10-plex sets described above.
68
   
 This improvement of Lambda Red recombination stands as a significant achievement in 
technology development, and enabled the varied recombineering applications described above.  
However, even with these enhancements, the power of recombineering still has some significant 
limitations.  For one, the recombination frequency for the insertion of gene-sized (i.e., ~1 kb) 
dsDNA fragments remains quite low – on the order of 10
-4
 recombinants per viable cell.
26,70
  As 
a result, selectable markers must be used to identify these rare insertion events.  This requires 
Red-mediated gene insertions to be performed serially, precluding their convenient use in large-
12 
 
scale genome engineering.  Improving the recombination frequency of gene insertion would 
enable a variety of powerful new applications.  For one, this would greatly simplify pathway 
transfer, and would allow for the seamless introduction of genes without needing to insert and 
then remove selectable markers.  Perhaps more importantly, this would also provide for the 
multiplex insertion of genes, enabling the combinatorial introduction of a panel of exogenous 
genes thought to be involved in facilitating a property of interest (e.g., heat resistance).  The 
resulting population of strains could then be screened or selected for that property.  Finally, 
improved gene insertion technology could be used to introduce hundreds of heterologous genes 
of interest (e.g., genes coding for biosynthetic enzymes) into a single strain.  Such a strain would 
serve as a versatile vessel for bioproduction, with genes being turned on or off by MAGE as 
needed to produce a desired compound.  
 Similarly, augmenting the power of MAGE and CoS-MAGE would also be highly 
beneficial.  Despite the considerable strides made in improving these techniques – as well as the 
impressive applications that they have already enabled – some substantial limitations remain.  
Even with CoS-MAGE, the average cell recombines just slightly more than 1 non-selectable 
oligo per cycle, and relatively few cells recombine more than four oligos out of ten.
68
  This 
constrains the degree of diversity that can be attained, as well as the extent to which a genome 
can feasibly be reengineered.  As an example, the reassignment of all 321 instances of the UAG 
stop codon was a laborious task, and required over ten scientist-years of work.
22
  Additional 
codons must also be reassigned in order to create an organism with a truly orthogonal genetic 
code;
22
 this would require tens of thousands of targeted mutations genome-wide,
24
 well outside 
of the reach of our current Red-mediated genome engineering capabilities.  Improving the 
average and top number of mutations generated per cycle will make such ambitious recoding 
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efforts more feasible, and will broadly enhance the power of MAGE for a number of additional 
applications in diversity generation and genome engineering. 
 In this thesis, I describe the studies that my collaborators and I have performed in order to 
improve Lambda Red dsDNA and ssDNA recombination in E. coli.  For this work, we used a 
mechanism-guided approach in which we first conducted experiments to better understand the 
recombineering process and the factors that constrain its efficiency.  We then used these 
mechanistic insights to suggest and test means for improving recombination frequency.  Thus, 
this work enabled both the improved understanding of Lambda Red recombination, as well as the 
significant enhancement of its performance. 
 In Chapter 2, I discuss our efforts to determine the mechanism by which Lambda Red 
recombines dsDNA.  In contrast to previously proposed mechanisms, we advance a model in 
which Lambda Exo entirely degrades one strand, leaving the other strand intact as ssDNA.  This 
single-stranded intermediate then recombines via Beta-catalyzed annealing at the replication 
fork.  We support this mechanism by showing that single-stranded insertion cassettes are highly 
recombinogenic, and that these cassettes preferentially target the lagging strand.  In contrast, we 
find that the recombination intermediate suggested by previously proposed mechanisms is 
minimally recombinogenic.  Finally, we demonstrate that the recombination of a dsDNA cassette 
containing multiple internal mismatches results in strand-specific mutations cosegregating 
roughly 80% of the time – a result much more consistent with our model than with previous 
models.  Elucidating the mechanism for dsDNA recombination enabled our subsequent work to 
improve the process, discussed in Chapter 3.   
 In Chapter 3, we first examine the effect of phosphorothioate (PT) bonds on the 
recombination frequency of dsDNA cassettes.  We show that using PT bonds to protect the 5ʹ 
14 
 
end of the lagging-targeting strand results in a significant improvement of recombination 
frequency.  In contrast, PT bonds on the leading-targeting strand diminish recombination 
frequency, presumably by preventing Lambda Exo from degrading that strand to generate the 
lagging-targeting intermediate.  We also observed that dsDNA with PT bonds on both 5ʹ ends is 
markedly recombinogenic, despite PT bonds blocking the action of Lambda Exo.  This 
surprising result led us to discover that the exonuclease ExoVII readily degrades these 5ʹ PT 
bonds, thereby enabling Lambda Exo to generate the ssDNA recombination intermediate.  We 
subsequently show that ExoVII also degrades non-phosphorothioated cassette ends, and that its 
removal results in significantly better dsDNA recombination frequency and inheritance of 
mutations near the ends of a cassette.  Thus, this work further supports our mechanism for 
dsDNA recombination, and demonstrates the impact that endogenous nucleases can have on this 
process.  Additionally, by removing ExoVII and protecting the lagging-targeting strand with PT 
bonds, we establish two straightforward means of improving dsDNA recombination frequency. 
 In Chapter 4, we study the impact of endogenous nucleases on CoS-MAGE performance.  
We show that ExoVII also acts on ssDNA oligonucleotides, and that its removal improves CoS-
MAGE frequencies and the inheritance of mutations encoded near the 3′ ends of oligos.  We go 
on to show that removing a set of five exonucleases (RecJ, ExoI, ExoVII, ExoX, and Lambda 
Exo) further improves the performance of CoS-MAGE.  In comparison with our standard 
recombineering strain EcNR2 (Escherichia coli MG1655 ∆mutS::cat ∆(ybhB-bioAB)::[λcI857 
∆(cro-ea59)::tetR-bla]), the resulting “nuc5
-
” strain demonstrates 46% more alleles converted 
per average clone, 200% more clones with five or more allele conversions, and 35% fewer 
clones without any allele conversions in a given 10-plex cycle of CoS-MAGE.  Finally, we use 
these nuclease knockout strains to investigate and clarify the effects of oligonucleotide 
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phosphorothioation on recombination frequency.  We show that PT bonds can be detrimental as 
well as beneficial, and that the net effect depends on the nuclease background of the 
recombineering strain.   
 In Chapter 5, we further improve the performance of CoS-MAGE, this time by 
manipulating the E. coli replisome.  We find that certain mutations in DnaG primase increase the 
amount of accessible ssDNA at the lagging strand of the replication fork, and that this 
significantly improves multiplex oligonucleotide recombination frequency.  Moreover, we show 
that primase modification and nuclease removal have additive beneficial effects on CoS-MAGE.  
By combining these two strategies, we generated a strain that demonstrates 111% more alleles 
converted per cycle, 527% more clones with five or more allele conversions, and 71% fewer 
clones with zero allele conversions, in comparison with EcNR2.  This indicates that the number 
of oligonucleotides within the cell and the amount of accessible ssDNA at the lagging strand are 
both limiting factors for Lambda Red recombination. Thus, this work provides further insight 
into multiplex oligonucleotide recombination, and yields a breakthrough improvement in CoS-
MAGE performance. 
 Finally, in Chapter 6, I take stock of the current state of Lambda Red recombination 
technology, and suggest additional ways by which recombineering performance may be 
improved in the future.  I conclude by briefly describing a recent project from the Church lab.  In 
this work, we utilized dsDNA recombineering and CoS-MAGE to demonstrate that many 
essential genes are amenable to radical codon changes, and that at least 13 codons are likely 
dispensable across the E. coli genome.
24
  Hence, in addition to markedly advancing our 
understanding of Lambda Red recombination and improving its performance, this thesis work 
has also enabled compelling new applications.  
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Chapter Two  
 
 
Lambda Red Recombination of Double-Stranded DNA  
Proceeds through a Fully Single-Stranded Intermediate 
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Introduction 
 As discussed in Chapter 1, the Lambda Red recombination system has emerged as a 
powerful and prevalently used tool in genetics and molecular biology.  Double-stranded DNA 
(dsDNA) recombination in particular has been applied toward a number of different ends, 
including replacing chromosomal genes,
1-4
 developing novel cloning methods,
5,6
 and inserting 
heterologous genes and pathways into the E. coli chromosome,
3,7
 plasmids,
8
 and BACs.
5,9
  
Additionally, larger-scale dsDNA recombineering projects have included creating a complete 
library of single-gene knockout E. coli strains,
10
 and generating an E. coli strain in which 15% of 
its original genomic material was removed.
11
  However, despite its widespread use over the past 
15 years, the mechanism of Lambda Red dsDNA recombination has remained a significant 
unanswered question.  By elucidating this mechanism, we hope to identify ways to improve the 
functionality, ease, and versatility of Lambda Red dsDNA recombineering. 
 As noted previously, it is well-established that three Lambda Red proteins are necessary 
for carrying out efficient dsDNA recombination: Gam, Exo, and Beta.
2,12
  Gam prevents the 
degradation of linear dsDNA by the E. coli RecBCD and SbcCD nucleases; Lambda 
Exonuclease (Exo) degrades the dsDNA in a 5′ to 3′ manner, leaving single-stranded DNA in the 
recessed regions; and Beta binds to the single-stranded regions produced by Exo, facilitating 
recombination by promoting annealing to the homologous genomic target sites.
13
  Two 
mechanisms proposed prior to this work each claimed that Exo binds to both 5′ ends of a dsDNA 
cassette, degrading in both directions simultaneously to produce a double-stranded region 
flanked on both sides by 3′ overhangs.
14,15
  However, neither mechanism provided a 
comprehensive and convincing explanation of how this construct ultimately recombines with the 
chromosome.  
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Figure 2.1: The Court Model for Lambda Red 
dsDNA Recombination. The Court mechanism posits 
that 1) Beta facilitates annealing of one 3′ overhang to 
the lagging strand of the replication fork.  2) This 
replication fork then stalls and backtracks so that the 
leading strand can template switch onto the synthetic 
dsDNA.  The heterologous dsDNA blocks further 
replication from this fork.  3) Once the second 
replication fork reaches the stalled fork, the other 3′ end 
of the integration cassette is annealed to the lagging 
strand in the same manner as prior.  Finally, the 
crossover junctions must be resolved by unspecified E. 
coli enzymes.  For all diagrams in this chapter, 
heterologous dsDNA is shown in green; homology 
regions are shown in black; Exo is an orange oval, and 
Beta is a yellow oval.  Figure adapted from Ref. 14. 
Initially, it was proposed that Red-
mediated recombination occurred via strand 
invasion.
16
  However, it has more recently been 
shown that Lambda Red dsDNA recombination 
remains highly proficient in a recA
-
 
background.
17
  Thus, in the absence of the long 
regions of homology required for RecA-
mediated recombination, strand invasion is 
unlikely to be a primary mechanism.  
Furthermore, a detailed analysis of Lambda Red 
recombination products showed characteristics 
consistent with strand annealing rather than 
strand invasion.
18
  Finally, Lambda Red dsDNA 
recombination has been shown to preferentially 
target the lagging strand during DNA 
replication, which suggests strand annealing 
rather than strand invasion.
15,19
  
To explain these results, Court et al. 
proposed a strand annealing model for 
insertional dsDNA recombination (Figure 
2.1),
14
 in which one single-stranded 3′ end 
anneals to its homologous target at the 
replication fork.  The replication fork then stalls due to the presence of a large dsDNA non-
25 
 
Figure 2.2: The Poteete Model for Lambda Red 
dsDNA Recombination. The Poteete mechanism 
suggests that 1) Beta facilitates 3′ overhang 
annealing to the lagging strand of the replication 
fork, and 2) positions the invading strand to serve as 
the new template for leading strand synthesis.  This 
structure is resolved by an unspecified host 
endonuclease (red triangle), and 3) the synthetic 
dsDNA becomes template for both lagging and 
leading strand synthesis.  A second template switch 
must then occur at the other end of the synthetic 
dsDNA in the same manner as prior.  Finally, the 
crossover junctions must be resolved by unspecified 
E. coli enzymes.  Figure adapted from Ref. 15. 
homology (i.e., the insertion cassette).  The stalled 
replication fork is ultimately rescued by the second 
replication fork, traveling in the opposite direction 
around the circular bacterial chromosome.  The 
other 3′ end of the recombinogenic DNA anneals to 
the homology region exposed by the second 
replication fork, forming a crossover structure, 
which is then resolved by unspecified E. coli 
enzymes.
14
 
 The Court mechanism was challenged by 
Poteete,
15
 who showed that a dsDNA Lambda 
phage chromosome readily recombines onto a 
unidirectionally-replicating plasmid.  Because such 
a plasmid lacks the second replication fork required 
by the Court mechanism, this result casts serious 
doubt on the Court model.
14
  Thus, Poteete 
proposed an alternate mechanism
15
 termed 
“replisome invasion” (Figure 2.2), in which a 3′ 
overhang of the Exo-processed dsDNA first anneals 
to its complementary sequence on the lagging 
strand of the replication fork.  Subsequently, this 
overhang displaces the leading strand, thereby 
serving as the new template for leading strand 
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synthesis.  The resulting structure is resolved by an unspecified endonuclease, after which the 
recombinogenic DNA becomes the template for the synthesis of both new strands.  In the context 
of recombineering using a linear dsDNA cassette, a second strand switching event must then 
occur at the other end of the incoming recombinogenic dsDNA. 
While Poteete's mechanism addresses some of the weaknesses of the Court mechanism, it 
is itself largely speculative.  This mechanism does not identify the endonuclease responsible for 
resolving the structure after the first template switching event, nor does it explain how the 
recombinogenic DNA and replication machinery form a new replication fork.  Additionally, the 
replisome would need to be transferred both on and off the incoming recombinogenic dsDNA in 
a well-coordinated manner, “like a train switching tracks.”
20
  This may not be consistent with the 
relatively high recombination frequencies often observed for Lambda Red-mediated dsDNA 
insertion.
2
  Finally, no direct experimental evidence has been advanced to support this model. 
To address the deficiencies in the Court and Poteete models, we propose an alternative 
model in which Lambda Red dsDNA recombination proceeds via a fully single-stranded 
intermediate, in contrast with the dual-overhang intermediate proposed by Court and Poteete.  
According to our mechanism, Exo binds to one 5′ end of the recombinogenic dsDNA cassette, 
and degrades that strand completely, leaving behind full-length ssDNA.  This ssDNA then 
anneals to its homology targets at the lagging strand of the replication fork, and is incorporated 
into the newly-synthesized strand as an Okazaki fragment (Figure 2.3).  This process is 
analogous to the accepted mechanism for the Lambda Red recombination of ssDNA 
oligonucleotides,
14
 and therefore unifies the mechanisms for ssDNA and dsDNA recombination.  
Notably, our mechanism also does not depend on the presence of multiple replication forks, 
thereby addressing Poteete’s criticism of the Court mechanism. 
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Figure 2.3: Our Model for Lambda Red dsDNA 
Recombination.  Instead of a recombination intermediate 
involving dsDNA flanked by 3′ ssDNA overhangs, we 
propose that one strand of linear dsDNA is entirely 
degraded by Exo.  Beta then facilitates the annealing of the 
remaining strand to the lagging strand of the replication 
fork, with subsequent incorporation as an Okazaki 
fragment.  The heterologous region does not anneal to the 
genomic sequence.  This mechanism could account for 
gene replacement (as shown), or for insertions in which no 
genomic DNA is removed. 
While it has not been previously 
suggested in this context, the degradation of 
an entire strand by Exo is feasible given the 
highly processive nature of the enzyme.
21
  
Whereas previously proposed mechanisms 
assume that both dsDNA ends are degraded 
approximately simultaneously, our 
hypothesis implies that some dsDNA 
molecules will be entirely converted to 
ssDNA before a second Exo enzyme can 
bind to the other end.  To support this 
mechanism, we demonstrate that single-
stranded DNA is a highly recombinogenic 
intermediate and has a lagging strand bias.   
In contrast, we show that the intermediate 
suggested by the previously proposed 
mechanisms is minimally recombinogenic.  
Finally, we show that alleles carried on the 
ends of a given strand of dsDNA co-
segregate during Lambda Red recombination.  These results provide strong support of our 
proposed mechanism. 
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Testing Predicted Recombination Intermediates 
To test our mechanistic hypothesis, we first designed a lacZ::kanR cassette (~1.2 kb), 
consisting of a kanamycin resistance gene (kanR) flanked by 45 bp regions homologous to the 
lacZ gene on the E. coli chromosome.  Successful Red-mediated recombination of the cassette at 
the lacZ chromosomal locus disrupts LacZ function, so proper targeting of the lacZ::kanR 
cassette could be verified by selecting on kanamycin and assaying for the inability to cleave X-
Gal and release a blue chromophore (i.e., white colonies on X-Gal/IPTG).  The lacZ::kanR 
dsDNA construct was generated by PCR and converted into lagging-targeting ssDNA using a 
biotin capture and DNA melting protocol.
22
  PAGE analysis confirmed the purity of the 
lacZ::kanR ssDNA construct, as no dsDNA band was observed.  This construct was then 
recombined into the standard Church lab E. coli strain used for Lambda Red recombineering, 
EcNR2 (Escherichia coli MG1655 ∆mutS::cat ∆(ybhB-bioAB)::[λcI857 ∆(cro-ea59)::tetR-bla]; 
see Appendix 1 for a list and description of strains used in this thesis).
23
  The lacZ::kanR ssDNA 
construct was found to yield 1.3 × 10
-5
 ± 4.5 × 10
-6
 recombinants per viable cell, in comparison 
with 1.9 × 10
-4
 ± 7.5 × 10
-5
 for the corresponding dsDNA construct.  Among the kanamycin 
resistant colonies, both ssDNA and dsDNA constructs gave over 99% white colonies, indicating 
correct targeting of the recombinogenic cassette. 
 This result demonstrates that a long ssDNA insertion cassette – the predicted intermediate 
for our mechanism – is considerably recombinogenic.  It is, however, 14.8-fold less 
recombinogenic than the corresponding dsDNA.  We hypothesize that this disparity is caused by 
ssDNA secondary structure, nuclease degradation of ssDNA, and/or the lack of Exo-Beta 
synergy.  Previous work has demonstrated that ssDNA oligonucleotides longer than 90 bases 
and/or having secondary structure with ∆G < -12 kcal/mol are likely to have substantially 
29 
 
reduced recombination frequency.
23
  Given the length of the ~1.2 kb ssDNA cassette used in this 
experiment, we expect it to have significant secondary structure, and therefore, depressed 
recombination frequency.  Secondly, it has been shown that several E. coli exonucleases readily 
degrade exogenous ssDNA, thereby compromising recombination frequency.
24,25
  Although our 
mechanism indicates that a dsDNA cassette must ultimately be processed into ssDNA, it is 
possible that this process occurs in a manner that mitigates the effects of secondary structure 
and/or nuclease degradation of the ssDNA intermediate.  For instance, dsDNA may be converted 
to ssDNA shortly before recombination occurs, or this process may be coordinated with the 
binding of proteins that protect ssDNA and/or reduce internal secondary structure.  Finally, it has 
previously been suggested
26
 that Exo and Beta act synergistically, with Exo facilitating the 
binding of Beta to recessed regions of ssDNA.  Since Exo does not bind to ssDNA, this 
synergistic action cannot occur on an exogenous ssDNA intermediate; therefore, recombination 
frequency may decrease in comparison with dsDNA.  However, even in light of these 
considerations, it is clear that our predicted ssDNA intermediate is highly capable of 
recombination. 
 In order to confirm that the observed recombinants arose from lacZ::kanR ssDNA rather 
than from dsDNA contamination, this recombination experiment was repeated in SIMD90,
26
 a 
strain of E. coli that expresses Beta, but lacks Exo and Gam.  In the absence of Exo and Gam, 
dsDNA recombination frequency should decline significantly due to increased dsDNA 
degradation and inefficient processing into ssDNA.  Indeed, lacZ::kanR dsDNA demonstrated a 
recombination frequency of only 8.7 x 10
-7
 in this strain, in comparison with a recombination 
frequency of 1.8 x 10
-4
 for the ssDNA (a 209-fold difference).  This confirms that ssDNA – and 
30 
 
Figure 2.4: Testing the Proposed Overhang Intermediate for Lambda Red dsDNA Recombination.  The 
overhang intermediate (OI) suggested by previous Lambda Red recombination mechanisms was generated by 
annealing together two ssDNA strands to give a dsDNA kanR insert, flanked on both sides by 45 bp 3′ ssDNA 
lacZ homology overhangs.  This construct was recombined into EcNR2 and found to have far lower recombination 
frequency than both the corresponding dsDNA as well as the full-length ssDNA intermediate suggested by our 
proposed mechanism.  Co-electroporation of the overhang intermediate with oligonucleotides designed to anneal 
to its ssDNA homology regions (as shown in Figure 2.5) increased recombination frequency, indicating that 
extension of the overhang intermediate can readily occur within the cell.  Thus, the recombinants observed for the 
overhang intermediate may arise due to the generation of one or both full-length strands via random priming and 
extension, followed by downstream recombination according to our proposed mechanism.  Three independent 
replicates were performed for each sample, and error bars are given as the standard error of the mean.  
not contaminating dsDNA within the ssDNA sample – gives rise to recombinants in SIMD90.  
Therefore, the observed recombinants in EcNR2 almost certainly also arose from ssDNA. 
 After the publication of the rest of the work described in this chapter,
27
 we also 
performed experiments to test the dual-overhang intermediate suggested in the models proposed 
by Court and Poteete.
14,15
  This predicted intermediate was constructed by generating 
complementary individual strands of ssDNA in the same manner as above, then annealing the 
two strands together.  We recombined this construct into EcNR2, side-by-side with the 
corresponding lacZ::kanR dsDNA and ssDNA.  Results are shown in Figure 2.4.   
 
We found that the overhang construct had 2340-fold lower recombination frequency than 
the corresponding dsDNA cassette, and 177-fold lower frequency than our predicted ssDNA 
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Figure 2.5: Co-electroporation of the Proposed Overhang 
Intermediate with Annealing Oligonucleotides.  The overhang 
intermediate (OI) suggested by previous mechanisms was co-
electroporated with either long (45 bp) oligonucleotides designed to 
anneal along the entire length of the homology overhang regions, or 
with short (20 bp) oligonucleotides designed to anneal to the 5′ ends 
of the overhang regions.  The short oligonucleotides could then be 
extended by an endogenous polymerase to generate one or both 
full-length strands.  Short oligonucleotides with a chain-terminating 
dideoxy base on the 3′ end were also tested.  Recombination 
frequency results were as shown in Figure 2.4. 
intermediate.  Thus, it appears clear 
that this overhang construct is not a 
primary intermediate in Lambda Red 
dsDNA recombination.  Indeed, the 
few recombinants observed with this 
construct may arise from the 
regeneration of a full-length double-
stranded molecule via random 
priming and extension, rather than by 
recombination according to one of the 
previously proposed mechanisms.  To investigate this, we co-electroporated the overhang 
intermediate with long (45 bp) oligonucleotides designed to anneal along the entire length of the 
homology overhang regions, or short (20 bp) oligonucleotides designed to anneal to the 5′ ends 
of the overhang regions, and then be extended by an endogenous polymerase to generate one or 
both full-length strands (Figure 2.5).  Both co-electroporations gave substantial recombination 
frequency enhancements, with the short oligos providing a 92-fold improvement despite 
requiring the action of an endogenous polymerase.  Capping the 3′ ends of these oligos with 
dideoxy bases decreases this improvement 4.8-fold (Figure 2.4), consistent with this model.  
These results suggest that extension of the overhang intermediate can readily occur within the 
cell, and that the recombinants observed for the overhang intermediate may indeed arise due to 
random priming and extension, followed by downstream recombination according to our 
proposed mechanism. 
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Figure 2.6: Strand Bias in Lambda Red ssDNA Insertion Recombination.  
Recombination frequencies were assessed for several leading-targeting and 
lagging-targeting complementary ssDNA pairs.  Lagging-targeting strands were 
found to be uniformly more recombinogenic than leading-targeting strands.  
Error bars indicate standard deviation (n=3); * indicates p < 0.05. 
Investigating the Strand Bias of the Recombination Intermediate 
According to our proposed mechanism for Lambda Red dsDNA recombination, the full-
length ssDNA intermediate recombines by annealing at the replication fork in the same manner 
as ssDNA oligonucleotides.
14
  It has been demonstrated that lagging-targeting oligonucleotides 
recombine with substantially greater frequency than the corresponding leading-targeting 
oligonucleotides, due to the greater accessibility of the lagging strand for annealing.
28
  In order to 
test whether long ssDNA recombines in the same manner, we investigated whether several pairs 
of lagging-targeting and leading-targeting ssDNA insertion cassettes demonstrated a similar 
strand bias.  We 
controlled for differential 
secondary structure and 
other sequence-specific 
effects by testing the 
recombination of three 
different antibiotic 
resistance markers into 
lacZ – kanamycin 
(lacZ::kanR), zeocin 
(lacZ::zeoR), and 
spectinomycin 
(lacZ::specR).  
Additionally, in order to 
demonstrate that any 
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strand bias was not caused by replichore-specific context or transcriptional direction, we 
constructed two additional kanR cassettes.  To this end, tolC::kanR targets a gene located on the 
opposite replichore from lacZ, and malK::kanR targets a gene transcribed from the opposite 
strand of the chromosome as lacZ.  
 As shown in Figure 2.6, the lagging-targeting strand was substantially more 
recombinogenic than the leading-targeting strand for all five tested cassettes.  As previously 
observed for oligonucleotides,
29
 there appears to be a significant amount of locus-specific and 
sequence-specific variability in recombination frequency.  Interestingly, a significant number of 
mistargeted recombinants (antibiotic-resistant colonies that retained LacZ function) were 
observed for both lacZ::specR strands.  These mistargeted colonies were not scored as 
recombinants, and do not affect the broader interpretation of our results.  Our results clearly 
indicate a robust lagging strand bias, likely arising from the greater accessibility of the lagging 
strand during DNA replication.  This supports our claim that long ssDNA insertion constructs 
recombine by annealing at the replication fork in a manner similar to ssDNA oligonucleotides. 
 
Testing Mechanistic Predictions by Tracking Designed Mutations 
The preceding experiments provide strong indirect evidence supporting our proposed 
ssDNA annealing mechanism, and refuting the double overhang intermediate suggested by prior 
mechanisms.  In order to more directly test the predictions of our mechanism, we designed a 
lacZ::kanR dsDNA cassette with internal mismatches (Figure 2.7), which enables us to 
empirically determine which strand provides genetic information during recombination.  This 
construct was generated by annealing two strands of ssDNA and purifying the resulting dsDNA 
by agarose gel extraction.  In each of the flanking lacZ homology regions, this construct contains 
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Figure 2.7: Using Designed Mismatches to Assess the Mechanism of Lambda Red dsDNA Recombination. 
Strand-specific mismatch alleles were used to identify the strand of origin for each recombined mutation.  The 
mismatched lacZ::kanR cassette contained two consecutive internal mismatches at two loci in both flanking 
homology regions; at these loci, neither strand’s sequence matched the targeted chromosomal copy of lacZ.  Strand 1 
was the lagging-targeting strand and strand 2 was the leading-targeting strand.  If Lambda Red dsDNA 
recombination proceeds via a ssDNA intermediate (left), a) one Exo binds to a dsDNA end, b) Exo fully degrades 
one strand while helping to load Beta onto the remaining strand, and c) this strand provides all of the genetic 
information during recombination.  This figure shows the case in which the lagging-targeting strand is recombined 
(coding strand genotypes: L1 = AA, L2 = AA, L3 = TT, L4 = TT), but the leading-targeting strand is also predicted 
to be observed (coding strand genotypes: L1 = CC, L2 = CC, L3 = GG, L4 = GG), albeit less frequently.  If the 
Lambda Red recombination intermediate is a heterologous dsDNA core flanked by 3′ ssDNA overhangs (right), a) 
one Exo binds to each dsDNA end, b) Exo recesses both strands while helping to load Beta onto both 3′ overhangs, 
and c) both strands provide genetic information for each recombination.  Since Exo always degrades 5′3′, the 
expected coding strand genotypes for the Court and Poteete mechanisms would be L1 = CC, L2 = CC, L3 = TT, L4 = 
TT. 
two sets of adjacent dinucleotide mismatches that differentiate the two strands.  At these loci, 
neither strand’s sequence matches the targeted chromosomal copy of lacZ.  Thus, one can infer 
which strand has recombined by observing which strand-specific alleles are present. 
Our proposed ssDNA annealing mechanism can be distinguished from the prevailing 
recombination mechanisms based on the results of this experiment.  Our mechanism predicts that 
the mutations located on either end of a single strand will be inherited together, and that the 
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mutations arising from the lagging-targeting strand will be observed more frequently than those 
arising from the opposite strand.  Conversely, as detailed in Figure 2.7, the previously proposed 
mechanisms predict that the alleles on the 3′ ends of both strands will be incorporated. 
 
Table 2.1: Recombination Results for Tracking Designed Mismatches 
This mismatched lacZ::kanR cassette was transformed into EcNR2, which is mutS
-
 and 
therefore deficient for mismatch repair.  Recombinants were obtained by plating on kanamycin, 
and colonies were screened using mismatch amplification mutation assay (MAMA) PCR
30
 in 
order to identify which strand-specific mutations were inherited in each colony.  Two replicates 
were performed, and 48 colonies were screened for each replicate (Table 2.1).  The accuracy of 
the assay was confirmed by sequencing the relevant alleles in several colonies, and by 
Mutation Inheritance Pattern
§ Count 
(Replicate 1) 
Count 
(Replicate 2) 
Total 
1/1/1/WT 10 8 18 
WT/1/1/1 0 3 3 
WT/1/1/WT 24 23 47 
Total – Inheritance from Strand 1 Only (Lagging-
targeting) 
34 34 68 (72%) 
2/2/2/WT 0 1 1 
WT/2/2/2 0 4 4 
WT/2/2/WT 0 2 2 
Total – Inheritance from Strand 2 Only (Leading-
targeting) 
0 7 7 (7%) 
WT/1/1/2 4 1 5 
WT/1/2/WT 4 0 4 
WT/1/2/2 0 1 1 
Total – Pattern Expected for 3′-to-5′ Dual 
Resection 
8 2 10 (11%) 
WT/2/1/WT 5 3 8 
WT/2/1/1 0 1 1 
Total – Pattern Expected for 5′-to-3′ Dual 
Resection 
5 4 9 (10%) 
Ambiguous 1 1 2 
Sum 48 48 96 
§
 Loci 1-4 (as in Figure 2.7) are listed in order.  “1” indicates inheritance from strand 1, “2” indicates inheritance from 
strand 2, and “WT” indicates no mutation (i.e., a wild type allele).  Inheritance patterns are grouped based on the 
manner of Exo processing that is implied, as detailed at the bottom of each section. 
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performing a complementary MAMA PCR assay to detect unaltered wild type alleles at the 
targeted loci.  In line with our predictions, we found that roughly 80% of the colonies inherited 
mismatch alleles from only one strand.  Furthermore, of these colonies, 91% inherited mismatch 
alleles from only the lagging-targeting strand, strongly supporting our mechanism involving a 
full-length ssDNA intermediate.   
Half of the remaining 20% of colonies showed an inheritance pattern consistent with 
resection from both 5′ ends, and the other half was consistent with resection from both 3′ ends. 
Resection from the 5′ ends is predicted by the previously proposed mechanisms, and indicates 
that it is conceivable that one of these mechanisms also operates as a secondary process.  
However, Lambda Exo has not been shown to degrade dsDNA in a 3′5′ manner, and our 
results imply that this occurs equally as often as 5′3′ resection.  Thus, we suggest two 
alternative explanations for the presence of colonies with apparent inheritance from both strands.  
First, another exonuclease may act on the dsDNA construct prior to Lambda Exo degrading one 
of the two strands.  This nuclease could recess a portion of one of the two strands; subsequent re-
extension by a polymerase would use the remaining strand as a template, and generate a dsDNA 
construct without internal mismatches in the affected region.  Recombination could then occur 
according to our mechanism.  Although only one of the two strands would be incorporated at the 
replication fork, the observed allele pattern would be consistent with inheritance from both 
strands, due to the previous nuclease degradation and repolymerization.  This is particularly 
plausible for 3′5′ degradation, as ExoIII from E. coli is known to process dsDNA in this 
manner,
31
 and such a nuclease would leave 3′ termini that could easily be re-extended by a 
polymerase.  However, it is also conceivable that a similar process could occur for 5′3′ 
degradation.  A second plausible explanation is that the colonies possessing alleles from both 
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strands may have undergone two sequential recombination events, each according to our 
proposed mechanism.  The first recombination would proceed normally, and the second 
recombination would involve a partially degraded complementary strand.  This second 
recombination event would be expected to occur quite frequently – after the first recombination 
event, the kanR gene is present in the genome, providing a large region of homology to which 
remaining fragments of kanR ssDNA can anneal in subsequent rounds of replication.   
Interestingly, mutations arising from distal loci one and four (Figure 2.7) were observed 
only rarely in the studied recombinants (Table 2.1).  This result suggests that a significant 
portion of DNA cassettes may be undergoing slight exonuclease degradation, or that annealed 
strands are processed at the replication fork in a manner that degrades or excludes the distal ends 
of the recombined DNA.  This is consistent with a previous observation that mutations placed 
near the ends of a 90 bp oligonucleotide are inherited at a substantially lower frequency than 
mutations placed nearer to the center of the oligo.
32
  This observation and its implications will be 
discussed further in Chapters 3 and 4.  Nevertheless, the results from this experiment provide 
strong direct evidence that our proposed single-stranded mechanism is the sole or dominant 
process by which Lambda Red dsDNA recombination occurs. 
 
Discussion 
 This work provides strong empirical support for the proposed mechanism in which 
Lambda Red dsDNA recombination operates through a full-length ssDNA intermediate.  This 
mechanism appears to be the dominant means of Lambda Red dsDNA recombination, although 
other mechanisms may still occur as minor processes.  While our mechanism had not previously 
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been postulated as the manner by which the Lambda Red system recombines large dsDNA 
segments, it is consistent with numerous results observed by other groups. 
 By annealing two staggered oligonucleotides together, Yu et al. previously generated a 
106 bp construct consisting of a dsDNA core flanked by 3′ overhangs – the recombination 
intermediate predicted by the previous models for Lambda Red dsDNA recombination.
33
  As the 
authors expected, recombination of this construct did not depend on the presence of Exo; 
however, even in the presence of Exo, the recombination frequency of this construct was roughly 
4000-fold lower than that of its corresponding dsDNA.  Given that the construct with 3′ 
overhangs is postulated to be a downstream intermediate of this dsDNA, this result casts doubt 
upon the claim that the tested construct is indeed the predominant recombination intermediate.  
However, this result is explained by our proposed mechanism – only the intact dsDNA can 
generate the full-length ssDNA needed to undergo recombination, as neither individual strand of 
the construct containing 3′ overhangs is sufficient for recombination.
33
  We suggest that this 3′ 
overhang construct recombines by a separate and disfavored process, or that one or both full-
length strands are generated by random priming and extension prior to recombination.  This line 
of reasoning is supported by the fact that the 3′ overhang construct had no greater recombination 
frequency than the corresponding structure with 5′ (rather than 3′) overhangs.
33
  It is unlikely that 
either of these structures represents the predominant intermediate in dsDNA recombination. 
 Muyrers et al.
12
 have also provided evidence contrary to a dsDNA recombination 
intermediate with 3′ overhangs.  The authors created a dsDNA construct in which 
phosphorothioate linkages placed between an antibiotic resistance gene and its flanking genomic 
homology regions were used to prevent exonuclease degradation beyond these homology 
regions.  Two 5′-to-3′ exonucleases other than Exo were then used in vitro to resect the 5′ ends of 
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this construct, in order to generate the putative intermediate for dsDNA recombination.  
However, it was found that none of the tested resection conditions could produce a construct that 
would recombine in the absence of Exo.  Thus, the experiments by Yu et al. and Muyrers et al. 
reinforce our result showing that the previously proposed intermediate containing 3′ overhangs is 
poorly recombinogenic and therefore highly unlikely to be the primary intermediate in Lambda 
Red dsDNA recombination. 
Additionally, other prior work supports our proposed mechanism by reinforcing the 
processive nature of Exo.  Hill et al. showed that non-replicating Lambda phage in E. coli is 
capable of converting linear phage dsDNA into ssDNA, creating single-stranded regions that 
span more than 1.4 kb.
34
  They also demonstrated that exo is sufficient for generating these 
regions of ssDNA, which are similar in length to the ~1.2 kb constructs used in this experiment.  
An additional implication of this result is that a single-stranded intermediate is also present 
during crosses involving an intact Lambda chromosome.  This suggests that our proposed 
mechanism may also be relevant for natural recombination between Lambda phage and bacterial 
chromosomes or plasmids.   
The results of Lim et al.
19
 further reinforce that Exo generates long strands of ssDNA.  
These researchers created a dsDNA construct in which two antibiotic resistance genes were 
attached via a genome homology region and flanked with two additional regions of genome 
homology.  Using this cassette, only about 10% of recombinants incorporated both resistance 
genes, while a majority of recombinants incorporated only one of the two.  This implies that a 
majority of recombination events involved the central homology region, which is roughly 1 kb 
away from either end of the dsDNA construct.  Given that strand annealing requires exposed 
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ssDNA, this result further supports that Exo is substantially processive in vivo, degrading large 
stretches of DNA rather than short flanking segments.   
Finally, around the time this work was initially published, Maresca et al.
35
 described 
complementary experiments in which strand-specific 5′ phosphorylation and phosphorothioation 
were used to bias Exo degradation to each strand of a selectable cassette, separately.  For both in 
vitro and in vivo Exo-mediated digestion, the authors observed a lagging-targeting strand bias in 
the subsequent recombination.  Building upon these observations, the authors identified ssDNA 
as a recombinogenic species, and proposed the same mechanism as the one advanced in our 
work.  These results further validate that Lambda Red dsDNA recombination proceeds through a 
fully single-stranded intermediate.  Our experiment involving the mismatched dsDNA cassette 
extends this work by showing that information from a single strand co-segregates during Lambda 
Red dsDNA recombination, thereby providing direct evidence of a single-stranded intermediate.  
This proposed mechanism may also describe other recombineering processes mediated by 
Lambda Red.  One example is gap repair cloning, in which linear plasmid DNA is used to 
capture chromosomal DNA and generate a circularized plasmid.
5,14
  Notably, while a detailed 
mechanism has not yet been advanced for Lambda Red-facilitated gap repair, our model 
involving a single-stranded intermediate provides a plausible explanation.  Given a full-length 
ssDNA intermediate, the linearized plasmid would anneal to the chromosomal target with its 
homology regions facing one another.  The 3′ end homology would then be elongated in the 
direction of the 5′ end homology, thereby introducing the chromosomal DNA of interest onto the 
plasmid.  The resulting linear single-stranded plasmid would be circularized by ligase in the 
same manner as Okazaki fragment joining.  The circular ssDNA would then be liberated from 
the chromosome, possibly during chromosomal replication.  Finally, the circular ssDNA would 
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be replicated to form a dsDNA plasmid, potentially via priming by residual ssDNA from the 
other strand of the linearized plasmid.  Notably, this mechanism explains how gap repair cloning 
of large (> 80 kb) genomic sequences can occur,
36
 since the two homology regions could anneal 
with multiple Okazaki fragments between them.  These fragments would then be joined via the 
natural lagging strand replication mechanism. 
The mechanism of Lambda Red dsDNA recombination has long been a matter of 
debate.
37
  Here, we propose that Lambda Red dsDNA recombination proceeds via the annealing 
of a full-length ssDNA intermediate to the lagging strand of the replication fork.  We support this 
mechanism with a body of evidence derived from both our work and from previous studies.  Just 
as the mechanistic understanding of Red-mediated oligonucleotide recombination facilitated its 
profound optimization,
23
 this work will likely indicate new strategies for improving the 
frequency and robustness of dsDNA recombineering.  One such example of how this mechanistic 
knowledge was translated into a tangible improvement in recombination frequency is discussed 
in the following chapter. 
 
Experimental Methods 
Preparation of DNA Constructs 
PCR primers were ordered from Integrated DNA Technologies and are listed and 
described in Table 2.2.  Phosphorothioated primers contained four phosphorothioate linkages on 
the 5′ end, dual-biotinylated primers contained a dual-biotin tag on the 5′ end, and dideoxy-
terminated primers contained a dideoxycytidine base terminating the 3′ end.  All primers were 
ordered with standard desalting, except dual-biotinylated primers, which were HPLC-purified.  
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Table 2.2: Oligonucleotides used in Chapter 2 
 
Name Use Sequence Versions used 
LacZ::KanR.full-f  
Forward strand for generation of 
the initial LacZ::KanR construct 
TGACCATGATTACGGATTCA
CTGGCCGTCGTTTTACAACG
TCGTGCCTGTGACGGAAGAT
CACTTCG 
Unmodified 
LacZ::KanR.full-r 
Reverse strand for generation of 
the initial LacZ::KanR construct 
GTGCTGCAAGGCGATTAAGT
TGGGTAACGCCAGGGTTTTC
CCAGTAACCAGCAATAGACA
TAAGCGG 
Unmodified 
MalK::KanR.full-f 
Forward strand for generation of 
the initial MalK::KanR construct 
AATGTTGCTGTCGATGACAG
GTTGTTACAAAGGGAGAAGG
GCATGCCTGTGACGGAAGAT
CACTTCG 
Unmodified 
MalK::KanR.full-r 
Reverse strand for generation of 
the initial MalK::KanR construct 
GACCTCGCCCCAGGCTTTCG
TTACATTTTGCAGCTGTACGC
TCGCAACCAGCAATAGACAT
AAGCGG 
Unmodified 
TolC::KanR.full-f 
Forward strand for generation of 
the initial TolC::KanR construct 
AGTTTGATCGCGCTAAATAC
TGCTTCACCACAAGGAATGC
AAATGCCTGTGACGGAAGAT
CACTTCG 
Unmodified 
TolC::KanR.full-r 
Reverse strand for generation of 
the initial TolC::KanR construct 
GAACCCAGAAAGGCTCAGGC
CGATAAGAATGGGGAGCAAT
TTCTTAACCAGCAATAGACA
TAAGCGG 
Unmodified 
LacZ::ZeoR.full-f  
Forward strand for generation of 
the initial LacZ::ZeoR construct 
TGACCATGATTACGGATTCA
CTGGCCGTCGTTTTACAACG
TCGTGGGTGTTGACAATTAA
TCATCGGC 
Unmodified 
LacZ::ZeoR.full-r 
Reverse strand for generation of 
the initial LacZ::ZeoR construct 
GTGCTGCAAGGCGATTAAGT
TGGGTAACGCCAGGGTTTTC
CCAGTAGCTTGCAAATTAAA
GCCTTCG 
Unmodified 
LacZ::SpecR.full-f  
Forward strand for generation of 
the initial LacZ::SpecR construct 
TGACCATGATTACGGATTCA
CTGGCCGTCGTTTTACAACG
TCGTGCAGCCAGGACAGAAA
TGC 
Unmodified 
LacZ::SpecR.full-r 
Reverse strand for generation of 
the initial LacZ::SpecR construct 
GTGCTGCAAGGCGATTAAGT
TGGGTAACGCCAGGGTTTTC
CCAGTTGCAGAAATAAAAAG
GCCTGC 
Unmodified 
LacZ.short-f 
Forward strand for generation of 
dual-biotinylated LacZ-targeting 
constructs 
TGACCATGATTACGGATTCA
CT 
Unmodified, 
Phosphorothioated, 
Dual-biotinylated 
LacZ.short-r 
Reverse strand for generation of 
dual-biotinylated LacZ-targeting 
constructs 
GTGCTGCAAGGCGATTAA 
Phosphorothioated, 
Dual-biotinylated 
LacZ.trunc-f 
Forward primer for generation of 
3′ overhang intermediate precursor 
CCTGTGACGGAAGATCACTT Unmodified 
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Table 2.2 (Continued) 
LacZ.trunc-r 
Reverse primer for generation of 
3′ overhang intermediate precursor 
AACCAGCAATAGACATAAGC
G 
Unmodified 
Overhang.Anneal.S1 
Short annealing oligo #1 for co-
electroporation with 3′ overhang 
intermediate 
TGACCATGATTACGGATTCA
CTGGCC 
Unmodified, dideoxy-
terminated 
Overhang.Anneal.S2 
Short annealing oligo #2 for co-
electroporation with 3′ overhang 
intermediate 
GTGCTGCAAGGCGATTAAGT
TGGGTAAC 
Unmodified, dideoxy-
terminated 
Overhang.Anneal.L1 
Long annealing oligo #1 for co-
electroporation with 3′ overhang 
intermediate 
TGACCATGATTACGGATTCA
CTGGCCGTCGTTTTACAACG
TCGTG 
Unmodified 
Overhang.Anneal.L2 
Long annealing oligo #2 for co-
electroporation with 3′ overhang 
intermediate 
GTGCTGCAAGGCGATTAAGT
TGGGTAACGCCAGGGTTTTC
CCAGT 
Unmodified 
MalK::KanR.short-f 
Forward strand for generation of 
dual-biotinylated MalK::KanR 
constructs 
AATGTTGCTGTCGATGACAG
G 
Phosphorothioated, 
Dual-biotinylated 
MalK::KanR.short-r 
Reverse strand for generation of 
dual-biotinylated MalK::KanR 
constructs 
GACCTCGCCCCAGGC 
Phosphorothioated, 
Dual-biotinylated 
TolC::KanR.short-f 
Forward strand for generation of 
dual-biotinylated TolC::KanR 
constructs 
AGTTTGATCGCGCTAAATAC
TG 
Phosphorothioated, 
Dual-biotinylated 
TolC::KanR.short-r 
Reverse strand for generation of 
dual-biotinylated TolC::KanR 
constructs 
GAACCCAGAAAGGCTCAGG 
Phosphorothioated, 
Dual-biotinylated 
MM.LacZ::KanR.AA
-f 
Forward strand for generation of 
Construct AA (For the creation of 
mismatched LacZ::KanR) 
TGACCATGAAAACGGATTCA
CTGGCCGTCGTTAAACAACG
TCGTGCCTGTGACGGAAGAT
CACTTCG 
Unmodified 
MM.LacZ::KanR.AA
-r 
Reverse strand for generation of 
Construct AA (For the creation of 
mismatched LacZ::KanR) 
GTGCTGCAAAACGATTAAGT
TGGGTAACGCCAAAGTTTTC
CCAGTAACCAGCAATAGACA
TAAGCGG 
Unmodified 
MM.LacZ::KanR.CC
-f 
Forward strand for generation of 
Construct CC (For the creation of 
mismatched LacZ::KanR) 
TGACCATGACCACGGATTCA
CTGGCCGTCGTTCCACAACG
TCGTGCCTGTGACGGAAGAT
CACTTCG 
Unmodified 
MM.LacZ::KanR.CC
-r 
Reverse strand for generation of 
Construct CC (For the creation of 
mismatched LacZ::KanR) 
GTGCTGCAACCCGATTAAGT
TGGGTAACGCCACCGTTTTC
CCAGTAACCAGCAATAGACA
TAAGCGG 
Unmodified 
MM.AA.short-f 
Forward strand for generation of 
dual-biotinylated Construct AA 
TGACCATGAAAACGGATTCA
C 
Unmodified 
MM.AA.short.DB-r 
Reverse strand for generation of 
dual-biotinylated Construct AA 
GTGCTGCAAAACGATTAAGT
TG 
Dual-biotinylated 
44 
 
Table 2.2 (Continued) 
MM.CC.short.DB-f 
Forward strand for generation of 
dual-biotinylated Construct CC 
TGACCATGACCACGGATTC Dual-biotinylated 
MM.CC.short-r 
Reverse strand for generation of 
dual-biotinylated Construct CC 
GTGCTGCAACCCGATTAAG Unmodified 
Kan.L1.AA.set1 
Forward MAMA PCR primer 
corresponding to the strand 1 
specific mismatch at position 1 in 
MM.LacZ::KanR 
CAGGAAACAGCTATGACCAT
GAAA 
Unmodified 
Kan.L2.AA.set1 
Forward MAMA PCR primer 
corresponding to the strand 1  
specific mismatch at position 2 in 
MM.LacZ::KanR 
GATTCACTGGCCGTCGTTAA Unmodified 
Kan.L3.TT.set1 
Forward MAMA PCR primer 
corresponding to the strand 1  
specific mismatch at position 3 in 
MM.LacZ::KanR 
ATTGCTGGTTACTGGGAAAA
CTT 
Unmodified 
Kan.L4.TT.set1 
Forward MAMA PCR primer 
corresponding to the strand 1 
specific mismatch at position 4 in 
MM.LacZ::KanR 
GGCGTTACCCAACTTAATCG
TT 
Unmodified 
Kan.L1.AA.set2 
Forward MAMA PCR primer 
corresponding to the strand 2 
specific mismatch at position 1 in 
MM.LacZ::KanR 
GGAAACAGCTATGACCATGA
CC 
Unmodified 
Kan.L2.AA.set2 
Forward MAMA PCR primer 
corresponding to the strand 2 
specific mismatch at position 2 in 
MM.LacZ::KanR 
TCACTGGCCGTCGTTCC Unmodified 
Kan.L3.TT.set2 
Forward MAMA PCR primer 
corresponding to the strand 2 
specific mismatch at position 3 in 
MM.LacZ::KanR 
GCTGGTTACTGGGAAAACGG Unmodified 
Kan.L4.TT.set2 
Forward MAMA PCR primer 
corresponding to the strand 2 
specific mismatch at position 4 in 
MM.LacZ::KanR 
GCGTTACCCAACTTAATCGG
G 
Unmodified 
Kan.L1.TT.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 1 in 
MM.LacZ::KanR 
CAGGAAACAGCTATGACCAT
GATT 
Unmodified 
Kan.L2.TT.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 2 in 
MM.LacZ::KanR 
GATTCACTGGCCGTCGTTTT Unmodified 
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Table 2.2 (Continued) 
Kan.L3.CC.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 3 in 
MM.LacZ::KanR 
GCTGGTTACTGGGAAAACCC Unmodified 
Kan.L4.CC.setWT 
Forward MAMA PCR primer 
corresponding to the wild type 
allele at position 4 in 
MM.LacZ::KanR 
GCGTTACCCAACTTAATCGC
C 
Unmodified 
Kan.L1.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L1.AA.set1, Kan.L1.AA.set2, 
and Kan.L1.TT.setWT 
ATGCATTTCTTTCCAGACTTG
TTCA 
Unmodified 
Kan.L2.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L2.AA.set1, Kan.L2.AA.set2, 
and Kan.L2.TT.setWT 
GCATCAACAATATTTTCACC
TGAATCA 
Unmodified 
Kan.L3.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L3.TT.set1, Kan.L3.TT.set2, 
and Kan.L3.CC.setWT 
CTGTAGCCAGCTTTCATCAA
CA 
Unmodified 
Kan.L4.rev 
Reverse MAMA PCR primer that 
is complementary to 
Kan.L4.TT.set1, Kan.L4.TT.set2, 
and Kan.L1.CC.setWT & 
Sequencing primer for MAMA 
PCR validation 
AGGGGACGACGACAGTATC Unmodified 
Kan.L1.L2.seq 
Sequencing primer for MAMA 
PCR validation 
TAGCTCACTCATTAGGCACC Unmodified 
 
Antibiotic resistance insertion cassettes were generated using long PCR primers 
containing 45 bp genome homology regions on the 5′ end, followed by roughly 20 bp of 
homology to the antibiotic resistance gene to be amplified.  The insertion cassettes were 
designed such that the resistance gene was inserted 46 base pairs into the coding DNA sequence 
in the case of lacZ, and directly after the start codon in the cases of malK and tolC.  This set of 
PCRs was performed using Qiagen HotStarTaq Plus Master Mix.  Final primer concentrations 
were 0.4 µM, and templates were resuspended bacterial colonies bearing the desired resistance 
gene (the tn903 aphA1 gene for kanamycin resistance, the Sh ble gene for zeocin resistance, and 
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the tn21 aadA1 gene for spectinomycin resistance; each cassette contained promoter and 
terminator sequences flanking the resistance gene).  These PCRs were heat activated at 95 °C for 
6:00, and then cycled 30 times using a denaturation step of 94 °C for 0:30, an annealing step of 
56 °C for 0:30, and an extension step of 72 °C for 2:30.  After a final 5:00 extension step at 72 
°C, PCRs were held at 4 °C, then purified via 1% agarose gel extraction using the Qiagen gel 
extraction kit.  DNA samples were quantitated using a NanoDrop ND1000 spectrophotometer. 
These constructs were used as template for subsequent PCRs to generate dual-
biotinylated dsDNA constructs.  In each reaction, one primer contained a 5′ dual-biotin tag.  The 
other primer was unmodified, or contained four 5′ phosphorothioate bonds.  Phosphorothioate 
bonds were used in the experiment comparing leading-targeting and lagging-targeting ssDNA, 
with the rationale that this would increase recombination frequency by mitigating exonuclease 
degradation.  PCR conditions were as above, but with 1 µM primers, a 1:30 extension step, and 
0.1 ng of the relevant insertion construct used as template.  PCR products were purified using the 
Qiagen PCR purification kit. 
These dual-biotinylated dsDNA constructs were used to generate ssDNA via a biotin 
capture protocol.  In this method, the dual-biotinylated DNA strand is bound by streptavidin-
coated magnetic beads.  Next, the dsDNA is chemically melted, allowing the non-biotinylated 
strand to be collected from the supernatant, while the biotinylated strand is retained by the beads.  
To this end, Invitrogen DynaBeads MyOne Streptavidin C1 beads were washed twice with 2x 
Bind and Wash buffer (10 mM Tris, 1 mM EDTA, 2 M NaCl, pH 7.5), then incubated in one 
initial bead volume of 1x Bind and Wash buffer, with 5 µg of dual-biotinylated dsDNA for every 
initial 100 µL of beads.  This was rotated in a microcentrifuge tube at room temperature for 20 
minutes, after which the beads were washed twice with 1x Bind and Wash buffer.  Single-
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stranded DNA was then released via incubation with one initial bead volume of chilled 0.125 M 
NaOH.  Beads were vortexed for 30 seconds, incubated for 30 seconds, then placed on a magnet 
so that the supernatant could be collected.  This process was repeated, and the two collected 
NaOH supernatants were pooled and neutralized using a 3 M solution of pH 5.0 sodium acetate.  
These samples were then cleaned using the Qiagen PCR purification kit; the standard protocol 
was used, with an additional rinse with Buffer PE.  The purity of the resulting ssDNA was 
confirmed by PAGE.  To this end, 10 ng of purified ssDNA was loaded onto a 6% TBE non-
denaturing PAGE gel (Invitrogen), post-stained with SYBR Gold (Invitrogen), and examined 
under UV light. 
 A similar strategy was employed for creating the internally mismatched lacZ::kanR 
dsDNA cassette, and the dual 3′ overhang intermediate suggested by previous mechanisms.  For 
each, two dual-biotinylated dsDNA constructs were generated, each intended to give rise to one 
of the two strands of the final construct.  The dsDNA constructs designed to give rise to the 
mismatched cassette were generated in the same manner as described above, with PCR primers 
as denoted in Table 2.2.  For the dsDNA constructs designed to give rise to the overhang 
intermediate, PCRs were performed using Kapa HiFi Master Mix and primer concentrations of 
0.5 µM.  Primers were as described in Table 2.2.  These PCRs were heat activated at 95 °C for 
5:00, and then cycled 30 times using a denaturation step of 98 °C for 0:20, an annealing step of 
62°C for 0:15, and an extension step of 72 °C for 0:45.  After a final 5:00 extension step at 72 
°C, PCRs were held at 4 °C, then purified via 1% agarose gel extraction using the Qiagen gel 
extraction kit.  For both sets of samples, the dual-biotinylated dsDNA constructs were used to 
produce ssDNA in the same manner as above.  The dual-biotin tags were arranged such that 
complementary strands were purified, allowing them to be annealed together to form the desired 
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dsDNA constructs.  Purified strands were annealed in equimolar amounts (25 nM for the strands 
used to generate the mismatched cassette, and 70 nM for the strands used to generate the 
overhang intermediate) in 5 mM Tris, 0.25 M NaCl, pH 8.0.  Samples were annealed in a 
thermocycler by heating to 95 °C and then decreasing the temperature by 1 °C every two 
minutes, to a final temperature of 25 °C.  The resulting annealed dsDNA was purified from a 1% 
agarose gel using the Qiagen gel extraction kit.  Samples were desalted with Microcon Ultracel 
YM-100 columns (spinning thrice at 500 × g for ~20 min, and bringing to 500 µL in deionized 
H2O before each spin). 
 
Recombination of DNA Constructs 
 The above DNA constructs were recombined into EcNR2 cells (Escherichia coli 
MG1655 ∆mutS::cat ∆(ybhB-bioAB)::[λcI857 ∆(cro-ea59)::tetR-bla]) in a similar manner as 
previously described.
23
  Briefly, cells were grown in a rotator drum at 32 °C in LB Lennox media 
(10 g tryptone, 5 g yeast extract, 5 g sodium chloride per 1 L water, pH 7.4) until they reached an 
OD600 of 0.4 – 0.6.  At this time, the expression of the Lambda Red proteins was induced by 
vigorously shaking the cells in a 42 °C water bath for 15 minutes.  Cells were then chilled on ice, 
washed twice with deionized water, and resuspended in 50 µL of deionized water containing the 
desired DNA construct.  For the experiment investigating strand bias, 20 ng of DNA was 
recombined.  For the experiment comparing the 3′ overhang construct with other recombinogenic 
species, 2 nM of overhang construct, ssDNA, or dsDNA was used (75 ng of dsDNA or the 
overhang construct; 37.5 ng of ssDNA).  Where the overhang construct was recombined along 
with annealing oligos, each oligo was included at 200 nM.  For all other experiments, 50 ng of 
DNA was used.  DNA was introduced into the cells via electroporation (BioRad Gene Pulser; 0.1 
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cm cuvette, 1.78 kV, 25 µF, 200 Ω).  After electroporation, cells were recovered in 3 mL LB 
Lennox media for 3 hours in a rotator drum at 32 °C.   
  
Analysis of Recombinants 
 Recombinants were identified by plating 50 µL or 1 mL (concentrated to 50 µL) of 
undiluted recovery culture onto selective media (LB Lennox agar plates with 30 µg/mL 
kanamycin sulfate, 95 µg/mL spectinomycin, or 10 µg/mL Zeocin).  The total viable cell count 
was determined by plating 50 µL of a 10
-4
 dilution of the recovery culture (in LB Lennox) onto 
LB Lennox + 20 µg/mL chloramphenicol plates (EcNR2 is chloramphenicol-resistant).  For 
experiments involving lacZ gene disruption, the plates also contained Fisher ChromoMax X-
Gal/IPTG solution at the manufacturer's recommended concentration.  Recombination 
frequencies were determined by dividing the number of recombinants by the extrapolated total 
viable cell count.  All experiments assessing recombination frequency were performed in 
triplicate, and the standard error of the mean was calculated.  We tested our hypothesis that 
lagging strand recombination frequency is higher than leading strand recombination frequency 
by using a one-tailed t-test assuming unequal variances.  
The mismatch amplification mutation assay (MAMA) PCR method
30
 was used to analyze 
the genotypes of mismatched lacZ::kanR dsDNA recombinants.  We used 2 bp mismatches in 
our mismatched lacZ::kanR cassette in order to increase the specificity of our MAMA primers 
and to decrease the chances of spontaneous point mutations confounding our results.  We 
designed four primers for each mismatch locus: a forward primer corresponding to the strand 1 
allele, a forward primer corresponding to the strand 2 allele, a forward primer corresponding to 
the wild type allele, and a universal reverse primer.  Primers were designed so that the 2 bp 
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mismatch loci occurred at the 3′ end of the primer, ensuring that amplification would only occur 
when these two nucleotides matched the recombinant colony's genotype.  Primers were designed 
with a target Tm of 62 °C, and a subsequent gradient PCR (annealing temperature between 62 °C 
and 68 °C) determined that the optimal annealing temperature for maximum specificity and yield 
was 64° C.  MAMA PCR reactions for loci 1&3 and loci 2&4 were each performed in a single 
mixture so as to minimize the number of reactions.  Each KanR colony was interrogated using 4 
MAMA PCR reactions: strand 1 L1&L3, strand 1 L2&L4, strand 2 L1&L3, and strand 2 L2&L4.  
For convenience, both strand 1 reactions and both strand 2 reactions were pooled prior to agarose 
gel analysis.  PCR template was prepared by growing a monoclonal colony to stationary phase 
and performing a 1/100 dilution of this culture into PCR-grade water.  Our 20 µL MAMA PCR 
reactions consisted of 10 µL Qiagen multiplex PCR master mix, 5 µL PCR grade water, 4 µL 
primer mix (1 µM each), and 1 µL template.  PCRs were heat activated at 95 °C for 15:00, and 
then cycled 27 times using a denaturation step of 94 °C for 0:30, an annealing step of 64 °C for 
0:30, and an extension step of 72 °C for 1:20.  After a final 5:00 extension step at 72 °C, PCRs 
were held at 4 °C until they were analyzed on a 1.5% agarose gel stained using ethidium 
bromide.  All 48 recombinants from replicate 1 were also screened using wild type MAMA PCR 
reactions, performed in an analogous manner as above.  This experiment verified that all sites 
that were not detected as mutants were wild type alleles.  The accuracy of the MAMA PCR 
method was also verified by Sanger sequencing the relevant loci in eight recombinant colonies 
(Genewiz).
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Chapter Three  
 
 
Studying and Improving Lambda Red Double-Stranded DNA 
Recombination via Phosphorothioate Placement and Nuclease 
Removal 
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Introduction 
 In Chapter 2, I propose and present data that support a novel mechanism detailing the 
process by which Lambda Red recombines dsDNA.
1
  According to this mechanism, three phage 
Lambda-derived proteins are required to mediate efficient dsDNA recombination.  The first, 
Gam, inhibits the endogenous RecBCD and SbcCD nucleases,
2
 which would otherwise degrade 
the exogenous dsDNA recombineering cassettes.  The second protein, Lambda Exonuclease 
(Exo), degrades one of the two strands in its entirety, leaving behind a full-length strand of 
ssDNA.
1,3
  The third protein, Beta, then binds to this ssDNA and catalyzes its annealing to the 
lagging strand of the replication fork, where it is incorporated into the newly synthesized strand 
as part of an Okazaki fragment.
1,3
  Given this mechanism, recombination predominantly occurs 
when Lambda Exo degrades the leading-targeting strand of dsDNA, leaving behind the lagging-
targeting strand for recombination at the replication fork.  The final step of Beta-catalyzed 
annealing and incorporation as an Okazaki fragment is analogous to the accepted mechanism for 
Red-mediated oligonucleotide recombination, which requires only the Beta recombinase.
4
 
 In addition to developing a greater understanding of the recombineering process, this 
work also pointed to ways in which the frequency of Lambda Red dsDNA recombination could 
be improved.  Because our mechanism states that the lagging-targeting strand is the predominant 
intermediate in dsDNA recombination, it implies that Exo-mediated degradation of the leading-
targeting strand promotes recombination, while Exo-mediated degradation of the lagging-
targeting strand hinders recombination.  Thus, it is possible that recombination frequencies could 
be improved by preventing Exo from degrading the lagging-targeting strand, and/or by 
promoting its digestion of the leading-targeting strand.  Given that phosphorothioate (PT) bonds 
are known to impede degradation by Lambda Exo,
5
 placing these bonds on the 5′ end of the 
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lagging-targeting strand may provide a straightforward means of biasing Exo toward the 
degradation of the undesired leading-targeting strand. 
 Beyond biasing Lambda Exo, PT bonds may also serve the function of protecting the 
recombinogenic lagging-targeting strand from deleterious endogenous exonuclease activity.  
Multiple lines of evidence suggest that endogenous nucleases can limit recombination.  First, it 
has been shown that protecting oligonucleotides with PT bonds improves recombination 
frequency,
6
 implying that endogenous exonuclease degradation can render ssDNA  non-
recombinogenic.  Additionally, mutations located near the ends of an oligonucleotide
7
 or dsDNA 
cassette (as discussed in Chapter 2) have been shown to be inherited less frequently than 
mutations located closer to the interior of the oligo or cassette, further implying the exonuclease 
degradation of both oligonucleotides and dsDNA.  Thus, protecting the lagging-targeting dsDNA 
strand with PT bonds could improve both recombination frequency and the preservation of 
mutations encoded at the ends of cassettes. 
Such phosphorothioate-mediated nuclease protection may be useful both before and after 
Lambda Exo digests the leading-targeting strand to yield the ssDNA intermediate.  In addition to 
Lambda Exo and other dsDNA nucleases, E. coli also contains several endogenous nucleases 
which readily degrade ssDNA.
8
  Indeed, it has recently been shown that knocking out four of 
these ssDNA exonucleases improves Lambda Red oligo recombination frequency when low 
concentrations of oligos are used.
9
  Phosphorothioate protection of the 5′ end of the lagging-
targeting dsDNA strand may similarly diminish the effect of such nucleases on the 
recombinogenic ssDNA intermediate, thereby improving recombination frequency. 
 On the other hand, while using PT bonds for nuclease protection may be beneficial, it is 
unlikely to be a complete solution for preventing the deleterious effect of nuclease activity.  For 
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one, 5′ phosphorothioation does nothing to preclude the degradation of 3′ ends of ssDNA or 
dsDNA, and while PT bonds can readily be incorporated onto the 5′ ends of a cassette (via 
phosphorothioated PCR primers), they are much more difficult to install on a 3′ end.  
Additionally, it is possible that some endogenous nucleases are not effectively inhibited by PT 
bonds.  Thus, it may be possible to further improve dsDNA recombination frequency through the 
targeted inactivation of endogenous nucleases, as in the aforementioned experiment involving 
oligonucleotide recombination.   
 Here, we describe a set of experiments utilizing phosphorothioate placement and nuclease 
removal in order to study Lambda Red dsDNA recombination and improve the frequency of 
gene insertion.  We show that phosphorothioate protection can significantly improve dsDNA 
recombination frequency, and that the effects of phosphorothioate placement on recombination 
frequency follow a pattern consistent with the predictions of our proposed mechanism.  These 
experiments also led to our identification of ExoVII as a key nuclease that degrades the ends of 
dsDNA cassettes.  Removing this nuclease further improves dsDNA recombination frequency, 
and facilitates the preservation of mutations encoded on the ends of dsDNA cassettes.  Thus, the 
work described in this chapter bolsters our understanding of Lambda Red dsDNA recombination, 
and also identifies concrete ways in which the process can be improved.  
 
Investigating the Effect of Phosphorothioate Placement on dsDNA Recombination 
Frequency 
 In order to determine the effect of PT bonds on dsDNA recombination frequency, we 
generated a set of seven variably phosphorothioated (VPT) lacZ::kanR insertion cassettes 
(Figure 3.1).  This VPT series of cassettes had four consecutive PT bonds located either 
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Figure 3.1: Diagram of the Variably Phosphorothioated (VPT) Cassette 
Series.  Homology arms to lacZ are shown in blue, and the inserted 
heterologous kanR gene is shown in gold; the lagging-targeting strand is 
represented as the top strand, and the leading-targeting strand is represented 
as the bottom strand.  The red asterisks indicate the presence of 4 
consecutive phosphorothioate bonds. 
Figure 3.2: In vitro Lambda Exo Digestion.  Non-phosphorothioated 
(VPT1, left), single-end phosphorothioated (VPT2, center), and dually 
phosphorothioated (VPT4, right) dsDNA cassettes were digested with no 
Lambda Exo (lanes 1, 5, & 9) and tenfold-increasing amounts of Lambda 
Exo, from left to right.  The bottom gel band is dsDNA, and the top band is 
the ssDNA product after Lambda Exo degrades one of the two strands. 
terminally (at the 5′ end of the cassette), or internally (between the 5′ homology and heterology 
regions).  These PT bonds were placed on neither strand, on the lagging-targeting strand only, on 
the leading-targeting strand only, or on both strands.   
We then used three of 
these cassettes in an in vitro 
digestion experiment with 
purified Lambda Exo, in order 
to confirm that PT bonds block 
Lambda Exo degradation as 
previously reported
5
 (Figure 
3.2).  Indeed, we found that 
while the non-
phosphorothioated dsDNA 
cassette (VPT1) is readily 
degraded by Lambda Exo, the 
cassette with phosphorothioate 
bonds on both 5′ ends (VPT4) 
exhibits no apparent 
degradation.  The tested 
cassette with phosphorothioate 
bonds on only one 5′ end 
(VPT2) shows digestion of one 
strand, leaving behind the 
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Figure 3.3: Recombination Frequencies of the VPT Cassette Series in EcNR2.  Insertion frequencies were 
measured as the number of kanamycin resistant recombinants over the total number of viable cells (as plated on 
non-selective media).  Three replicates were performed; data are presented as the mean with the error bars 
representing standard deviation. 
remaining strand as ssDNA.  Thus, it is clear that these phosphorothioated cassettes are highly 
effective at blocking the action of Lambda Exo in an in vitro context. 
To determine how phosphorothioate placement affects recombination frequency in vivo, 
we recombined each of the VPT cassettes into the EcNR2 recombineering strain.
6
  
Recombination frequencies were calculated by dividing the number of kanamycin-resistant 
recombinant cfu (colony forming units) by the number of total cfu, and results are shown in 
Figure 3.3. 
 Several interesting observations are apparent.  First, the cassette with phosphorothioate 
bonds on the 5′ end of the lagging-targeting strand (VPT2) had significantly greater 
recombination frequency than VPT1, the unmodified lacZ::kanR cassette (p = 0.03, by unpaired 
t-test).  No other cassette had significantly greater recombination frequency than VPT1, and 
placing PT bonds on the 5′ end of the leading-targeting strand (in VPT3) decreased frequency 
roughly four-fold.  These results provide further support of our proposed mechanism for dsDNA 
recombination.  For one, they argue against the mechanisms proposed by Court and Poteete, as 
alternating which of the two strands is protected by PT bonds would not be expected to have 
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differential effects if Exo resection occurred from both 5′ ends.  These results also confirm our 
hypothesis that protecting the 5′ end of the lagging-targeting strand improves recombination 
frequency.  Conversely, protecting the 5′ end of the leading-targeting strand decreases 
recombination frequency, as it prevents Lambda Exo from degrading that strand to generate the 
lagging-targeting ssDNA intermediate.  Consistent with these results, the cassette with terminal 
PTs placed on both 5′ ends (VPT4) is roughly equivalent (1.23 times more recombinogenic) to 
unmodified dsDNA, presumably due to a cancellation of these two effects.   
Nevertheless, it is surprising that VPT4 can so readily be processed by Lambda Exo and 
undergo recombination, given the degree to which this cassette resists Exo digestion in vitro 
(Figure 3.2).  It is possible that Lambda Exo behaves differently in vivo than in vitro (e.g., due to 
the presence of protein partners or cofactors), and is able to degrade phosphorothioate bonds in a 
cellular context.  Alternatively, an endogenous E. coli nuclease may degrade the 5′ PT bonds on 
one or both strands, thereby allowing Lambda Exo to degrade the remainder of the strand and 
generate the ssDNA recombination intermediate. 
 The recombination frequencies of the VPT cassettes with internal PT bonds support the 
latter explanation. When placed on the lagging-targeting strand only (VPT5), internal PT bonds 
do not decrease recombination frequency.  However, internal PT bonds on the leading-targeting 
strand (VPT6 and VPT7) are highly detrimental to recombination frequency.  These cassettes 
have substantially lower recombination frequencies than the corresponding terminally 
phosphorothioated cassettes (VPT3 and VPT4, respectively), with a VPT4:VPT7 ratio of 12.3 
and a VPT3:VPT6 ratio of 4.9.  This suggests that internal PT bonds are significantly more 
effective than terminal PT bonds at blocking Lambda Exo from degrading the leading-targeting 
strand and generating the ssDNA recombination intermediate.  Thus, it is unlikely that Lambda 
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Exo can independently degrade phosphorothioates in vivo; rather, it appears that an endogenous 
nuclease is able to cleave terminally located PT bonds, thereby allowing Lambda Exo to degrade 
the remainder of the strand.  Internally located PT bonds are likely not directly accessible to this 
endogenous nuclease, and/or cannot be removed without rendering the cassette non-
recombinogenic due to the degradation of one of its homology regions.  Thus, blocking the 
leading-targeting strand with internal PT bonds has a uniquely detrimental effect on 
recombination frequency. 
 
Utilizing the VPT Cassettes to Investigate Nuclease Processing of dsDNA 
 The above results suggest a strategy for identifying the nuclease(s) putatively responsible 
for degrading the phosphorothioated ends of dsDNA cassettes: inactivate candidate nucleases, 
and then compare the recombination frequencies of unmodified dsDNA (VPT1) and dsDNA 
with terminal 5′ PT bonds on both strands (VPT4).  If the postulated nuclease(s) responsible for 
pruning terminal PT bonds is/are still present, then VPT4 will have a recombination frequency 
that is roughly equal to that of VPT1 (VPT4:VPT1 ≈ 1.0, as in EcNR2).  However, if the 
nuclease(s) have been removed, the strain will no longer be able to degrade the phosphorothioate 
bonds on the 5′ ends of the VPT4 dsDNA.  Thus, the recombination frequency of VPT4 will 
drop well below that of VPT1 (VPT4:VPT1 << 1), as Lambda Exo can no longer generate the 
ssDNA recombination intermediate. 
We first tested VPT1 and VPT4 in a strain lacking Endonuclease I (endA), a potent 
periplasmic endonuclease capable of degrading dsDNA.
10
  This resulted in a VPT4:VPT1 ratio 
of 1.55, similar to that observed for the EcNR2 strain (Table 3.1).  Thus, Endonuclease I is not 
responsible for degrading the phosphorothioated ends of dsDNA cassettes. 
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Figure 3.4: Recombination Frequencies of the VPT Cassette Series in nuc4
-
.  Insertion frequencies were 
measured as the number of kanamycin resistant recombinants over the total number of viable cells (as plated on 
non-selective media).  Two replicates were performed; data are presented as the mean with the error bars 
representing standard deviation. 
Table 3.1: Identifying the Nuclease(s) which Degrade Phosphorothioated Cassette Ends 
 
Strain Background    VPT4:VPT1  
EcNR2 1.23 
EcNR2.endA
-
 1.55 
EcNR2.xonA
-
,recJ
-
,xseA
-
,exoX
-
 (nuc4
-
) 0.09 
EcNR2.xonA
-
,recJ
-
,exoX
-
 (xseA
+
) 0.77 
EcNR2.xonA
-
,xseA
-
,exoX
-
 (recJ
+
) 0.06 
EcNR2.recJ
-
,xseA
-
,exoX
-
 (xonA
+
) 0.09 
EcNR2.xonA
-
,recJ
-
,xseA
-
 (exoX
+
) N/A
§ 
EcNR2.xseA
-
 0.07 
 
We next tested a strain which lacked the four primary
8
 E. coli ssDNA exonucleases – 
recJ/RecJ,
11
 xonA/ExoI,
12
 xseA/ExoVII,
13
 and exoX/ExoX.
14
  This strain (EcNR2.recJ
-
,xonA
-
,xseA
-
,exoX
-
, or “nuc4
-
”) demonstrated a VPT4:VPT1 ratio of 0.09, far lower than that of EcNR2 
(Table 3.1).  Thus, recombination frequency data for the full VPT series was collected in this 
strain (Figure 3.4).   
 
§
 EcNR2.xonA
-
,recJ
-
,xseA
-
 did not give KanR recombinants for either cassette; 
this strain was recreated by restoring exoX function in nuc4
-
, whereupon it 
exhibited the same non-recombinogenic phenotype.  The biological basis of 
this phenotype is unclear.   
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Figure 3.5: VPT4:VPT1 Ratios of Tested Strains.  Cassette 
insertion frequencies were measured in technical replicates for 
strains EcNR2, nuc4
-
, and EcNR2.xseA
-
.  Data are presented as 
the mean with the standard error of the mean. The ratio 
between VPT4 and VPT1 indicates a strain’s ability to 
recombine cassettes with terminal 5′ PT bonds preventing the 
direct action of Lambda Exo. 
Figure 3.6: VPT4:VPT7 Ratios of Tested Strains.  Cassette 
insertion frequencies were measured in technical replicates for 
strains EcNR2, nuc4
-
, and EcNR2.xseA
-
.  Data are presented as 
the mean with the standard error of the mean. The ratio 
between VPT4 and VPT7 indicates whether a strain is more 
able to process terminal PT bonds (VPT4) in comparison with 
internal PT bonds (VPT7). 
These data show a strikingly 
different trend than observed for EcNR2.  
The recombination frequency of VPT4 in 
nuc4
-
 is indeed far lower than that of 
VPT1 (Figure 3.5).  Additionally, 
terminal PT bonds on the leading-
targeting strand are just as detrimental to 
recombination frequency as internal PT 
bonds (VPT3:VPT6 = 1.41; VPT4:VPT7 
= 0.75, Figure 3.6).  Because constructs 
with terminal PT bonds on the leading-
targeting strand are minimally 
recombinogenic in nuc4
-
, this suggests 
that these constructs can no longer be 
processed by Lambda Exo, and therefore 
that the nuclease(s) capable of cleaving 
off these PT bonds is/are absent in this 
strain.  Residual recombinants for such 
cassettes may be due to a limited ability 
of Lambda Exo to degrade PT bonds, or to slight endogenous nuclease activity that is still 
present. 
 To identify which of the four nucleases is/are responsible for cleaving terminal PT bonds, 
four strains were generated, each of which restored one of the nucleases removed in nuc4
-
 (i.e., 
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Figure 3.7: Recombination Frequencies of the VPT Cassette Series in EcNR2.xseA
-
.  Insertion frequencies 
were measured as the number of kanamycin resistant recombinants over the total number of viable cells (as plated 
on non-selective media).  Three replicates were performed; data are presented as the mean with the error bars 
representing standard deviation. 
three of the four nucleases were inactivated in each of these strains).  VPT1 and VPT4 were 
recombined into these strains, and the VPT4:VPT1 ratio of recombinants was measured (Table 
3.1).  One of the four strains (EcNR2.recJ
-
,xonA
-
,xseA
-
) was surprisingly found to be non-
recombinogenic.  This was the case regardless of whether the strain was generated by 
inactivating the three nucleases from an EcNR2 background, or by reactivating ExoX in nuc4
-
; 
this suggests that the non-recombinogenic phenotype did not arise from an off-target mutation.  
Of the remaining strains, two showed a VPT4:VPT1 ratio similar to that of nuc4
-
, while the 
strain containing xseA (EcNR2.recJ
-
,xonA
-
,exoX
-
) showed a ratio similar to that of EcNR2.  This 
suggests that ExoVII (xseA) may be the nuclease responsible for the ability of EcNR2 to degrade 
phosphorothioated ends of dsDNA cassettes.  An ExoVII single knockout strain (EcNR2.xseA
-
) 
was therefore generated. 
 
Recombineering Properties of the ExoVII Mutant Strain 
 The VPT series of cassettes was recombined into EcNR2.xseA
-
, and recombination 
frequencies were determined (Figure 3.7).   
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 This strain shows a pattern of relative frequencies similar to that of nuc4
-
: terminal 
phosphorothioation on the leading-targeting strand is highly detrimental to recombination, and 
has impact equivalent to that of internal phosphorothioation (Figures 3.5 and 3.6).  This suggests 
that these terminal PT bonds can no longer be cleaved off, and therefore that ExoVII is the 
primary E. coli nuclease responsible for degrading phosphorothioated 5′ ends of dsDNA 
cassettes.  Moreover, removing ExoVII significantly increases the recombination frequency of 
unmodified dsDNA (VPT1) above levels observed in EcNR2 (2.6-fold improvement; p = 0.0076 
by unpaired t-test).  This strongly suggests that the action of ExoVII on the ends of dsDNA 
cassettes may compromise recombination frequency.  Furthermore, the recombination frequency 
of VPT2 also appears to be slightly improved in EcNR2.xseA
-
, although this result was not 
statistically significant (1.6-fold improvement; p = 0.18).   
 ExoVII is a nuclease encoded by the xseA and xseB genes.
15
  It is processive, and can 
degrade from either the 5′ or 3′ end of a DNA strand.
16
  While it is highly specific for ssDNA 
substrates, it is capable of degrading short overhangs and then continuing into duplex regions of 
DNA.
16
  Its observed ability to degrade dsDNA ends is likely due to strand “breathing,” possibly 
aided by endogenous helicase enzymes, or by PT bonds decreasing the strength of the annealing 
interaction between the two strands.
17
  Alternatively, an endogenous 3′-to-5′ exonuclease may 
degrade part of the strand complementary to the 5′ PT bonds, leaving behind an ssDNA overhang 
to which ExoVII can bind.  While ExoVII is classified as an exonuclease due to its requirement 
for a free ssDNA end, it technically has endonucleolytic activity, given that its degradation 
products are 4-12 bp oligonucleotides.
16
  Thus, ExoVII likely cleaves to the 3′ end of the four 
terminal PT bonds used in the VPT cassette series, rather than degrading the PT bonds directly.  
This explains the ability of ExoVII to readily process terminally phosphorothioated cassettes. 
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Figure 3.8: Removal of ExoVII Improves dsDNA Mutation Inheritance.  A) A non-phosphorothioated 
lacZ::kanR dsDNA cassette encoding two 2-bp sets of mismatch mutations (placed 7&8 bp from each end of the 
cassette) was recombined into EcNR2 and EcNR2.xseA
-
 cells.  Resulting kanamycin-resistant recombinants were 
then genotyped in order to determine whether they inherited these distally-located mutations.  The distribution of 
mutations in EcNR2 (two independent experiments, n = 180) and EcNR2.xseA
-
 (two independent experiments, n = 
177) was plotted as the frequency of clones inheriting 0 (empty), 1 (hatched black bars), or 2 (filled black bars) 
sets of mutations.  B) When the inheritance of each 2-bp mutation is considered individually, both show increased 
preservation in EcNR2.xseA
-
, although this is only statistically significant for the 2-bp mutation on the 3′ end of 
the cassette (as defined with respect to the lagging-targeting strand).  Data are presented as the mean with the 
standard deviation from the mean.  
 
Given that the action of ExoVII on the ends of dsDNA cassettes appears to compromise 
recombination frequency, we investigated whether its removal would increase the inheritance of 
mutations encoded near the ends of a dsDNA insertion cassette.  Thus, we designed a non-
phosphorothioated lacZ::kanR cassette with 2-bp mutations encoded in each homology region, 7 
and 8 bp from the end of the cassette.  This construct was then recombined into EcNR2 and 
EcNR2.xseA
-
.  KanR colonies were selected, and their genotypes were analyzed at the mutation 
loci.  The strain with ExoVII removed showed greater inheritance of these end-located mutations 
(Figure 3.8A), although the difference was only statistically significant for the mutation encoded 
at the 3′ end of the cassette (as defined with respect to the lagging-targeting strand; Figure 3.8B, 
right panel).  This confirms that ExoVII also degrades non-phosphorothioated dsDNA cassettes, 
and that it is partially responsible for the poor inheritance of mutations located at the ends of 
such cassettes.  However, given that the EcNR2.xseA
-
 strain still demonstrates low levels of 
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inheritance of these mutations, it is likely that other endogenous nucleases are also responsible 
for degrading the ends of dsDNA cassettes. 
 
Discussion 
The results described in this chapter provide additional insight into the cellular processes 
occurring during recombineering.  First, our surprising observation that dual 5′-
phosphorothioated dsDNA is still highly recombinogenic – despite the fact that PT bonds block 
Lambda Exo – was explained by our discovery that ExoVII degrades the ends of dsDNA 
cassettes.  Thus, dually-phosphorothioated dsDNA enters the cell, after which ExoVII degrades 
the 5′ PT bonds of one or both strands.  This step may also require the action of a helicase or 
another endogenous nuclease in order to generate ssDNA ends to which ExoVII can bind.  After 
the action of ExoVII, Lambda Exo degrades the rest of the leading-targeting strand, leaving 
behind the lagging-targeting ssDNA recombination intermediate.
1,3
  Therefore, dually-
phosphorothioated dsDNA recombines with a frequency equal to or exceeding that of 
unmodified dsDNA, despite requiring the action of one or more endogenous nucleases in 
addition to Lambda Exo.  This suggests that there is a great deal of interaction between 
endogenous nucleases and recombineering cassettes.  This notion is further supported by the 
variability of the dsDNA recombination frequencies exhibited by the tested nuclease knockout 
strains.  For example, the nuc4
-
 strain exhibits sharply decreased recombination frequency for all 
tested VPT cassettes.  The origin of this phenotype is uncertain; it is possible that one of the 
removed exonucleases has a role in dsDNA recombination, or that the presence of exogenous 
linear dsDNA is somewhat toxic to cells with these four nucleases removed, thereby selecting 
against cells which take up the cassettes necessary for recombination.  Along similar lines, strain 
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EcNR2.recJ
-
,xonA
-
,xseA
-
 appears to be non-recombinogenic, for reasons that are unclear, while 
EcNR2.xseA
-
 has slightly enhanced recombination frequency for cassettes without PT bonds 
blocking the leading-targeting strand.  Taken together, this suggests that modifying endogenous 
nuclease activity may be a powerful lever for affecting Lambda Red recombination, and possibly 
a valuable strategy for engineering further improvements of dsDNA recombination frequency. 
 This work also further validates our mechanistic hypothesis for Lambda Red dsDNA 
recombineering, described in Chapter 2.  As noted above, we found that EcNR2 recombination 
frequency could be improved by using 5′ PT bonds to prevent Exo from degrading the lagging-
targeting strand.  In contrast, 5′ PT bonds on the leading-targeting strand were detrimental, as 
they block Exo from processing that strand.  This observation is predicted by our mechanism, but 
not by previously proposed mechanisms; those mechanisms posit resection occurring from both 
5′ ends, and therefore suggest that phosphorothioate bonds on the two strands should have 
equivalent effects.  The behavior of the VPT7 cassette (Figure 3.1) in EcNR2 also helps 
differentiate our mechanism from the previously proposed mechanisms.  According to our 
mechanism, VPT7 would be expected to have a recombination frequency significantly less than 
that of unmodified dsDNA, as placing PT bonds between the 5′ homology and heterology 
regions of both strands would prevent Lambda Exo from degrading one strand to generate a full-
length ssDNA intermediate.  In contrast, the placement of PT bonds in VPT7 would be expected 
to facilitate Lambda Exo’s generation of the 3′ overhang intermediate suggested by the 
previously proposed mechanisms.
4,18
  Thus, if one of those mechanisms were correct, VPT7 
would be expected to have equal or greater recombination frequency than unmodified dsDNA.  
As shown in Figure 3.3, VPT7 has 10.2-fold lower recombination frequency than unmodified 
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dsDNA (VPT1) in EcNR2.  This result is consistent with those from similar experiments,
3,19
 and 
supports our mechanism while further refuting the previously proposed mechanisms. 
 Beyond providing additional mechanistic insight into Lambda Red recombination, this 
work also achieved several meaningful improvements of dsDNA recombineering.  First, we 
established that recombination frequency can be improved by protecting the 5′ end of the 
lagging-targeting strand of a dsDNA cassette.  This is easily accomplished by using a 
phosphorothioated PCR primer, and represents a straightforward way to reliably improve gene 
insertion frequencies.  Additionally, we found that removing ExoVII from E. coli improves gene 
insertion frequencies for unmodified cassettes, and likely also for cassettes with 
phosphorothioated lagging-targeting strands.  Thus, this work establishes two simple and 
effective strategies for improving Lambda Red dsDNA insertion frequencies.  Finally, we also 
showed that removing ExoVII improves the inheritance of mutations encoded near the 3′ end of 
a dsDNA cassette.  In sum, this work may enable new and more powerful applications of 
Lambda Red dsDNA recombineering technology, and also point to additional ways in which 
recombination frequency can be improved through nuclease modification and phosphorothioate 
placement. 
 
Experimental 
Oligonucleotides used in this Study 
A full list of primers and recombineering oligonucleotides used in this work is presented 
in Table 3.2.  Asterisks represent phosphorothioate bonds between the two indicated nucleotides.  
For these primers, “wt-f” refers to a forward allele-specific colony PCR (ascPCR) or multiplex 
allele-specific colony PCR (mascPCR) primer used to detect a wild type allele, “mut-f” refers to 
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a forward ascPCR/mascPCR primer used to detect a mutated allele, and “rev” refers to the 
reverse ascPCR/mascPCR primer used with both forward primers.  All oligonucleotides were 
ordered from Integrated DNA Technologies with standard purification and desalting.   
Table 3.2: Oligonucleotides used in Chapter 3 
Name Use
 
Sequence
 
endA.KO* endA inactivating oligo 
T*C*G*T*TTTAACACGGAGTAAGTGATGTACCGTTATTT
GTCTATTGCTGCTGAGTGGTACTGAGCGCAGCATTTTCC
GGCCCGGCGTTGGCC 
exoX.KO* exoX inactivating oligo 
T*T*C*G*GCCTGGAGCATGCCATGTTGCGCATTATCGAT
ACAGAAACTGATGCGGTTTGCAGGGAGGGATCGTTGAG
ATTGCCTCTGTTGATG 
xseA.KO* xseA inactivating oligo 
G*A*A*T*TTGATCTCGCTCACATGTTACCTTCTCAATCCC
CTGCAATTGATTTACCGTTAGTCGCCTGAATCAAACGGT
TCGTCTGCTGCTTG 
recJ.KO* recJ inactivating oligo 
G*G*A*G*GCAATTCAGCGGGCAAGTCTGCCGTTTCATCG
ACTTCACGTCACGACGAAGTTGTATCTGTTGTTTCACGC
GAATTATTTACCGCT 
xonA.KO* xonA inactivating oligo 
A*A*T*A*ACGGATTTAACCTAATGATGAATGACGGTAAG
CAACAATCTGAACCTTTTTGTTTCACGATTACGAAACCTT
TGGCACGCACCCCG 
endA.KO*-wt-f 
endA wt-f mascPCR 
primer 
CCGTTATTTGTCTATTGCTGCGG 
exoX.KO*-wt-f 
exoX wt-f mascPCR 
primer 
GCGCATTATCGATACAGAAACCT 
xseA.KO*-wt-f 
xseA wt-f mascPCR 
primer 
CTTCTCAATCCCCTGCAATTTTTACC 
recJ.KO*-wt-f 
recJ wt-f mascPCR 
primer 
CAACAGATACAACTTCGTCGCC 
xonA.KO*-wt-f 
xonA wt-f mascPCR 
primer 
GAATGACGGTAAGCAACAATCTACC 
endA.KO*-mut-f 
endA mut-f mascPCR 
primer 
CCGTTATTTGTCTATTGCTGCTGA 
exoX.KO*-mut-f 
exoX mut-f mascPCR 
primer 
GCGCATTATCGATACAGAAACTGA 
xseA.KO*-mut-f 
xseA mut-f mascPCR 
primer 
CTTCTCAATCCCCTGCAATTGA 
recJ.KO*-mut-f 
recJ mut-f mascPCR 
primer 
CAACAGATACAACTTCGTCGTGA 
xonA.KO*-mut-f 
xonA mut-f mascPCR 
primer 
GAATGACGGTAAGCAACAATCTGA 
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Table 3.2 (Continued) 
endA.KO*-r 
endA rev mascPCR 
primer 
GCACGATTGCAGATCAACAACG 
exoX.KO*-r 
exoX rev mascPCR 
primer 
GACCATGGCTTCGGTGATG 
xseA.KO*-r 
xseA rev mascPCR 
primer 
GGTACGCTTAAGTTGATTTTCCAGC 
recJ.KO*-r recJ rev mascPCR primer GGCCTGATCGACCACTTCC 
xonA.KO*-r 
xonA rev mascPCR 
primer 
GAAATGTCTCCTGCCAAATCCAC 
L:K.mut7-8.f 
Forward primer for 
generating lacZ::kanR 
with distal mutations 
TGACCATCCTTACGGATTCACTG 
L:K.mut7-8.r 
Reverse primer for 
generating lacZ::kanR 
with distal mutations 
GTGCTGCTTGGCGATTAAG 
L:K.mut7-8.L1-mut 
mut-f mascPCR primer 
for lacZ::kanR 5′ distal 
mutation 
AGGAAACAGCTATGACCATCC 
L:K.mut7-8.L1-wt 
wt-f mascPCR primer for 
lacZ::kanR 5′ distal 
mutation 
CAGGAAACAGCTATGACCATGA 
L:K.mut7-8.L4-mut 
mut-f mascPCR primer 
for lacZ::kanR 3′ distal 
mutation 
CGTTACCCAACTTAATCGCCAA 
L:K.mut7-8.L4-wt 
wt-f mascPCR primer for 
lacZ::kanR 3′ distal 
mutation 
CGTTACCCAACTTAATCGCCTT 
Kan.L1.rev 
rev mascPCR primer for 
lacZ::kanR 5′ distal 
mutation 
ATGCATTTCTTTCCAGACTTGTTCA 
Kan.L4.rev 
rev mascPCR primer for 
lacZ::kanR 3′ distal 
mutation 
AGGGGACGACGACAGTATC 
Kan:LacZ.NoPT-f 
Forward primer for 
generating VPT1, VPT3, 
VPT6 
TGACCATGATTACGGATTCACTGGCCGTCGTTTTACAA 
Kan:LacZ.NoPT-r 
Reverse primer for 
generating VPT1, VPT2, 
VPT5 
GTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTT
CCCAGT 
Kan:LacZ.BlockPT-f 
Forward primer for 
generating VPT5, VPT7 
TGACCATGATTACGGATTCACTGGCCGTCGTTTTACAAC
GT*C*G*T*G 
Kan:LacZ.BlockPT-r 
Reverse primer for 
generating VPT6, VPT7 
GTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTT
CC*C*A*G*T 
73 
 
Table 3.2 (Continued) 
Kan:LacZ.StartPT-f 
Forward primer for 
generating VPT2, VPT4 
T*G*A*C*CATGATTACGGATTCACTGGCCGTCGTTTTAC
AA 
Kan:LacZ.StartPT-r 
Reverse primer for 
generating VPT3, VPT4 
G*T*G*C*TGCAAGGCGATTAAGTTGGGTAACGCCAGGGT
TTTCCCAGT 
 
Generating dsDNA Recombineering Cassettes 
Both the VPT series of dsDNA recombineering cassettes and the lacZ::kanR cassette 
with mutations encoded in its homology arms were generated by PCR using the primers denoted 
in Table 3.2.  PCRs were performed using Kapa HiFi HotStart ReadyMix, with primer 
concentrations of 0.5 µM, and 0.1 ng of lacZ::kanR dsDNA (as generated in previous work)
1
 
used as template.  PCRs had a total volume of 50 µL, and were heat activated at 95 °C for 5 min, 
then cycled 30 times with a denaturation temperature of 98 °C (20 sec), an annealing temperature 
of 62 °C (15 sec), and an extension temperature of 72 °C (45 sec).  PCRs were brought to 72 °C 
for 5 min, and then held at 4 °C.  PCR products were cleaned with the Qiagen PCR purification 
kit (elution in 50 µL H2O).  Samples were desalted with Microcon Ultracel YM-100 columns 
(spinning twice at 500 × g for 20 min, and bringing to 500 µL in H2O before each spin).  
Resulting samples were then brought to 100 µL in H2O and quantitated on a NanoDrop ND1000 
spectrophotometer.  All samples were analyzed on a 1% agarose/ethidium bromide (EtBr) gel to 
confirm that the expected band was present and pure.  
 
In vitro Digestion by Lambda Exo 
lacZ::kanR dsDNA (20 ng) with neither, one, or both ends phosphorothioated (VPT1, 
VPT2, and VPT4, respectively; see Figure 3.1) was added to Lambda Exonuclease Buffer (New 
England Biolabs), such that the resulting volume was 9 µL and the resulting buffer concentration 
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was 1X.  Lambda Exonuclease (New England Biolabs) was serially diluted in 1X Lambda 
Exonuclease Buffer, and 1 µL of the appropriate dilution was then added to the reaction.  
Reactions were incubated at 37 °C for 30 min, heat inactivated at 75 °C for 10 min, and then 
analyzed on an Invitrogen 6% TBE non-denaturing PAGE gel (180 V for 40 min, then post-
stained in Invitrogen SYBR Gold for 15 min).  This gel was then examined and imaged under 
UV light. 
 
Strain Creation 
EcNR2 (Escherichia coli MG1655 ∆mutS::cat ∆(ybhB-bioAB)::[λcI857 N(cro-
ea59)::tetR-bla])
6
 was used as the basis for all strains created in this work.  From an EcNR2 
background, nuclease genes endA, xonA, recJ, xseA, and exoX were inactivated singly or in 
combination, using oligo-mediated Lambda Red recombination as described below.  Knockout 
oligos (Table 3.2) were designed to introduce a premature stop codon and a frameshift mutation 
at the beginning of the nuclease gene, thereby rendering the targeted nuclease inactive.  Strain 
genotypes were verified using ascPCR as described below. 
 
Performing Lambda Red Recombination 
 Lambda Red recombination was performed as previously described.
1,6
  In brief, cultures 
were grown in LB Lennox media (10 g tryptone, 5 g yeast extract, 5 g NaCl per 1 L water, pH 
7.4), from a 1:100 dilution of an overnight culture.  Cultures were placed in a rotator drum at 30 
°C until they reached an OD600 of 0.4-0.6 (typically 2.25-2.5 hrs).  Lambda Red expression was 
then induced by shaking cultures at 300 rpm in a 42 °C water bath (15 min).  Induced cultures 
were immediately cooled on ice, and 1 mL of cells were washed twice in ice cold deionized 
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water (dH2O).  The resulting cell pellet was resuspended in 50 µL of dH2O containing the 
intended recombineering construct(s).  For experiments in which dsDNA cassettes were 
recombined, 100 ng was used; for experiments in which oligonucleotide(s) were recombined, 1 
µM of each oligo was used.  Samples were electroporated (BioRad GenePulser; 0.1 cm cuvette, 
1.78 kV, 200 Ω, 25 µF), and allowed to recover in 3 mL LB Lennox in a rotator drum at 30 °C.  
Cultures were recovered for at least 3 hours, and then were plated and analyzed as below. 
 
Analyzing Recombination 
 In order to analyze the recombination of lacZ::kanR insertion cassettes, recovery cultures 
were plated onto LB Lennox agar plates with kanamycin sulfate (30 µg/mL).  Plates were 
incubated at 30 °C overnight, and the number of resulting colonies was counted.  To determine 
the total number of cells present, recovery cultures were diluted (in LB Lennox) and similarly 
plated onto LB Lennox plates with carbenicillin (50 µg/mL; EcNR2 and its derived strains are 
carbenicillin-resistant).  These results were used to determine the recombination frequency of a 
given sample (# recombinants / # total viable cells), or the ratio of the number of kanR 
recombinants yielded by two different cassettes in a given strain.  All platings were performed in 
duplicate.  Recovery cultures from recombinations with nuclease knockout oligos were plated on 
non-selective LB Lennox media, and several clones were isolated and analyzed as described 
below. 
Allele-specific colony PCR (ascPCR) or multiplex allele-specific colony PCR 
(mascPCR)
20,21
 was used to detect the 1-2 bp mutations generated in the inactivation of 
endogenous nucleases, and in the recombination of the lacZ::kanR cassette with mutations 
encoded in its homology arms.  In these experiments, two PCRs are performed for each tested 
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clone – one with a forward primer designed to hybridize to the wild type sequence at a locus 
targeted by a recombineering cassette, and one with a forward primer designed to hybridize to 
the mutated sequence conferred by the recombineering cassette.  The same reverse primer is used 
in both reactions.  If the mutant detecting PCR gives an amplification band but the wild type 
detecting PCR does not, the clone is scored as a recombinant.  In mascPCR, primer sets for 
interrogating several wild type or several mutant loci are combined in a single reaction, and each 
amplicon is designed to have a different size ranging from 100 bp to 850 bp.   
Singleplex ascPCR reactions (used to determine whether a given nuclease had been 
inactivated) were performed with Kapa 2GFast HotStart ReadyMix including 10X Kapa dye.  
PCRs had a total volume of 20 µL, with 0.5 µM of each primer, and a template of 1 µL of 
stationary phase culture derived from a given clone.  These PCRs were carried out with an initial 
activation step at 95 °C for 2 min, then cycled 30 times with a denaturation temperature of 95 °C 
(15 sec), an annealing temperature of 63-67 °C (15 sec; temperature as optimized for a given pair 
of ascPCR reactions), an extension temperature of 72 °C (40 sec), and a final extension at 72 °C 
for 90 sec.   
Multiplex allele-specific colony PCR (mascPCR) was used to detect the two mutations 
encoded in the homology arms of the lacZ::kanR cassette, and to simultaneously genotype 
several nuclease knockout mutations.  To this end, monoclonal colonies were grown to stationary 
phase under proper antibiotic selection, and PCR template was prepared by diluting 2 µL of 
culture into 100 µL of H2O.  These mascPCRs used Kapa 2GFast Multiplex PCR ReadyMix 
with 10X Kapa dye, and had a total volume of 10 µL, with 0.2 µM of each primer and 2 µL of 
template.  PCRs were carried out with an initial activation step at 95 °C for 3 min, then cycled 26 
times with a denaturation temperature of 95 °C (15 sec), an annealing temperature of 63-67 °C 
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(30 sec; temperature as optimized for a given pair of mascPCR reactions), an extension 
temperature of 72 °C (1 min), and a final extension at 72 °C for 5 min.  All ascPCRs and 
mascPCRs were analyzed on 1.5% agarose/EtBr gels (180 V, 60 min).   
We repeated recombination experiments with the mutation-encoding lacZ::kanR cassette 
twice for EcNR2 and EcNR2.xseA
-
.  In each experiment, 96 individual colonies were genotyped 
for both strains.  Only monoclonal and unambiguous mascPCR results were counted towards the 
final analysis presented here.  5′ and 3′ mutation inheritance data points were separately 
combined and analyzed for statistically significant differences between strains using the Mann-
Whitney U-test with significance defined as p < 0.05.    
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Chapter Four  
 
 
Studying and Improving Lambda Red Oligonucleotide 
Recombination via Phosphorothioate Placement and Nuclease 
Removal 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from a portion of the following published paper: 
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*
, Lajoie, M.J.
*
, Wang, H.H. & Church, G.M. Improving lambda red 
genome engineering in Escherichia coli via rational removal of endogenous nucleases. PLoS One 
7, e44638 (2012) 
*
Indicates co-first authorship 
 
 
 
 
 
 
 
 
 
 
 
 
Research contributions are as follows: 
 
J. Mosberg and M. Lajoie jointly came up with the idea for using nuclease removal to improve 
MAGE performance.  J. Mosberg, C. Gregg, M. Lajoie, and G. Church designed the experiments 
and interpreted their results.  J. Mosberg, C. Gregg, and M. Lajoie performed the experiments.  J. 
Mosberg wrote a majority of this portion of the published paper, with additional writing and 
editing contributions from C. Gregg, M. Lajoie, and G. Church. 
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Introduction 
 As discussed in Chapter 1, the recent discovery
1
 that Lambda Red can simultaneously 
recombine multiple oligonucleotides has enabled several exciting new recombineering 
applications.  This strategy, called “Multiplex Automatable Genome Engineering” (MAGE),
1
 has 
been used to diversify and rapidly optimize the pathway coding for the biosynthesis of the small 
molecule lycopene,
1
 to engineer promoters,
2
 to simultaneously append hexa-histidine tag 
sequences onto a panel of genes,
3
 and to change all E. coli amber (TAG) stop codons into ochre 
(TAA) stop codons.
4
  However, despite the considerable power of this method, only a limited 
number of simultaneous mutations can reliably be generated in a given cycle of MAGE.
4
  This 
has recently been improved by the development of co-selection MAGE (CoS-MAGE),
5
 in which 
an oligo is directed to repair a defective selectable marker in the vicinity of the other targeted 
loci.  Subsequent selection for the repaired marker significantly increases recombination 
frequencies.  While CoS-MAGE represents the state of the art prior to the work described in this 
chapter and Chapter 5, it nevertheless yields only about 1 oligonucleotide recombined per 
average cell in a given cycle.
6
  This limitation constrains the degree of diversity that can be 
generated, as well as the extent to which a genome can feasibly be reengineered.  By improving 
allele conversion frequencies in CoS-MAGE, we hope to develop this methodology into an even 
more powerful tool for ambitious diversification and genome engineering projects. 
 In Chapter 3, we showed that endogenous nucleases limit the frequency of dsDNA 
recombination.  By protecting cassettes with phosphorothioate (PT) bonds and/or removing the 
nuclease ExoVII, we were able to improve dsDNA recombination frequency.  Several lines of 
evidence suggest that these approaches could be similarly useful for improving the performance 
of CoS-MAGE.  For one, it has been shown that the singleplex recombination frequency of 
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oligos can also be improved by protection with PT bonds,
1
 and that mutations encoded near the 
ends of an oligo are inherited less frequently than mutations encoded closer to the center.
7
  Both 
of these results strongly imply exonuclease degradation of oligonucleotides.  Secondly, ExoVII – 
the exonuclease which we identified to degrade the ends of dsDNA recombineering cassettes – is 
reportedly highly specific for ssDNA substrates.
8
  Thus, it may degrade recombineering oligos 
even more readily than dsDNA, and removing ExoVII may therefore substantially improve oligo 
recombination frequencies.  Furthermore, it has been shown that while oligo-mediated 
recombination can occur in E. coli cells lacking Lambda Red, this recombination is severely 
limited by endogenous nucleases.
9
  Removing four potent ssDNA exonucleases improved the 
efficiency of this process by nearly 1000-fold, demonstrating that exonuclease degradation 
strongly hinders oligonucleotide recombination in this context.
9
  It has more recently been shown 
that this also holds true for Lambda Red singleplex oligo recombination, although only when low 
concentrations of oligos are used.
10
  However, because MAGE involves the simultaneous 
introduction of several different oligos, we hypothesize that the resulting intracellular 
concentration of any given oligo is low.  Therefore, removing endogenous exonucleases may 
have a beneficial effect, even when normal oligo concentrations are used. 
 In this chapter, we show that removing ExoVII improves the inheritance of mutations 
encoded on the 3′ ends of oligonucleotides, and slightly increases CoS-MAGE frequencies.  We 
then extend this approach to show that removing a set of five exonucleases (RecJ, ExoI, ExoVII, 
ExoX, and Lambda Exo) further improves the performance of CoS-MAGE.  In a given round of 
CoS-MAGE with ten ssDNA oligonucleotides, this “nuc5
-
” strain yields on average 46% more 
alleles converted per clone, 200% more clones with five or more allele conversions, and 35% 
fewer clones without any allele conversions.  Finally, we use these nuclease knockout strains to 
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investigate and clarify the effects of oligonucleotide phosphorothioation on recombination 
frequency.  We show that PT bonds can be detrimental as well as beneficial, and that the net 
effect depends on the nuclease background of the recombineering strain.  The results described 
in this chapter provide further mechanistic insight into Lambda Red oligonucleotide 
recombination, and achieve substantial improvement of recombineering performance. 
 
Removal of ExoVII Improves Oligonucleotide Mutation Inheritance 
 In Chapter 3, we found that the removal of ExoVII improves the inheritance of mutations 
located on the ends of a dsDNA cassette.  Given that ExoVII degrades ssDNA preferentially to 
dsDNA,
8
 we sought to assess whether ExoVII removal also improves the inheritance of 
mutations located on the ends of an oligonucleotide.  Thus, we tested a 90mer oligo previously 
designed to disrupt the lacZ gene,
7
 with seven premature stop codons distributed along its 
sequence.  This oligo was protected with four PT bonds on each end.  This “lacZ.7.stop” oligo 
was recombined into three strains – EcNR2,
1
 EcNR2.xseA
-
,
6
 and nuc5
-
 (EcNR2.recJ,
-
xonA
-
,xseA
-
,exoX
-
,redα
-
), a strain with Lambda Exo inactivated in addition to all four of the potent ssDNA 
exonucleases removed in the aforementioned prior work.
9,10
  LacZ
-
 colonies were identified by 
IPTG/X-Gal screening, and the relevant portion of lacZ was amplified and sequenced.  From 
these sequences, it was determined which of the seven mutations were inherited in a given clone, 
and the total proportion of recombinants with each mutation was thereby calculated.   
The results shown in Figure 4.1 clearly demonstrate that nuc5
-
 and EcNR2.xseA
-
 facilitate 
the inheritance of 3′ mutations.  Nuc5
-
 clones inherited significantly more of the mutations 
encoded by the lacZ.7.stop oligo (4.94 ± 0.20, **p = 0.001, Figure 4.1A) compared to EcNR2 
(3.92 ± 0.22).  This was due to enhanced conferral of mutations at the 3′ end of the 90mer 
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oligonucleotide (Figure 4.1B).  Interestingly, removing ExoVII phenocopies the performance of 
nuc5
-
, leading to improved mean conversions (4.89 ± 0.18, **p = 0.0004, Figure 4.1A) compared 
to EcNR2, and no significant difference from nuc5
-
 (p = 0.8416).  Moreover, EcNR2.xseA
-
 also 
provides for significantly greater inheritance of mutations at the 3′ end of the 90mer 
oligonucleotide (Figure 4.1B).  Despite the dual polarity of ExoVII, its removal has no apparent 
effect on the inheritance of 5′ mutations, nor does the removal of the other four exonucleases 
inactivated in nuc5
-
.  This suggests that another unidentified nuclease may be responsible for 
degrading the 5′ ends of oligonucleotides.  Such degradation may be occurring postsynaptically, 
possibly mediated by the 5′-to-3′ exonuclease domain of polymerase I.
11
  The 3′ protection effect 
of the ExoVII knockout strain is equivalent to that observed for the nuc5
-
 strain, suggesting that 
ExoVII is the only one of the five removed exonucleases which compromises the inheritance of 
mutations along the length of phosphorothioated oligos.  Thus, the removal of ExoVII provides a 
simple solution for improving the conferral of mutations carried on the 3′ ends of oligos. 
 
Figure 4.1: Removal of ExoVII Improves Oligonucleotide Mutation Inheritance A 90mer lagging strand-
targeting oligonucleotide was designed to introduce 7 stop codons (placed at the +2, +23, +35, +49, +61, +73, +87 
base pair positions with respect to the 5′ end) into the lacZ gene.  This oligo was transformed into EcNR2, 
EcNR2.xseA
-
, and nuc5
-
 cells.  A) Average total number of stop codons introduced per clone for a given strain.  Data 
are presented as the mean with the standard error of the mean.  Both EcNR2.xseA
-
 (**p = 0.0004, n = 54) and nuc5
-
 
(**p = 0.001, n = 46) exhibit similar, statistically significant increases in total mutation inheritance compared to 
EcNR2 controls (n = 45).  “ns” = not significant.  B) A breakdown of each strain’s inheritance of each mutation.  
Both EcNR2.xseA
-
 and nuc5
-
 show similarly increased inheritance of 3′-located mutations, but no increased 
inheritance of 5′-located mutations.  No clones inherited the mutation encoded at position +2.   
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Figure 4.2: Orientation of the Tested Oligo 
Sets.  The E. coli MG1655 genome is represented 
with the origin (Ori) and terminus (Term) of 
replication indicated, thus splitting the genome 
into Replichore 1 (R1) and Replichore 2 (R2). 
The genomic regions targeted by of each of the 
three tested oligo sets are denoted in gray. Co-
selection marker (tolC, cat, and bla) positions for 
each oligo set are indicated by radial lines.  
 
Nuclease Knockouts Improve CoS-MAGE Performance 
Given our reasoning described in the chapter introduction, as well as our above 
observation that ExoVII degrades oligonucleotides and may hinder their ability to recombine, we 
next tested whether the removal of ExoVII could improve multiplex oligonucleotide 
recombination frequency.  To investigate this, we compared the MAGE performance of EcNR2 
and EcNR2.xseA
-
.  The nuc5
-
 strain discussed previously was also tested, in order to determine if 
other exonucleases impact MAGE performance; Lambda Exo was removed from this strain 
along with the four potent endogenous ssDNA exonucleases,
9
 as Lambda Exo has been shown
12
 
to have trace activity against ssDNA, and is not required for oligo recombination.  In these 
experiments, we used co-selection MAGE (CoS-MAGE)
5
 in order to determine whether the 
nuclease knockout strains are able to improve upon the current best practices for MAGE.  In 
CoS-MAGE, a co-selection oligo is directed to repair a mutated selectable marker near the loci 
targeted by the other recombineering oligos.
5
  
Selection for the repaired marker thereby enriches for 
cells with high levels of recombination in the targeted 
vicinity, and increases recombination frequencies 
significantly. 
We tested three different sets of 10 
recombineering oligos (each specifying a single 
TAGTAA mutation, as designed previously),
4
 so 
as to ascertain the CoS-MAGE performance of the 
strains at multiple loci, and in both replichores 
(Figure 4.2).  This was done in order to confirm the 
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Figure 4.3: Effect of Nuclease Removal on CoS-MAGE Performance.  CoS-MAGE was carried out in three 
strains (EcNR2, EcNR2.xseA
-
, and nuc5
-
), using three sets of ten oligos and a co-selection oligo, as shown in Figure 
4.2.  A) Set 1 was co-selected with cat, inserted at the mutS locus.  In comparison with EcNR2 (n = 319), both 
EcNR2.xseA
-
 (**p = 0.0001, n = 135) and nuc5
-
 (***p < 0.0001, n = 257) show statistically significant increases in 
mean allele conversions, decreased proportions of clones exhibiting no allele conversions, and more clones with 5+ 
conversions.  B) Set 2 was co-selected with bla, inserted with the Lambda prophage.  Here, nuc5
-
 (n = 142) shows a 
statistically significant increase in recombineering performance compared to both EcNR2 (***p < 0.0001, n = 268) 
and EcNR2.xseA
-
 (***p < 0.0001, n = 184).  C) Set 3 was co-selected with endogenous tolC.  Here, nuc5
-
 (n = 139) 
shows a statistically significant increase in mean allele conversion compared to EcNR2 (*p = 0.002, n = 327).  
EcNR2.xseA
-
 (n = 92) shows an intermediate phenotype between EcNR2 (p = 0.2) and nuc5
-
 (p = 0.3).  All oligos 
used in this experiment had two PT bonds on both ends.  Data shown in the right-hand panels are presented as the 
mean with the standard error of the mean.  Statistical significance is denoted as follows: ns indicates a non-significant 
variation, * indicates p < 0.003, ** indicates p < 0.001, and *** indicates p < 0.0001. 
 
robustness of the results, as oligo recombination frequency can vary due to largely unelucidated 
oligo-specific and locus-specific effects.
4
  Each of the three oligo sets was paired with a co-
selection oligonucleotide as described below.  All recombineering oligos had two PT bonds on 
each end, as had previously been optimized for MAGE.
4
  Targeted loci were screened by 
mascPCR
4,13
 in order to determine which alleles were converted in a given clone. 
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Results are shown in Figure 4.3.  For all three recombineering oligo sets (Sets 1-3 in 
Figure 4.3A-C, respectively), nuc5
-
 significantly outperformed EcNR2 (***p < 0.0001, ***p < 
0.0001, *p = 0.002, respectively).  An average of 46% more alleles were converted per clone in 
nuc5
-
, and the frequency of clones with 5 or more conversions was increased by 200%.  
Furthermore, nuc5
-
 reduced the frequency of clones with no conversions by 35%.  All of these 
recombination improvements are particularly important given that MAGE can be performed in 
iterative cycles, thereby compounding these enhancements.  Thus, removing all potent ssDNA 
exonucleases significantly improves the performance of CoS-MAGE.   
The EcNR2.xseA
-
 strain appears to have intermediate properties between those of EcNR2 
and nuc5
-
.  Although EcNR2.xseA
-
 demonstrated a statistically significant increase in CoS-
MAGE performance with Set 1 (1.47 ± 0.13) compared to EcNR2 (0.96 ± 0.07, **p = 0.0001), 
this strain’s performance with Sets 2 & 3 was not statistically different from that of EcNR2 (p = 
0.7 & 0.2).  Given that Set 1 also exhibited the largest difference in performance between EcNR2 
and nuc5
-
 (65% higher average allele conversion in nuc5
-
), it is possible that Set 1 is the most 
susceptible to nuclease repression; as such, the effect of removing ExoVII would be most 
apparent for this set.  Overall, nuc5
-
 was superior to EcNR2.xseA
-
 for the three tested oligo sets.  
This suggests that the action of ExoVII somewhat compromises CoS-MAGE frequency, but that 
some or all of the other exonucleases removed in nuc5
-
 also have roles in oligo degradation. 
 
Examining the Effect of Phosphorothioate Bonds on CoS-MAGE Frequency 
 As noted, the above experiments were performed with recombineering oligonucleotides 
with two PT bonds on each end.  We next sought to determine whether the optimal number of PT 
bonds was the same for each of our nuclease knockout strains, whether the benefits of nuclease 
88 
 
Figure 4.4: Effect of Phosphorothioate Bonds on CoS-MAGE Performance.  We assessed the effect of oligo 
phosphorothioation on the CoS-MAGE performance of the various nuclease knockout strains.  Variants of oligo Set 1 
with no PT bonds (0 PT) and four PT bonds on both ends (4 PT) were compared with the initial version of Set 1, 
which had two PT bonds on both ends (2 PT).  Recombination was performed with cat co-selection as prior.  A) For 
EcNR2, n = 133 (0 PT), n = 319 (2 PT), n = 186 (4 PT).  B) For EcNR2.xseA
-
, n = 94 (0 PT), n = 92 (2 PT), n = 86 (4 
PT).  C) For nuc5
-
, n = 132 (0 PT), n = 257 (2 PT), n = 183 (4 PT).  Data shown in the right-hand panels are 
presented as the mean with the standard error of the mean.  Statistical significance is as denoted in Figure 4.3. 
 
removal could be recapitulated simply by adding more PT bonds to the recombineering oligos, 
and whether the differences between the strains would be more pronounced if no PT bonds were 
used.  Thus, we recombined EcNR2 (Figure 4.4A), EcNR2.xseA
-
 (Figure 4.4B), and nuc5
-
 
(Figure 4.4C) with versions of recombineering oligo Set 1, co-selected with a restoration oligo 
for the nearby mutated cat gene.  A non-phosphorothioated version of oligo Set 1 was tested, as 
was a version with 4 PT bonds on each end.  The resulting allele conversion distributions were 
determined as above, and compared with those previously observed for the version of Set 1 with 
2 PT bonds on each end. 
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 The results are shown in Figure 4.4.  Notably, for all tested strains, the oligo set with 2 
PT bonds gave the greatest average number of allele conversions per clone.  Comparatively, 4 
PT bonds had a detrimental effect on recombination frequency that was most notable in nuc5
-
 
(Figure 4.4C), where the 2 PT set (1.58 ± 0.10) significantly outperformed the 4 PT set (1.09 ± 
0.11, *p = 0.001).  Similarly, for EcNR2.xseA
-
 (Figure 4.4B), the 2 PT set (1.47 ± 0.13) exhibited 
a local optimum compared to the 0 PT set (0.52 ± 0.08, ***p < 0.0001) and the 4 PT set (1.02 ± 
0.14, p = 0.03), corroborating the detrimental effect of too many PT bonds.  Thus, the 
EcNR2.xseA
-
 and nuc5
-
 strains confer recombineering advantages that cannot be recapitulated 
simply by preventing nuclease degradation through the use of more PT bonds.  The detrimental 
effect of high levels of phosphorothioation may be due to PT bonds decreasing the strength of 
the annealing interaction between the oligo and the lagging strand of the replication fork.
14
  
Alternatively, oligos with PT bonds may be somewhat toxic, thereby killing cells that take up a 
large number of oligos and would otherwise yield many converted alleles.   
The relative performance of the differently phosphorothioated oligo sets in the tested 
strains suggests that this detrimental effect of PT bonds is counterbalanced by the beneficial 
effect of nuclease protection.  In EcNR2 (Figure 4.4A), which has a full complement of 
endogenous nucleases, the 4 PT set (0.84 ± 0.08) greatly outperformed the 0 PT set (0.45 ± 0.08, 
**p = 0.0006), suggesting that the effect of nuclease protection outweighs the detrimental impact 
of PT bonds on recombination frequency.  Conversely, in nuc5
-
 (Figure 4.4C), where nuclease 
degradation is mitigated by knockouts, the 0 PT set (1.44 ± 0.12) slightly outperformed the 4 PT 
set (1.09 ± 0.11, p = 0.04), suggesting that the detrimental impact of the PT bonds outweighs any 
beneficial effect of nuclease protection.  Interestingly, in this strain, the 2 PT set (1.58 ± 0.10) is 
statistically equivalent to the 0 PT set (1.44 ± 0.12, p = 0.38), suggesting that most or all relevant 
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nuclease activity has been abrogated.  However, some level of residual exonuclease activity in 
nuc5
-
 is suggested by the strain’s poor inheritance of mutations encoded at the 5′ end of oligos 
(Figure 4.1B). 
When no PT bonds were used to protect the recombineering oligonucleotides, the nuc5
-
 
strain yielded roughly threefold more allele conversions per average clone than EcNR2.  This 
stands to reason, as non-PT oligos are likely to be particularly susceptible to the activity of 
endogenous ssDNA exonucleases.  Similarly, EcNR2.xseA
-
 also had low recombination 
frequency (roughly similar to that of EcNR2) when 0 PT oligos were used.  This suggests that 
exonucleases other than ExoVII (i.e., RecJ, ExoI, ExoX, and/or Lambda Exo) are readily capable 
of degrading non-protected oligos.  However, when PT bonds were used, EcNR2.xseA
-
 notably 
outperformed EcNR2, and was only slightly less recombinogenic than nuc5
-
 for such oligo sets.  
Thus, the exonuclease activity of ExoVII is relevant primarily for phosphorothioated 
oligonucleotides.  Taken together, these results reinforce the importance of using 
phosphorothioated oligos when performing MAGE in a strain containing endogenous nucleases, 
but caution that the overuse of phosphorothioates can be detrimental. 
 
Discussion 
The work described in this chapter adds to our understanding of Lambda Red 
oligonucleotide recombination.  We have shown that removing selected endogenous nucleases 
improves multiplex recombination frequency, despite the use of a high total concentration (5.2 
µM) of oligos.  This suggests that the intracellular concentration of any given oligo is not enough 
to overcome the action of endogenous nucleases, and therefore that oligo entry into the cell is a 
limiting factor in MAGE.  This observation initially appears to contradict the conclusion 
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presented in a recent study by Sawitzke et al.,
10
 which showed that the singleplex recombination 
frequency of a given oligonucleotide could be increased by the addition of non-specific carrier 
oligos.  These carrier oligos saturate endogenous exonucleases, preventing them from degrading 
the recombinogenic oligonucleotide.  However, this phenomenon was tested only for very low 
concentrations of the recombinogenic oligo (up to 0.01 µM).  Even at this concentration, adding 
carrier oligos (at 0.1 µM) yielded less than a 2-fold enhancement of recombination frequency; a 
more pronounced enhancement was observed only for even lower concentrations of 
recombinogenic oligo (0.001 µM and below).  In concentration regimes typical for MAGE (> 1 
µM total oligos), it has been shown that adding a second oligonucleotide decreases the 
recombination frequency of the first oligonucleotide.
5
  Presumably, at these concentrations 
(which have previously been shown to be optimal for recombination frequency
1
 and were 
therefore used in this work), any benefit conferred by the saturation of endogenous exonucleases 
is outweighed by competition for cellular entry.  These findings therefore suggest that enhancing 
oligo uptake is likely to be a fruitful avenue for further improving MAGE. 
Additionally, studying the consequences of different levels of oligonucleotide 
phosphorothioation in the EcNR2, EcNR2.xseA
-
, and nuc5
-
 strains enabled the deconvolution of 
the countervailing effects of phosphorothioation.  Phosphorothioate bonds can improve 
recombination frequency by protecting oligos from nuclease degradation, but can also diminish 
recombination frequency – possibly by reducing the strength of the annealing interaction 
between the oligo and the lagging strand of the replication fork,
14
 or by causing toxicity to the 
cell.  Placing two PT bonds on both ends of recombineering oligonucleotides was found to be 
optimal for all three strains tested in this work, but future nuclease-modified strains will need to 
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be optimized in order to determine the ideal number of PT bonds for oligos recombined into that 
strain. 
Beyond providing additional insight into the recombination process, this work also 
achieves several important improvements of oligonucleotide recombineering.  Firstly, removing 
ExoVII was shown to improve the inheritance of mutations at the 3′ ends of oligonucleotides.  
This may be quite useful, as it allows more mutations to reliably be introduced by a single oligo.  
This could be leveraged for several applications, such as simultaneously modifying several 
residues near the active site of a protein, recoding a larger region with a given oligonucleotide,
4
 
or modifying several genetic features (e.g., promoter strength, ribosome binding site strength, 
and the presence or absence of a premature stop codon) with a single oligo.  Similarly, the 
improvement of CoS-MAGE recombination frequency via the use of EcNR2.xseA
-
 and nuc5
-
 
will also have substantial utility.  These strains facilitate greater modification of a population of 
cells, which will be useful for projects that seek rapid genomic diversification.
1
  Such 
advancements are also expected to be useful for improving the Red-mediated diversification of 
BACs and plasmids.  Similarly, the enhanced recombination frequency of these strains means 
that fewer cycles will be needed in order to achieve an isogenic recoded population of cells, or to 
identify a strain with all desired genetic changes among a set of screened clones.  This will be 
highly useful for future genome engineering efforts. 
Finally, this work provides guidelines as to the appropriate strain to use for a given 
recombineering application.  It should be noted that the nuc5
-
 strain was observed to have poor 
regrowth after electroporation, taking roughly twice as long as EcNR2 or EcNR2.xseA
-
 to 
recover to confluence.  The pre-electroporation growth rate of nuc5
-
 was only slightly less than 
those of EcNR2 and EcNR2.xseA
-
 (~150 minutes vs. ~125 minutes to reach mid-logarithmic 
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growth phase from a 1:100 dilution of overnight culture), likely due to the ability of mutS 
removal to suppress the known cold-sensitive growth phenotype of recJ/xonA/xseA/exoX 
quadruple mutants.
15
  Therefore, while nuc5
-
 has somewhat better multiplex recombination 
frequency than EcNR2.xseA
-
, its poor regrowth properties cause each recombination cycle to 
take notably longer.  Thus, using EcNR2.xseA
-
 is likely optimal for applications in which 
multiple cycles are necessary; the nuc5
-
 strain may be preferable for applications in which a 
single cycle is sufficient and fast regrowth is not necessary.  Additionally, while quadruple 
mutants for recJ, xonA, xseA, and exoX have increased point mutation rates, this phenomenon is 
epistatic to mutS.
15
  Given that strains used for genome engineering are often mutS
-
, removing 
these nucleases (as in nuc5
-
) does not further exacerbate the mutator phenotype.  However, the 
combined removal of xonA, recJ, and exoX has been shown to increase rates of rearrangement 
mutations involving repetitive sequences,
16
 and therefore this strain should not be used for 
applications in which genomic stability is paramount.  Directed evolution and/or the restoration 
of selected nucleases may facilitate improved growth rates and genomic stability, without 
substantially compromising recombination frequency.  Indeed, we have recently conducted 
experiments on nuc5
-
 strains with either xonA or recJ reactivated.  Preliminary results suggest 
that both of these strains have post-electroporation recovery rates equivalent to those of EcNR2 
and EcNR2.xseA
-
, and CoS-MAGE recombination frequencies equivalent to that of nuc5
-
.  
Additionally, given that these strains have active RecJ or ExoI, they would not be expected to 
have increased rates of rearrangement mutations.  Thus, these strains may be ideal for 
recombineering. 
In conclusion, the work presented in this chapter increases our understanding of the 
oligonucleotide recombineering process, confirming that nuclease degradation limits 
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recombination frequency.  Additionally, our results indicate that oligo entry is a major limiting 
factor in recombination, and that phosphorothioate bonds can be detrimental as well as 
beneficial.  This work also yielded strains with markedly improved mutation inheritance and 
allele conversion frequency.  These strains will be highly useful as chassis in future 
recombineering efforts, and may enable new and powerful applications of Lambda Red 
technology. 
 
Experimental 
Oligonucleotides used in this Study 
A full list of oligonucleotides used in this study is given in Table 4.1.  For 
oligonucleotides described in this table, “wt-f” refers to a forward ascPCR/mascPCR primer used 
to detect a wild type allele, “mut-f” refers to a forward ascPCR/mascPCR primer used to detect a 
mutated allele, and “rev” refers to the reverse ascPCR/mascPCR primer used with both forward 
primers.  Oligonucleotides from the three tested TAGTAA recombineering sets are denoted 
“X.Y,” where X is the set that the oligo is from, and Y is the size of its corresponding mascPCR 
amplification band.  Asterisks represent phosphorothioate bonds between the two indicated 
nucleotides.  For oligo sequences denoted in the table with a §, variants with no PT bonds and 4 
PT bonds at each end were also used.  All oligonucleotides were ordered from Integrated DNA 
Technologies with standard purification and desalting. 
Table 4.1: Oligonucleotides used in Chapter 4 
Name Use
 
Sequence
 
ygaR Set 1.850 TAG  TAA 
§G*C*GAAGATCAGTAAAGATATAGAAGGTGGTATCCCT
GGCTATTAACAAGGTCAGGTTTTGATTCCATTCATTAAA
GATCCAGTAACAA*A*A 
yqaC Set 1.700 TAG  TAA 
§A*T*TAAAAATTATGATGGGTCCACGCGTGTCGGCGGTG
AGGCGTAACTTAATAAAGGTTGCTCTACCTATCAGCAGC
TCTACAATGAAT*T*C 
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Table 4.1 (Continued) 
gabT Set 1.600 TAG  TAA 
§T*C*ACCATTGAAGACGCTCAGATCCGTCAGGGTCTGGA
GATCATCAGCCAGTGTTTTGATGAGGCGAAGCAGTAACG
CCGCTCCTATGC*C*G 
ygaU Set 1.500 TAG  TAA 
§T*G*ACGCCAATTCCCATTATCCAGCAGGCGATGGCTGG
CAATTAATTACTCTTCCGGAATACGCAACACTTGCCCCG
GATAAATTTTAT*C*C 
ygaM Set 1.400 TAG  TAA 
§G*T*AGGTATTTTTATCGGCGCACTGTTAAGCATGCGCA
AATCGTAATGCAAAAATGATAATAAATACGCGTCTTTGA
CCCCGAAGCCTG*T*C 
luxS Set 1.300 TAG  TAA 
§T*T*TGAACTGGCTTTTTTCAATTAATTGTGAAGATAGTT
TACTGATTAGATGTGCAGTTCCTGCAACTTCTCTTTCGGC
AGTGCCAGTT*C*T 
mltB Set 1.250 TAG  TAA 
§A*A*TTTTACGAGGAGGATTCAGAAAAAAGCTGATTAG
CCAGAGGGAAGCTCACGCCCCCCTCTTGTAAATAGTTAC
TGTACTCGCGCCA*G*C 
srlE Set 1.200 TAG  TAA 
§A*C*TGTACTGATCGCCTGGTTTGTCTCCGGTTTTATCTA
TCAATAAAGGCTGAAACATGACCGTTATTTATCAGACCA
CCATCACCCGT*A*T 
norW Set 1.150 TAG  TAA 
§A*T*CGGATGAAAGAGGCATTTGGATTGTTGAAAACATT
GCCGATGTAAGTGGGCTACTGTGCCTAAAATGTCGGATG
CGACGCTGGCGC*G*T 
ascB Set 1.100 TAG  TAA 
§A*T*CATTCTGGTGGTATAAAAAAGTGATTGCCAGTAAT
GGGGAAGATTTAGAGTAAGTAACAGTGCCGGATGCGGC
GTGAACGCCTTAT*C*C 
bioD Set 2.850 TAG  TAA 
T*C*GAAGACGCGATCTCGCTCGCAATTTAACCAAATAC
AGAATGGTTACAACAAGGCAAGGTTTATGTACTTTCCGG
TTGCCGCATTTT*C*T 
moaE Set 2.700 TAG  TAA 
C*G*TAAACGTATGTACTGAGCGGTGAAATTGCCGGACG
CAGCGGTGCCTTATCCGGCTAACAAAAAATTACCAGCGT
TTTGCCGCCTGC*T*G 
ybhM Set 2.600 TAG  TAA 
G*C*GATGTGAAGTTTAGTTAAGTTCTTTAGTATGTGCAT
TTACGGTTAATGAAAAAAACGCGTATGCCTTTGCCAGAC
AAGCGTTATAG*C*T 
ybhS Set 2.500 TAG  TAA 
T*T*TATCGGCCTGACGTGGCTGAAAACCAAACGTCGGC
TGGATTAAGGAGAAGAGCATGTTTCATCGCTTATGGACG
TTAATCCGCAAA*G*A 
ybiH Set 2.400 TAG  TAA 
C*A*TATCGACCTGATTTTGCAAGGATTATCGCAAAGGA
GTTTGTAATGATGAAAAAACCTGTCGTGATCGGATTGGC
GGTAGTGGTACT*T*G 
ybiR Set 2.300 TAG  TAA 
T*C*TGAATTAATCTTCAAAACTTAAAGCAAAAGGCGGA
CTCATAATCCGCCTTTTTTATTTGCCAGACCTTAGTTGGC
CGGGAGTATAA*C*T 
yliD Set 2.250 TAG  TAA 
T*T*TCCTGTGAGGTGATTACCCTTTCAAGCAATATTCAA
ACGTAATTATCCTTTAATTTTCGGATCCAGCGCATCGCGT
AAACCATCGC*C*C 
yliE Set 2.200 TAG  TAA 
G*A*CTGACTGTAAGTACGAACTTATTGATTCTGGACATA
CGTAAATTACTCTTTTACTAATTTTCCACTTTTATCCCAG
GCGGAGAATG*G*C 
ybjK Set 2.150 TAG  TAA 
T*C*GGTTCAAGGTTGATGGGTTTTTTGTTATCTAAAACT
TATCTATTACCCTGCAACCCTCTCAACCATCCTCAAAATC
TCCTCGCGCG*A*T 
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Table 4.1 (Continued) 
rimK Set 2.100 TAG  TAA 
C*G*CAAAAAGCGCAGGCAAAACCATGATCAGTAATGTG
ATTGCGATTAACCACCCGTTTTCAGGCAATATTCTGTCGT
AGCGTGGCGTT*C*G 
ygfJ Set 3.850 TAG  TAA 
C*C*GGACGACTTTATTACAGCGAAGGAAAGGTATACTG
AAATTTAAAAAACGTAGTTAAACGATTGCGTTCAAATAT
TTAATCCTTCCG*G*C 
recJ Set 3.700 TAG  TAA 
G*G*GATTGTACCCAATCCACGCTCTTTTTTATAGAGAAG
ATGACGTTAAATTGGCCAGATATTGTCGATGATAATTTG
CAGGCTGCGGT*T*G 
argO Set 3.600 TAG  TAA 
C*T*CTGGAGGCAAGCTTAGCGCCTCTGTTTTATTTTTCC
ATCAGATAGCGCTTAACTGAACAAGGCTTGTGCATGAGC
AATACCGTCTC*T*C 
yggU Set 3.500 TAG  TAA 
A*A*TCCGCAACAAATCCCGCCAGAAATCGCGGCGTTAA
TTAATTAAGTATCCTATGCAAAAAGTTGTCCTCGCAACC
GGCAATGTCGGT*A*A 
mutY Set 3.400 TAG  TAA 
G*T*GGAGCGTTTGTTACAGCAGTTACGCACTGGCGCGC
CGGTTTAACGCGTGAGTCGATAAAGAGGATGATTTATGA
GCAGAACGATTT*T*T 
glcC Set 3.300 TAG  TAA 
G*C*CACCATTTGATTCGCTCGGCGGTGCCGCTGGAGATG
AACCTGAGTTAACTGGTATTAAATCTGCTTTTCATACAAT
CGGTAACGCT*T*G 
yghQ Set 3.250 TAG  TAA 
A*C*TGAGTCAGCCGAGAAGAATTTCCCCGCTTATTCGCA
CCTTCCTTAAATCAGGTCATACGCTTCGAGATACTTAAC
GCCAAACACCA*G*C 
yghT Set 3.200 TAG  TAA 
T*G*GTTGATGCAGAAAAAGCGATTACGGATTTTATGAC
CGCGCGTGGTTATCACTAATCAAAAATGGAAATGCCCGA
TCGCCAGGACCG*G*G 
ygiZ Set 3.150 TAG  TAA 
T*T*CTCTGTCTATGAGAGCCGTTAAAACGACTCTCATAG
ATTTTATTAATAGCAAAATATAAACCGTCCCCAAAAAAG
CCACCAACCAC*A*A 
yqiB Set 3.100 TAG  TAA 
A*G*GGTTAACAGGCTTTCCAAATGGTGTCCTTAGGTTTC
ACGACGTTAATAAACCGGAATCGCCATCGCTCCATGTGC
TAAACAGTATC*G*C 
ygaR_wt-f Set 1.850_wt-f mascPCR AAGGTGGTATCCCTGGCTATTAG 
yqaC_wt-f Set 1.700_wt-f mascPCR CGGCGGTGAGGCGTAG 
gabT_wt-f Set 1.600_wt-f mascPCR TTTTGATGAGGCGAAGCAGTAG 
ygaU_wt-f Set 1.500_wt-f mascPCR GTTGCGTATTCCGGAAGAGTAG 
ygaM_wt-f Set 1.400_wt-f mascPCR GTTAAGCATGCGCAAATCGTAG 
luxS_wt-f Set 1.300_wt-f mascPCR GTTGCAGGAACTGCACATCTAG 
mltB_wt-f Set 1.250_wt-f mascPCR GCTGGCGCGAGTACAGTAG 
srlE_wt-f Set 1.200_wt-f mascPCR GGTTTGTCTCCGGTTTTATCTATCAATAG 
norW_wt-f Set 1.150_wt-f mascPCR GATTGTTGAAAACATTGCCGATGTAG 
ascB_wt-f Set 1.100_wt-f mascPCR CCAGTAATGGGGAAGATTTAGAGTAG 
bioD_wt-f Set 2.850_wt-f mascPCR AGTACATAAACCTTGCCTTGTTGTAG 
moaE_wt-f Set 2.700_wt-f mascPCR GCGGCAAAACGCTGGTAG 
ybhM_wt-f Set 2.600_wt-f mascPCR AAGGCATACGCGTTTTTTTCATTAG 
ybhS_wt-f Set 2.500_wt-f mascPCR CCAAACGTCGGCTGGATTAG 
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Table 4.1 (Continued) 
ybiH_wt-f Set 2.400_wt-f mascPCR AAGGATTATCGCAAAGGAGTTTGTAG 
ybiR_wt-f Set 2.300_wt-f mascPCR TTAGTTATACTCCCGGCCAACTAG 
yliD_wt-f Set 2.250_wt-f mascPCR CGCTGGATCCGAAAATTAAAGGATAG 
yliE_wt-f Set 2.200_wt-f mascPCR TGGGATAAAAGTGGAAAATTAGTAAAAGAGTAG 
ybjK_wt-f Set 2.150_wt-f mascPCR TTGAGAGGGTTGCAGGGTAG 
rimK_wt-f Set 2.100_wt-f mascPCR GCCTGAAAACGGGTGGTTAG 
ygfJ_wt-f Set 3.850_wt-f mascPCR AGCGAAGGAAAGGTATACTGAAATTTAG 
recJ_wt-f Set 3.700_wt-f mascPCR TCATCGACAATATCTGGCCAATTTAG 
argO_wt-f Set 3.600_wt-f mascPCR TGCACAAGCCTTGTTCAGTTAG 
yggU_wt-f Set 3.500_wt-f mascPCR CAGAAATCGCGGCGTTAATTAATTAG 
mutY_wt-f Set 3.400_wt-f mascPCR GGCGCGCCGGTTTAG 
glcC_wt-f Set 3.300_wt-f mascPCR GCTGGAGATGAACCTGAGTTAG 
yghQ_wt-f Set 3.250_wt-f mascPCR CTCGAAGCGTATGACCTGATTTAG 
yghT_wt-f Set 3.200_wt-f mascPCR CGCGCGTGGTTATCACTAG 
ygiZ_wt-f Set 3.150_wt-f mascPCR TGGGGACGGTTTATATTTTGCTATTAG 
yqiB_wt-f Set 3.100_wt-f mascPCR CGATGGCGATTCCGGTTTATTAG 
ygaR_mut-f Set 1.850_mut-f mascPCR AAGGTGGTATCCCTGGCTATTAA 
yqaC_mut-f Set 1.700_mut-f mascPCR CGGCGGTGAGGCGTAA 
gabT_mut-f Set 1.600_mut-f mascPCR TTTTGATGAGGCGAAGCAGTAA 
ygaU_mut-f Set 1.500_mut-f mascPCR GTTGCGTATTCCGGAAGAGTAA 
ygaM_mut-f Set 1.400_mut-f mascPCR GTTAAGCATGCGCAAATCGTAA 
luxS_mut-f Set 1.300_mut-f mascPCR GTTGCAGGAACTGCACATCTAA 
mltB_mut-f Set 1.250_mut-f mascPCR GCTGGCGCGAGTACAGTAA 
srlE_mut-f Set 1.200_mut-f mascPCR GGTTTGTCTCCGGTTTTATCTATCAATAA 
norW_mut-f Set 1.150_mut-f mascPCR GATTGTTGAAAACATTGCCGATGTAA 
ascB_mut-f Set 1.100_mut-f mascPCR CCAGTAATGGGGAAGATTTAGAGTAA 
bioD_mut-f Set 2.850_mut-f mascPCR AGTACATAAACCTTGCCTTGTTGTAA 
moaE_mut-f Set 2.700_mut-f mascPCR GCGGCAAAACGCTGGTAA 
ybhM_mut-f Set 2.600_mut-f mascPCR AAGGCATACGCGTTTTTTTCATTAA 
ybhS_mut-f Set 2.500_mut-f mascPCR CCAAACGTCGGCTGGATTAA 
ybiH_mut-f Set 2.400_mut-f mascPCR AAGGATTATCGCAAAGGAGTTTGTAA 
ybiR_mut-f Set 2.300_mut-f mascPCR TTAGTTATACTCCCGGCCAACTAA 
yliD_mut-f Set 2.250_mut-f mascPCR CGCTGGATCCGAAAATTAAAGGATAA 
yliE_mut-f Set 2.200_mut-f mascPCR TGGGATAAAAGTGGAAAATTAGTAAAAGAGTAA 
ybjK_mut-f Set 2.150_mut-f mascPCR TTGAGAGGGTTGCAGGGTAA 
rimK_mut-f Set 2.100_mut-f mascPCR GCCTGAAAACGGGTGGTTAA 
ygfJ_mut-f Set 3.850_mut-f mascPCR AGCGAAGGAAAGGTATACTGAAATTTAA 
recJ_mut-f Set 3.700_mut-f mascPCR TCATCGACAATATCTGGCCAATTTAA 
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Table 4.1 (Continued) 
argO_mut-f Set 3.600_mut-f mascPCR TGCACAAGCCTTGTTCAGTTAA 
yggU_mut-f Set 3.500_mut-f mascPCR CAGAAATCGCGGCGTTAATTAATTAA 
mutY_mut-f Set 3.400_mut-f mascPCR GGCGCGCCGGTTTAA 
glcC_mut-f Set 3.300_mut-f mascPCR GCTGGAGATGAACCTGAGTTAA 
yghQ_mut-f Set 3.250_mut-f mascPCR CTCGAAGCGTATGACCTGATTTAA 
yghT_mut-f Set 3.200_mut-f mascPCR CGCGCGTGGTTATCACTAA 
ygiZ_mut-f Set 3.150_mut-f mascPCR TGGGGACGGTTTATATTTTGCTATTAA 
yqiB_mut-f Set 3.100_mut-f mascPCR CGATGGCGATTCCGGTTTATTAA 
ygaR_rev Set 1.850_rev mascPCR TAGGTAGAGCAACCTTTATTAAGCTACG 
yqaC_rev Set 1.700_rev mascPCR TAAAAATATCTACATTTCTGAAAAATGCGCA 
gabT_rev Set 1.600_rev mascPCR GCGGCGATGTTGGCTT 
ygaU_rev Set 1.500_rev mascPCR AGGGTATCGGGTGGCG 
ygaM_rev Set 1.400_rev mascPCR CGCAACGCTTCTGCCG 
luxS_rev Set 1.300_rev mascPCR ATGCCCAGGCGATGTACA 
mltB_rev Set 1.250_rev mascPCR AGACTCGGCAGTTGTTACGG 
srlE_rev Set 1.200_rev mascPCR GGATGGAGTGCACCTTTCAAC 
norW_rev Set 1.150_rev mascPCR GTGTTGCATTTGGACACCATTG 
ascB_rev Set 1.100_rev mascPCR CGCTTATCGGGCCTTCATG 
bioD_rev Set 2.850_rev mascPCR CGGGAAGAACTCTTTCATTTCGC 
moaE_rev Set 2.700_rev mascPCR CGTCAATCCGACAAAGACAATCA 
ybhM_rev Set 2.600_rev mascPCR TTACTGGCAGGGATTATCTTTACCG 
ybhS_rev Set 2.500_rev mascPCR CTGTTGTTAGGTTTCGGTTTTCCT 
ybiH_rev Set 2.400_rev mascPCR GTCATAGGCGGCTTGCG 
ybiR_rev Set 2.300_rev mascPCR ATGAGCCGGTAAAAGCGAC 
yliD_rev Set 2.250_rev mascPCR AATAAAATTATCAGCCTTATCTTTATCTTTTCGTATAAA 
yliE_rev Set 2.200_rev mascPCR CAGCAATATTTGCCACCGCA 
ybjK_rev Set 2.150_rev mascPCR AACTTTTCCGCAGGGCATC 
rimK_rev Set 2.100_rev mascPCR TACAACCTCTTTCGATAAAAAGACCG 
ygfJ_rev Set 3.850_rev mascPCR GATGAACTGTTGCATCGGCG 
recJ_rev Set 3.700_rev mascPCR CTGTACGCAGCCAGCC 
argO_rev Set 3.600_rev mascPCR AATCGCTGCCTTACGCG 
yggU_rev Set 3.500_rev mascPCR TAACCAAAGCCACCAGTGC 
mutY_rev Set 3.400_rev mascPCR CGCGAGATATTTTTTCATCATTCCG 
glcC_rev Set 3.300_rev mascPCR GGGCAAAATTGCTGTGGC 
yghQ_rev Set 3.250_rev mascPCR ACCAACTGGCGATGTTATTCAC 
yghT_rev Set 3.200_rev mascPCR GACGATGGTGGTGGACGG 
ygiZ_rev Set 3.150_rev mascPCR ATCGCCAAATTGCATGGCA 
yqiB_rev Set 3.100_rev mascPCR AAAATCCTGACTCTGGCCTCA 
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Table 4.1 (Continued) 
Lexo.KO.MM* Lambda Exo inactivating oligo 
T*G*A*A*ACAGAAAGCCGCAGAGCAGAAGGTGGCAGCA
TGACACCGTAACATTATCCTGCAGCGTACCGGGATCGAT
GTGAGAGCTGTCGAAC 
Lexo_WT-f 
Lambda Exo wt-f mascPCR 
primer 
GGCAGCATGACACCGGA 
Lexo_MUT-f 
Lambda Exo mut-f mascPCR 
primer 
TGGCAGCATGACACCGTAA 
Lexo-r 
Lambda Exo rev mascPCR 
primer 
CAAGGCCGTTGCCGTC 
cat_mut* cat inactivation oligo 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTG
CTTAATGTACCTATAACCAGACCGTTCAGCTGGATATTA
CGGCCTTTTTA*A*A  
cat_restore* 
cat reactivation oligo (for 
coselection) 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTCAGTTG
CTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTA
CGGCCTTTTTA*A*A 
tolC-
r_null_mut* 
tolC inactivation oligo 
A*G*CAAGCACGCCTTAGTAACCCGGAATTGCGTAAGTC
TGCCGCTAAATCGTGATGCTGCCTTTGAAAAAATTAATG
AAGCGCGCAGTCCA 
tolC-
r_null_revert* 
tolC reactivation oligo (for 
coselection) 
C*A*GCAAGCACGCCTTAGTAACCCGGAATTGCGTAAGT
CTGCCGCCGATCGTGATGCTGCCTTTGAAAAAATTAATG
AAGCGCGCAGTCCA 
bla_mut* bla inactivation oligo 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATCATTGG
AAAACGTTATTAGGGGCGAAAACTCTCAAGGATCTTACC
GCTGTTGAGATCCAG 
bla_restore* 
bla reactivation oligo (for 
coselection) 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATCATTGG
AAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACC
GCTGTTGAGATCCAG 
lacZ.seq-f  
Forward primer for 
amplifying/sequencing lacZ 
CGCAATTAATGTGAGTTAGCTCACTC 
lacZ.seq-2-r  
Reverse primer for 
amplifying/sequencing lacZ 
CGCCGAGTTAACGCCATCAA 
LacZ7Stop.PT 
Oligo for disrupting lacZ gene 
w/7 stop codons 
T*A*G*C*GCAGCCTGAATGGCGAATAGCGCTTTGCCTAG
TTTCCGGCACCATAAGCGGTGCCGTAAAGCTGGCTGTAG
TGCGATCTTCC*T*T*A*G 
 
Strain Creation 
 Strains were created as described in Chapter 3.  The nuc5
-
 strain was generated from the 
nuc4
-
 strain, using the recombineering oligonucleotide denoted in Table 4.1 to inactivate Lambda 
Exo.  Strains used for CoS-MAGE were generated by recombining an oligonucleotide designed 
to inactivate a chromosomal resistance marker (cat, tolC, or bla) and identifying resulting 
colonies with the appropriate sensitivity to antibiotic or SDS.
17
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Performing Lambda Red Recombination 
 Lambda Red recombination was performed as described in Chapter 3.  For the 
lacZ.7.stop experiment, in which a single oligonucleotide was recombined, 1 µM of oligo was 
used.  For experiments in which sets of ten recombineering oligos were recombined along with a 
co-selection oligo, 0.5 µM of each recombineering oligo was used, along with 0.2 µM of the co-
selection oligo (5.2 µM total).  CoS-MAGE recovery cultures were regrown for 5 or more hours 
at 30 °C, so as to eliminate polyclonal colonies. 
 
Analyzing Recombination 
CoS-MAGE recovery cultures were plated on media selective for the co-selected 
resistance marker (LB Lennox agar plates with 50 µg/mL carbenicillin for bla, 20 µg/mL 
chloramphenicol for cat, or 0.005% SDS for tolC, with 20 µg/mL chloramphenicol added to 
enhance the robustness of selection).  Targeted loci in the resulting clones were screened by 
mascPCR (as described in Chapter 3) using Kapa 2GFast Multiplex PCR ReadyMix with 10X 
Kapa dye.  Monoclonal colonies were grown to stationary phase under proper antibiotic 
selection, and PCR template was prepared by diluting 2 µL of culture into 100 µL of H2O.  
These mascPCR reactions had a total volume of 10 µL, with 0.2 µM of each primer and 2 µL of 
template.  PCRs were carried out with an initial activation step at 95 °C for 3 min, then cycled 26 
times with a denaturation temperature of 95 °C (15 sec), an annealing temperature of 63-67 °C 
(30 sec; temperature as optimized for a given pair of mascPCR reactions), an extension 
temperature of 72 °C (1 min), and a final extension at 72 °C for 5 min.  All mascPCRs were 
analyzed on 1.5% agarose/EtBr gels (180 V, 60 min).   
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In CoS-MAGE experiments, all strains were recombined with all oligo sets at least twice.  
Replicates were combined to generate a complete data set for each strain’s performance with 
each set of oligos.  At least 96 total colonies were genotyped for each strain tested with each 
recombineering oligo set.  Only monoclonal and unambiguous mascPCR results were counted 
toward the final analysis presented here.  Given the large sample sizes tested (n > 85), we used 
parametric one way ANOVA to test for significant variance in the CoS-MAGE performance of 
the strains (EcNR2, EcNR2.xseA
-
, nuc5
-
) for a given oligo set.
18
  Subsequently, we used a 
Student’s t-test to make pairwise comparisons, with significance defined as p < 0.05/n, where n 
is the number of pairwise comparisons.  Here, n = 15, as these data were planned and collected 
as part of a larger set with 6 different strains (the remainder are discussed in Chapter 5), although 
only the results for EcNR2, EcNR2.xseA
-
, and nuc5
-
 are presented here.  As such, significance 
was defined as p < 0.003 for the analyses presented in Figures 4.3 and 4.4.  Statistical 
significance in Figures 4.3 and 4.4 is denoted using a system where * denotes p < 0.003, ** 
denotes p < 0.001, and *** denotes p < 0.0001.  For the experiment in which oligo sets were 
tested with 0, 2, or 4 PT bonds on both ends, comparisons were made between EcNR2, 
EcNR2.xseA
-
, and nuc5
-
 (the only three tested strains in this experiment) for each of the three 
differently phosphorothioated oligo sets, separately.  Additionally, comparisons were made 
between each oligo set for each of the three strains, also separately.  Thus, 15 pairwise 
comparisons were performed, and significance thresholds are as above. 
For the experiment in which a lacZ-inactivating oligo with 7 stop codons (lacZ.7.stop) 
was recombined, recombinants were identified as white colonies on plates containing Fisher 
ChromoMax IPTG/X-Gal solution, and recombination frequencies (# of white colonies / # of 
total colonies) were determined for every replicate.  For the white colonies, the relevant portion 
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of the lacZ gene was amplified with primers lacZ.seq-f and lacZ.seq-2-r (Table 4.1) at 0.5 µM, 
using Kapa HiFi HotStart ReadyMix.  PCRs were heat activated at 95 °C for 5 min, then cycled 
30 times with a denaturation temperature of 98 °C (20 sec), an annealing temperature of 62 °C 
(15 sec), and an extension temperature of 72 °C (45 sec).  PCRs were brought to 72 °C for 5 min, 
and then held at 4 °C.  Samples were then purified with the Qiagen PCR purification kit and 
quantitated on a NanoDrop ND1000 spectrophotometer.  Purified DNA was submitted to 
Genewiz for Sanger sequencing (40 ng DNA, with 25 pmol of either lacZ.seq-f or lacZ.seq-2-r 
primer).  Good quality sequence pairs were stitched together using SeqMan (Lasergene 
DNAstar) and exported as FASTA sequences.  These sequences were then analyzed for their 
genotypes at the loci where the lacZ.7.stop oligo could impart inheritance of mutations.  
Recombinations and recombination frequency counts were repeated thrice so as to ensure 
consistency, but sequencing was only performed on one biological replicate.  Mean allele 
conversion metrics were generated from the sequencing data by scoring each mutation locus as 1 
for a mutant sequence or 0 for a wild type sequence.  We tested for statistically significant 
variance in mean allele conversions using a parametric one way ANOVA.  Subsequently, we 
used a Student’s t-test to make pairwise comparisons, with significance defined as p < 0.05 / 3, 
i.e., p < 0.01.  Statistical significance in Figure 4.1A is denoted using a system where * denotes p 
< 0.01, ** denotes p < 0.001, and *** denotes p < 0.0001. 
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Chapter Five  
 
 
Improving Lambda Red Oligonucleotide Recombination via 
Primase Modification 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is adapted from the following published paper: 
 
Lajoie, M.J.*, Gregg, C.J.*, Mosberg, J.A.*, Washington, G.C. & Church, G.M. Manipulating 
replisome dynamics to enhance lambda Red-mediated multiplex genome engineering. Nucleic 
Acids Res 40, e170 (2012). 
*
Indicates co-first authorship 
 
 
 
 
 
 
 
 
 
 
 
 
Research contributions are as follows: 
 
M. Lajoie came up with the idea for using primase modification to improve MAGE performance.  
M. Lajoie, J. Mosberg, C. Gregg, and G. Church designed the experiments and interpreted their 
results.  M. Lajoie, C. Gregg, J. Mosberg, and G. Washington performed the experiments.  M. 
Lajoie wrote a majority of the published paper, with sections written by J. Mosberg and C. 
Gregg, and additional writing and editing contributions from G. Church. 
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Introduction 
 As discussed in Chapter 1 and Chapter 4, Multiplex Automatable Genome Engineering 
(MAGE) is a highly useful tool for E. coli diversity generation and genome engineering, and has 
enabled a variety of novel applications.  However, the power of this technique is constrained by 
the limited number of simultaneous mutations that can be generated in a given recombination 
cycle.  In Chapter 4, we established that MAGE recombination frequency can be improved by 
inactivating endogenous nucleases which would otherwise degrade the oligonucleotides used for 
recombineering.
1
  Additionally, we introduced the technique of co-selection MAGE (CoS-
MAGE), whereby a co-selection oligo is directed to repair a mutated antibiotic resistance gene 
(or another selectable marker) near the loci targeted by the other recombineering 
oligonucleotides.
2
  CoS-MAGE thereby enhances the average multiplex allele conversion 
frequency approximately four-fold by selecting for cells that have high levels of recombination 
in the desired region of the genome.
2
   Additionally, this approach selects against cells that do 
not take up oligos during electroporation, as it removes the population that does not revert the 
selectable allele. 
As a result of these features, co-selection significantly augments the power of MAGE for 
diversity generation and genome engineering; furthermore, it points to additional means by 
which the process may be improved.  The fact that CoS-MAGE is most effective for 
recombineering oligonucleotides targeted in close proximity to the selectable marker suggests 
that replication fork position and accessibility have a strong impact on Lambda Red 
recombination frequency.
2
  Thus, we reasoned that we may be able to further improve 
recombination frequency by manipulating replication fork dynamics to increase the amount of 
accessible ssDNA on the lagging strand.  To accomplish this, we took advantage of prior work 
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Figure 5.1: Effect of DnaG Attenuation on Replication Fork 
Dynamics. Mutations to DnaG primase such as Q576A and K580A 
disrupt the interaction between DnaG and DnaB helicase.  This 
protein-protein interaction recruits DnaG primase to the replication 
fork and initiates the formation of an Okazaki fragment; thus, 
weakening the interaction decreases the number of Okazaki 
fragments formed.  This, in turn, increases the average length of 
Okazaki fragments, as well as the amount of accessible ssDNA 
between nascent Okazaki fragments.  Figure not to scale.   
 
that showed that Okazaki Fragment (OF) size can be altered by modulating the frequency of OF 
primer synthesis by DnaG primase.
3
  This work also established that DnaB helicase is 
responsible for recruiting DnaG primase to the replichore, where it initiates primer synthesis.  
Thus, the frequency of primer synthesis can be controlled by altering the strength of the protein-
protein interaction between DnaG 
primase and DnaB helicase.
4
  We 
hypothesized that attenuating this 
interaction would also increase the 
amount of accessible ssDNA on the 
lagging strand of the replication fork 
(as diagramed in Figure 5.1), and 
possibly enhance multiplex 
recombination frequencies as a 
result.  To test this, we took 
advantage of previously reported E. 
coli primase variants with impaired 
DnaB helicase binding, but normal 
replication fork rate, priming 
efficiency, and primer utilization 
during in vitro replication.
5
  These 
variants, DnaG K580A and Q576A, resulted in in vitro OFs that were significantly longer than 
those initiated by wild type DnaG.
4
  We therefore generated these DnaG mutations in our 
recombineering strain EcNR2,
6
 and used the resulting strains to explore whether increasing 
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Table 5.1: Estimation of EcNR2.dnaG.K580A and 
EcNR2.dnaG.Q576A Okazaki Fragment Lengths 
 
a
 All data in this table are from Tougu et al.
4
 
 
accessible ssDNA on the lagging strand could improve multiplex oligonucleotide recombination 
frequency.  
 In this chapter, we demonstrate that accessible ssDNA on the lagging strand of the 
replication fork is a limiting factor for multiplex oligonucleotide recombination, and show that 
weakening the interaction between DnaG primase and DnaB helicase significantly improves 
MAGE and CoS-MAGE frequencies.  We further describe the creation of an optimized strain for 
CoS-MAGE.  This strain builds upon the work presented in Chapter 4, combining approaches to 
mitigate the nuclease degradation of oligos and to expose more accessible ssDNA on the lagging 
strand of the replication fork.  This strain demonstrates greatly improved CoS-MAGE 
performance, and provides a foundation for genome engineering projects of a much more 
ambitious scope. 
 
Impaired Primase Activity Enhances MAGE and CoS-MAGE Frequency 
 It is generally accepted that the Beta protein from Lambda Red facilitates annealing of 
exogenous recombinogenic DNA to the lagging strand of the replication fork, prior to 
incorporation as an Okazaki Fragment.
7-10
  Therefore, we sought to increase the amount of 
accessible ssDNA on the 
lagging strand by disrupting 
the ability of DnaG primase 
to initiate OFs.  Prior work,
4
 
as described above,  has 
indicated that the  DnaG 
K580A and Q576A 
[Primase] (nM) 
WT  DnaG 
OF Size (kb)
a 
K580A 
OF Size (kb) 
Q576A  
OF Size (kb) 
80 2.5 5 23 
160 1.5 2.5 18 
320 1 1 8 
640 0.8 N/A 3 
Average 
(fold vs. WT) 
1 1.6 8.2 
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Figure 5.2: DnaG Q576A Mutation Improves MAGE Performance. 
EcNR2 (“wt”) and EcNR2.dnaG.Q576A (“Q576A”) were assessed for their 
MAGE performance using the three sets of oligos indicated in Figure 4.2, 
without co-selection. Data are presented using stacked allele replacement (AR) 
frequency plots, which show the distribution of clones exhibiting a given 
number of allele conversions.  For all three oligo sets, EcNR2.dnaG.Q576A 
displayed a greater proportion of clones with 2 or more allele conversions.  For 
oligo sets 1 and 2, EcNR2.dnaG.Q576A also had fewer clones with 0 allele 
conversions.  For EcNR2, n = 69, 47, and 96 for Sets 1, 2, and 3, respectively.  
For EcNR2.dnaG.Q576A, n = 90, 46, and 96. 
 
mutations confer this effect, hindering OF formation and increasing OF lengths in vitro; Table 
5.1 shows the in vitro OF lengths previously reported for these variants at a number of different 
primase concentrations.  For each tested primase concentration, we compared both variants’ OF 
size to that of wild type DnaG, and then determined the average fold difference.  We thereby 
estimated that the K580A and Q576A mutations increase OF length by approximately 1.6-fold 
and 8.2-fold, respectively (Table 5.1).  Given the reported ~1.5-2 kb OF lengths of wild type E. 
coli cells grown in rich media,
11-13
 we therefore extrapolated that the K580A and Q576A variants 
have in vivo OF lengths of roughly 2.3-3.1 kb and 12-16 kb, respectively.  However, these 
approximations may be imperfect since Tougu et al.
4
 performed their analysis solely in vitro.  
Other conditions and/or host factors not accounted for in vitro may affect priming efficiency, 
thereby rendering these calculations inaccurate. 
Nevertheless, to 
investigate whether longer 
OFs could improve 
oligonucleotide 
recombination frequency, 
we first compared the 
MAGE performance of 
EcNR2 and 
EcNR2.dnaG.Q576A, the 
more attenuated of the two 
primase variants.  Three 
different sets of 
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recombineering oligos (the same as used in Chapter 4, but without co-selection) were tested, in 
order to control for potential oligo-, allele-, region-, and replichore-specific effects.
14
   Results 
are shown in Figure 5.2; for all three tested oligo sets, EcNR2.dnaG.Q576A exhibited a mean 
allele replacement (AR) frequency that was slightly higher than that of EcNR2. 
 
 
Figure 5.3: DnaG Mutations Improve CoS-MAGE Performance.  EcNR2, EcNR2.dnaG.K580A, 
EcNR2.dnaG.Q576A, and nuc5
-
.dnaG.Q576A were tested for their CoS-MAGE performance with oligo Sets 1-3, 
co-selected with cat, bla, and tolC, respectively.  A) Allele replacement data are presented using stacked 
frequency plots.  B) The mean number of alleles converted for each strain is shown with p-values indicated above 
the bars; “ns” denotes non-significant variation, * denotes p < 0.003, ** denotes p < 0.001, and *** denotes p < 
0.0001.  Data are presented as the mean allele replacement frequency ± the standard error of the mean.  C) Allele 
replacement frequencies for each individual allele are shown for all tested strains.  For Set 1, n = 319, 93, 141, and 
47 for EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, and nuc5
-
.dnaG.Q576A, respectively.  For Set 2, n = 
269, 111, 236, and 191.  For Set 3, n = 327, 136, 184, and 92. 
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Table 5.2: CoS-MAGE Performance versus EcNR2 
 
a
 Fold change was calculated as (strain performance)/(EcNR2 
performance), where performance refers to the average number of 
allele conversions per clone, or the fraction of clones with 5+ or 0 
conversions. Nuc5
-
 data are as described in Chapter 4. 
 Encouraged by these results, we next used CoS-MAGE
2
 to try to augment the observed 
effects.  In this experiment, each of the three oligo sets was paired with a co-selection oligo 
which restored the function of a nearby mutated selectable marker (cat for Set 1, bla for Set 2, 
and tolC for Set 3).  Here, we compared the performance of EcNR2, EcNR2.dnaG.K580A, and 
EcNR2.dnaG.Q576A.  We also generated and tested the nuc5
-
.dnaG.Q576A strain, in order to 
determine whether additive beneficial effects could be attained by combining primase 
modification with nuclease removal (i.e., the nuc5
-
 strain described in Chapter 4).  Results are 
shown in Figure 5.3. 
For all three oligo sets, 
EcNR2.dnaG.Q576A robustly 
outperformed EcNR2, yielding a 
significantly increased mean 
number of alleles converted (**p = 
0.0003, **p = 0.0003, and ***p < 
0.0001, respectively, for Sets 1-3).  
On average, EcNR2.dnaG.Q576A 
yielded 62% more alleles converted 
per clone, 239% more clones with 
five or more allele conversions, and 
38% fewer clones with zero allele 
conversions (Table 5.2).  
EcNR2.dnaG.K580A demonstrated an intermediate phenotype between EcNR2 (shortest OF 
length) and EcNR2.dnaG.Q576A (longest OF length), and was only significantly more 
Metric Set nuc5
-
 
EcNR2.dnaG 
.Q576A 
nuc5
-
.dnaG 
.Q576A 
A
v
er
a
g
e
 
1 1.65
a
 1.49 2.40 
2 1.41 1.29 1.82 
3 1.32 2.08 2.12 
Average 1.46 1.62 2.11 
5
+
 C
o
n
v
er
si
o
n
s 
1 5.28 3.96 10.18 
2 2.65 2.01 4.11 
3 1.07 4.20 4.52 
Average 3.00 3.39 6.27 
0
 C
o
n
v
er
si
o
n
s 1 0.67 0.68 0.24 
2 0.58 0.79 0.35 
3 0.71 0.40 0.30 
Average 0.65 0.62 0.29 
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recombinogenic than EcNR2 for one of the three tested oligo sets (Set 3; ***p < 0.0001).  Thus, 
there appears to be a direct correlation between the degree of primase attenuation and the 
resulting recombination frequency.  This result supports our hypothesis that exposing more 
ssDNA at the lagging strand of the replication fork enhances Lambda Red recombination 
frequency.  Visualizing AR frequency for individual alleles in all three sets (Figure 5.3C) further 
reinforces the relationship between OF size and CoS-MAGE performance; compared to EcNR2, 
the K580A variant generally exhibits a modest increase in individual AR frequency, whereas the 
Q576A variant exhibits dramatically improved AR frequency. 
Table 5.3: Summary of Mean Number of Alleles Converted per Clone  
Set 
EcNR2 nuc5
-
 EcNR2.dnaG.Q576A nuc5
-
.dnaG.Q576A 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
Mean ± SEM  
(n) 
1 
0.96 ± 0.07  
(319) 
1.58 ± 0.10  
(257) 
1.43 ± 0.12  
(141) 
2.30 ± 0.25  
(92) 
2 
2.04 ± 0.10  
(269) 
2.89 ± 0.19  
(142) 
2.63 ± 0.13  
(236) 
3.72 ± 0.17  
(191) 
3 
1.22 ± 0.07  
(327) 
1.61 ± 0.12  
(139) 
2.54 ± 0.14  
(184) 
2.59 ± 0.19  
(92) 
 
Interestingly, as shown in Table 5.3, EcNR2.dnaG.Q576A strongly outperformed nuc5
-
 
for oligo Set 3 (***p < 0.0001), but had slightly lower AR frequency than nuc5
-
 for Sets 1 and 2 
(p = 0.33 and 0.26, respectively).  This suggests that the relative importance of oligo protection 
and the availability of accessible lagging strand ssDNA can vary, possibly due to oligo- and/or 
locus-specific effects that have not yet been elucidated.  Since both factors are clearly important, 
combining impaired primase mutants with nuclease knockouts would be expected to improve 
recombineering performance.  Indeed, the nuc5
-
.dnaG.Q576A strain exhibited markedly better 
multiplex recombination frequency than either the EcNR2.dnaG.Q576A strain or the nuc5
-
 
strain, and yielded 111% more alleles converted per clone, 527% more clones with five or more 
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allele conversions, and 71% fewer clones with zero allele conversions in comparison with 
EcNR2 (Table 5.2).  This demonstrates that primase modification and nuclease removal have 
additive beneficial effects on recombination frequency, and confirms that the number of 
oligonucleotides within the cell and the amount of accessible ssDNA at the lagging strand are 
both limiting factors for Lambda Red recombination.  
 
Targeting Oligonucleotides to a Single Putative Okazaki Fragment 
 Given the significant enhancement of CoS-MAGE performance in EcNR2.dnaG.Q576A, 
we next sought to determine whether localizing all 10 targeted alleles to a single putative OF 
would result in frequent "jackpot" recombinants with nearly all 10 alleles converted.  We 
hypothesized that nascent Okazaki Fragments sometimes obstruct target alleles, leading to a non-
accessible lagging strand.  According to this hypothesis, successful replacement of one allele 
would indicate permissive OF localization, greatly increasing the chance that other alleles 
occurring within the same OF could be replaced.  Therefore, we speculated that the weakened 
primase-helicase interaction in EcNR2.dnaG.Q576A might allow many changes to occur within 
12-16 kb, the predicted OF size in this strain.  To test this, we designed 10 MAGE oligos that 
introduce premature stop codons into an 1829 bp region of lacZ.  Despite their close proximity, 
all 10 alleles were spaced far enough apart so that their corresponding MAGE oligos would not 
overlap.  Given the difference in average OF sizes between strains, we predict it to be fairly 
unlikely for all 10 alleles to be located within the same OF in EcNR2, but quite likely that all 10 
alleles would be located within the same OF in EcNR2.dnaG.Q576A. 
To carry out this experiment, a tolC cassette was installed ~50 kb upstream of lacZ, and 
then inactivated to facilitate co-selection.  Since the lacZ mutations were too densely clustered to 
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enable mascPCR
15
 analysis, we used Sanger sequencing to analyze allele inheritance in white 
(LacZ
-
) colonies, while blue colonies were scored as having zero conferred mutations.  Results 
for this experiment are shown in Figure 5.4.   
 
 For EcNR2, 59% of the clones were white, with 1.24 ± 0.23 (mean ± standard error of the 
mean) conversions per clone; in contrast, 84% of the EcNR2.dnaG.Q576A clones were white, 
Figure 5.4: Enhanced Recombination Frequencies are not Achieved by Targeting a Single Putative Okazaki 
Fragment.  EcNR2 and EcNR2.dnaG.Q576A were tested for their CoS-MAGE performance with 10 non-
overlapping oligos that each introduce a premature stop codon in the first 1,890 bp of lacZ – a distance predicted 
to be within a single OF for EcNR2.dnaG.Q576A.  A) EcNR2.dnaG.Q576A (5.33:1) exhibited a substantial 
increase in lacZ
-
:lacZ
+
 ratio compared to EcNR2 (1.46:1), consistent with the improved allele replacement 
frequency previously observed for this strain.  B) EcNR2 and EcNR2.dnaG.Q576A both exhibited similar AR 
distributions with this oligo set compared with those observed for Sets 1-3 (which span 70 kb, 85 kb, and 162 kb, 
respectively).  C) Compared to EcNR2, EcNR2.dnaG.Q576A exhibited a higher mean number of alleles 
converted (***p < 0.0001).  For EcNR2, n = 39; for EcNR2.dnaG.Q576A, n = 55.  D) Compared to EcNR2, AR 
frequencies increased for 9 out of 10 individual alleles in EcNR2.dnaG.Q576A.  Taken together, these results 
show improved CoS-MAGE performance in EcNR2.dnaG.Q576A, but not to a significantly greater extent than 
observed with the other oligo sets.  Thus, no significant additional enhancement is attained by targeting all oligos 
to a single putative OF. 
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with 2.52 ± 0.25 allele conversions per clone (Figure 5.4A,C).  While EcNR2.dnaG.Q576A 
exhibited more mean allele conversions than EcNR2 (***p < 0.0001), the magnitude of this 
improvement was not notably greater than those observed for Sets 1-3, where recombineering 
oligos were spread across 70, 85, and 162 kb, respectively.  Moreover, “jackpot” clones with 7+ 
converted alleles were not frequently observed for EcNR2.dnaG.Q576A using this oligo set.  
Thus, multiplex AR frequencies cannot markedly be enhanced by targeting oligos to a single 
putative OF.  This may be due to limited oligo entry, target sites being occluded by host proteins, 
OF extension occurring more quickly than oligo annealing, or multiple synthetic 
oligonucleotides destabilizing a nascent OF. 
 
Testing a Larger Oligonucleotide Pool Size 
 A MAGE pool size of approximately 10 distinct oligos was found to be most effective in 
prior studies.
14
  However, given the improved performance of the strains discussed in this 
chapter, we next tested whether using a larger pool of oligos could lead to more alleles being 
converted in average and top clones.  Thus, we designed an expansion set of ten oligonucleotides 
(Set 3X) to be recombined along with Set 3 and tolC co-selection.  CoS-MAGE was then 
performed using this expanded 20-plex set, and results are shown in Figure 5.5.   
For all strains, the new set of 20 oligonucleotides yielded more alleles converted per 
average clone than the 10-plex Set 3 alone.  The fold increase in average number of alleles 
converted was 1.74 for nuc5
-
.dnaG.Q576A, which was greater than the fold increases for 
EcNR2, EcNR2.dnaG.K580A, and EcNR2.dnaG.Q576A (1.35, 1.02, and 1.17, respectively).  
The markedly beneficial effect of nuclease removal on the performance of this 20-plex set 
supports that a limited number of oligonucleotides are internalized during electroporation, as 
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Figure 5.5: Testing DnaG Variants with an Expanded CoS-MAGE Oligo Set. EcNR2, 
EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, and nuc5
-
.dnaG.Q576A (n = 96, 113, 95, and 96, respectively) 
were tested for their CoS-MAGE performance using an expanded set of 20 oligos (Set 3+3X, with tolC co-
selection).  A) AR frequency distributions.  B) Mean number of alleles converted ± standard error of the 
mean, with p-values indicated above the bars; “ns” denotes a non-significant variation, * denotes p < 0.003, 
** denotes p < 0.001, and *** denotes p < 0.0001.   C) Individual AR frequencies; allele ygfT from Set 3X 
could not be assayed by mascPCR.  Overall, nuc5
-
.dnaG.Q576A had strongly improved performance with 
the 20-plex set (compared with Set 3 alone), while the other strains did not.  This suggests that nuclease 
removal allows larger oligo sets to be used more effectively. 
 
suggested in Chapter 4.  This results in low intracellular concentrations of each individual 
oligonucleotide in a large set, therefore augmenting the beneficial impact of nuclease protection.  
Notably, in this experiment, nuc5
-
.dnaG.Q576A yielded the greatest number of simultaneous 
allele conversions observed to date (12, plus tolC reversion).  However, given that this is 
substantially less than the total possible number of conversions (20, plus tolC reversion), this 
suggests that further increases in oligo pool size may not markedly increase the mean or 
maximum number of alleles converted. 
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Figure 5.6: Effect of DnaG Modification on Oligo-mediated Deletion 
Frequency. Oligonucleotides were designed to delete regions of various 
sizes within and around the galK gene.  These oligos were recombined 
into EcNR2 (“E2”; white) and EcNR2.dnaG.Q576A (red).  Three 
independent replicates were performed for each oligo; error bars are 
shown as the standard error of the mean.  EcNR2.dnaG.Q576A 
demonstrates a significant advantage over EcNR2 for the 100 bp and 
1149 bp deletions, but not for the 7895 bp deletion. 
 
 
Disrupting DnaG Primase Activity Enhances Deletions but not Insertions 
 MAGE is most effective at introducing very short mismatches, insertions, and deletions, 
as these can efficiently be generated using Red-mediated recombination without direct selection.
6
  
However, large deletions and gene-sized insertions are also important classes of mutations that 
could increase the scope of applications for MAGE.  Thus, we investigated whether decreasing 
DnaG primase function could also enhance recombination frequency for large deletions and/or 
insertions.  
Based on the accepted model for Lambda Red recombination,
7,8
 we expected enhanced 
deletion frequency in EcNR2.dnaG.Q576A, given the increased amount of accessible lagging 
strand ssDNA to which the 
deletion oligos could anneal.  We 
further predicted that this effect 
might be particularly pronounced 
for intermediate-sized deletions 
(e.g., 1 – 10 kb), since less 
frequent priming would also 
increase the probability of both 
homology targets for such oligos 
being located within the same 
OF.  In contrast, the two 
annealing events required for larger deletions may span multiple OFs.  Thus, to test the effect of 
OF size on oligo-mediated deletion frequency, we designed three oligos that deleted 100 bp, 
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1149 bp, or 7895 bp of the genome, including a portion of galK.  The oligo that deleted 7895 bp 
also removed several nonessential genes in addition to galK.  Recombined populations were 
screened for the GalK
-
 phenotype (white colonies) on MacConkey agar plates supplemented with 
galactose, and recombination frequencies were thereby determined.  As shown in Figure 5.6, 
EcNR2.dnaG.Q576A significantly outperformed EcNR2 for the 100 bp (*p = 0.03) and 1149 bp 
(*p = 0.03) deletions, but there was no difference detected between the two strains for the 7895 
bp deletion (p = 0.74).  This lack of a primase-mediated improvement for the 7895 bp deletion 
oligo may be due to the two homology sites frequently being split across multiple OFs even in 
EcNR2.dnaG.Q576A. 
 To determine whether primase modification also results in improved insertion 
frequencies, we quantified the recombination frequency of a kanamycin resistance insertion 
cassette targeted to lacZ (lacZ::kanR,
8
 ~1.2 kb).  Recombination frequencies of 1.81E-04 ± 
6.24E-05 and 1.28E-04 ± 4.52E-05, respectively, were observed for EcNR2 and 
EcNR2.dnaG.Q576A (n = 3, p = 0.30 by unpaired t-test).  Thus, primase modification does not 
improve insertion frequency, suggesting that gene insertion is constrained by factors other than 
the accessibility of ssDNA at the replication fork.  Such factors may include cassette entry into 
cells, a low propensity for the heterologous portion of the cassette to loop out and allow the 
flanking homologies to anneal to their adjacent targets,
7,8
 or a limited probability that Lambda 
Exo degrades the entire leading-targeting strand before degradation of the lagging-targeting 
strand occurs.
7
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Figure 5.7: Effect of Primase Modification on Leading-targeting CoS-MAGE.  A) EcNR2.dnaG.Q576A 
(n = 91) outperformed EcNR2 (n = 88) in leading-targeting Set 3 CoS-MAGE, with fewer clones exhibiting 
zero allele conversions, a greater proportion of clones exhibiting two or more conversions, and a greater 
average number of alleles converted per clone.  B) For leading-targeting Set 3 oligos, recombination 
frequency decayed rapidly with increasing distance from the selectable marker (top panel).  In contrast, the 
corresponding set of lagging-targeting oligos (bottom panel) demonstrated robust co-selection; linear 
regression analyses (solid trendlines) show that for both strains, recombination frequency did not decrease 
with distance over this 162 kb genomic region.   C) Individual AR frequencies.  AR frequency was improved 
for 9/10 alleles in EcNR2.dnaG.Q576A.  Please note the broken y-axis, reinforcing that the recombination 
frequency of the most proximal allele to the selectable marker was much higher than those of the other 
alleles. 
 
 
Disrupting DnaG Primase Activity Enhances Leading-targeting CoS-MAGE  
 
 
Finally, we tested whether primase modification results in improved recombination 
frequency for oligos that target the leading strand.  To examine this, we used the reverse 
complements of the Set 3 oligos; the tolC-reverting co-selection oligo was also redesigned to 
target the leading strand.  We anticipated that leading strand recombination frequencies would 
not significantly be impacted by primase modification, as DnaG predominantly acts on the 
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lagging strand.  Surprisingly, however, we found (Figure 5.7) that the leading-targeting oligos 
yielded significantly more average allele conversions for EcNR2.dnaG.Q576A (1.39 ± 0.18) than 
for EcNR2 (0.85 ± 0.13; *p = 0.018).  Similar to lagging-targeting Set 3, we also observed a 
reduction in zero conversion events for EcNR2.dnaG.Q576A, as well as a greater maximum 
number of alleles converted.  Also contrary to our expectations, EcNR2.dnaG.Q576A exhibited 
greater AR frequency than EcNR2 at 9 out of 10 alleles targeted on the leading strand (Figure 
5.7C).  Interestingly, we further observed that for leading-targeting oligos, recombination 
frequency diminished quickly with increasing distance from the co-selected marker (Figure 5.7B, 
top panel).  The co-selection advantage for lagging-targeting oligos, in contrast, typically persists 
over a large genomic distance (~0.5 Mb).
2
  Indeed, this distance-robust co-selection advantage is 
clearly demonstrated by the lagging-targeting Set 3 oligos (Figure 5.7B, bottom panel).  We 
discuss possible explanations for these surprising results in the section below. 
 
Discussion 
In order to increase the amount of accessible ssDNA on the lagging strand of the 
replication fork, we separately introduced two mutations into E. coli DnaG primase: K580A and 
Q576A.  These mutations have been shown in vitro to increase OF size by interrupting the 
primase-helicase interaction on the replisome.
4
  Based on the measurements of Tougu et al.,
4
 we 
estimate that the K580A mutation increases OF length by about 1.6-fold, and the Q576A 
mutation increases OF length by about 8.2-fold (Table 5.1).  Strains EcNR2.dnaG.K580A and 
EcNR2.dnaG.Q576A exhibited significant increases in the mean number of alleles converted 
during CoS-MAGE, as well as decreases in the proportion of clones with zero non-selectable 
alleles converted.  Furthermore, the strongest recombination frequency enhancement was 
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observed in EcNR2.dnaG.Q576A (the variant with the longest OFs of the strains tested in this 
chapter), with an intermediate enhancement observed in EcNR2.dnaG.K580A (the variant with 
intermediate-sized OFs).  This relationship between recombination frequency and OF length 
further supports the model in which Beta mediates annealing at the lagging strand of the 
replication fork,
7-10
 as well as our hypothesis that accessible ssDNA on the lagging strand is a 
limiting factor for this process.  With this in mind, we unsuccessfully attempted to generate a 
DnaG Q576A/K580A double mutant; this failure suggests that such extensive manipulation of 
the DnaG C-terminal helicase interaction domain
16
 is lethal. 
The results described here clearly establish that the intracellular concentration of MAGE 
oligos and the accessibility of their genomic targets are both limiting factors in multiplex 
oligonucleotide recombination.  This is evidenced by the fact that the nuclease-depleted strains 
discussed in Chapter 4 and the primase-modified strains described in this chapter both displayed 
robust CoS-MAGE recombination frequency enhancements.  Interestingly, the nuc5
-
 strain
1
 
slightly outperformed the EcNR2.dnaG.Q576A strain for oligo Sets 1 and 2, while 
EcNR2.dnaG.Q576A strongly outperformed the nuc5
-
 strain for Set 3 (Table 5.3).  While oligo 
design parameters such as the type of designed mutation,
6
 oligo length,
6
 oligo secondary 
structure,
6
 and the amount of off-target genomic homology
14
 are major determinants of 
recombination frequency, these results also highlight the relevance of genomic context.  For 
instance, one possible explanation for the variable effect of primase modification is that different 
genomic regions may have different replication fork speed or priming efficiency.  These factors 
could locally modulate OF length (although replication fork speed did not appear to be a major 
determinant of OF length in vitro),
4
 thereby affecting the impact of further OF modulation on 
recombination frequency.  Alternatively, certain oligos may be more susceptible to nuclease 
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degradation; therefore, removing the responsible nucleases would disproportionately improve 
recombination frequency for sets containing several of such oligos.  With this in mind, we tested 
whether combining primase modification and nuclease removal would enhance CoS-MAGE 
performance more than either strategy used individually.  Indeed, nuc5
-
.dnaG.Q576A 
consistently performed the best of all tested strains (Figures 5.3 & 5.5).  Therefore, these two 
disparate strategies can be combined to yield a larger and more robust recombination frequency 
enhancement, reinforcing that both oligo availability and lagging strand ssDNA accessibility are 
limiting factors in MAGE and CoS-MAGE. 
To explore the extent to which OF localization impacts CoS-MAGE performance, we 
tested whether targeting 10 oligos to a single putative OF would yield a bimodal AR frequency 
distribution, with subpopulations of little-modified (few or no alleles converted) and "jackpot" 
(most or all alleles converted) recombinants.  However, CoS-MAGE in EcNR2.dnaG.Q576A 
using the densely-clustered lacZ oligos (Figure 5.4) produced a similar AR distribution to the 
ones observed for Sets 1-3 (Figure 5.3), which targeted regions of the genome spanning several 
putative OFs.  Since mutations targeted to a single putative OF yielded an inheritance pattern 
similar to those observed when mutations were spread across many OFs, nascent OF localization 
does not appear to be a critical determinant of multiplex oligonucleotide recombination 
frequency.  A number of hypotheses could explain why the expected "jackpots" are not observed.  
For one, it is likely that MAGE oligos are limiting due to degradation and/or lack of uptake.  
Thus, it is possible that most cells lack the oligos necessary for generating a majority of the 
desired mutations.  Additionally, OF extension may occur too fast for all of the MAGE oligos to 
anneal before the nascent OF occludes their targets.  Still another explanation could be that host 
factors such as ssDNA binding proteins occupy portions of the lagging strand, rendering these 
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regions inaccessible for Beta-mediated annealing.  Finally, it is also possible that several MAGE 
oligos annealing within a single OF could destabilize lagging strand synthesis, leading to 
selection against highly-modified "jackpot" clones.  Indeed, polIIIlag dissociates from the 
replisome after completing an OF,
13
 and the repeated dissociation of polIIIlag due to multiple 
nearby MAGE oligos could cause the replisome to proceed beyond the target region before 
lagging strand synthesis is completed.  In the absence of the rest of the replisome, a cytosolic 
PolIII holoenzyme demonstrates considerably diminished activity.
17
  Therefore, if OFs are not 
completed while the replisome is in close proximity, this could result in persisting ssDNA 
lesions that lethally destabilize the chromosome.  
We also investigated whether targeting a greater number of alleles would increase the 
resulting number of conversions in our enhanced strains (Figure 5.5).  Although nuc5
-
.dnaG.Q576A demonstrated 1.74-fold greater average allele conversion frequency for 20-plex 
Set 3+3X versus 10-plex Set 3, a difference of only 1.17-fold was observed for 
EcNR2.dnaG.Q576A.   The superior enhancement for the nuclease-depleted nuc5
-
.dnaG.Q576A 
strain suggests that intracellular oligo concentration is a particularly limiting factor for highly 
multiplexed MAGE (i.e., more than 10 alleles targeted).  Therefore, enhancing DNA uptake 
and/or preservation may be a fruitful means of further improving MAGE.  However, this 
improved multiplexibility of nuc5
-
.dnaG.Q576A could also be due to the Set 3X oligos being 
more responsive to decreased exonuclease degradation than to increased lagging strand ssDNA 
availability.  Additionally, there may be other limiting factors such as insufficient Beta or 
unidentified host proteins with a role in Lambda Red recombination.  Although there is no 
known precedent for the quantity of Lambda Red proteins being a limiting factor for 
recombination,
18
 our novel ability to attain 12 simultaneous non-selectable allele replacements 
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indicates that our improved strains are in uncharted territory for probing the limits of Lambda 
Red recombination. 
Given that DnaG primase acts predominantly on the lagging strand of the replication 
fork, we expected that the tested primase modifications would enhance only lagging-targeting 
recombination.  Therefore, the performance of leading-targeting CoS-MAGE in our strains was 
surprising, as EcNR2.dnaG.Q576A significantly outperformed EcNR2 (*p = 0.018).  
Furthermore, while the total number of co-selected tolC
+
 recombinants was considerably (~100-
fold) lower for leading-targeting CoS-MAGE versus lagging-targeting, the AR frequency of non-
selectable alleles in these recombinants was still quite impressive, especially for alleles in close 
proximity to the selectable marker.  This suggests that one leading strand recombination event 
correlates strongly with additional recombination events.  Two possible explanations for the 
superior performance of EcNR2.dnaG.Q576A in leading-targeting CoS-MAGE are that 1) an 
impaired primase-helicase interaction increases accessible leading strand ssDNA as well as 
lagging strand ssDNA, or 2) infrequent Beta-mediated strand invasion initiates a new replication 
fork that travels in the opposite direction and swaps which strands are leading and lagging.  
There is some support for primase function affecting the dynamics of replication on both 
the leading and lagging strands.
13,17,19
  Lia et al.
13
 previously observed phases of replication in 
which OF synthesis was faster than helicase progression at the replication fork, alternating with 
phases in which the opposite was true.  These results demonstrate that DnaB-PolIIIlead does not 
always progress at the same speed as PolIIIlag.
13
  Furthermore, Yao et al.
19
 showed that the 
velocity of leading-strand synthesis decreases during lagging strand synthesis, while its 
processivity increases.  Thus, as a result of its effect on lagging strand synthesis, altering 
primase-helicase binding could bring about periods of transiently increased fork rate and 
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decreased PolIIIlead processivity.  Given that PolIII tends to release from the replication fork more 
readily than DnaB helicase,
19
 this could exacerbate this effect, leading to helicase progression 
durably outstripping leading strand synthesis.  This would increase the amount of accessible 
ssDNA on the leading strand, and likely improve leading-targeting CoS-MAGE frequencies. 
Alternatively, the Beta protein from Lambda Red has been reported to facilitate strand 
invasion in vitro.
20
  Although there is little evidence to suggest that such strand invasion also 
occurs in vivo, if it does, it could produce a D-Loop that acts as a new origin of replication.
21
  
Thus, invasion of one leading-targeting MAGE oligo could initiate a new replication fork 
traveling in the opposite direction.  In the reverse orientation, the leading strand would become 
the lagging strand, and oligos would thereby become lagging-targeting and much more likely to 
recombine.  If this is the case, the non-selectable alleles would then be upstream of the co-
selection marker.  Since co-selection is most effective downstream of the selectable marker,
2
 this 
may explain why co-selection enhancements were observed to decay rapidly with distance on the 
leading strand (Figure 5.7B).   
In this chapter, we have identified accessible lagging strand ssDNA as a limiting factor in 
multiplex oligonucleotide recombination, and shown that such ssDNA can be increased via 
manipulation of the primase-helicase interaction.  Compared to a standard recombineering strain 
(EcNR2), primase-modified strain EcNR2.dnaG.Q576A displayed on average 62% more alleles 
converted per clone, 239% more clones with five or more allele conversions, and 38% fewer 
clones with zero allele conversions in a given round of CoS-MAGE with ten oligonucleotides 
(Table 5.2).  We used this strategy to build on the advances described in Chapter 4, generating 
the nuc5
-
.dnaG.Q576A strain, which has increased accessible lagging strand ssDNA and also 
lacks five potent exonucleases.  These modifications exploited two distinct mechanisms that 
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together increased the robustness and potency of CoS-MAGE, enabling an average of 4.50 and a 
maximum of 12 non-selectable allele replacements in cells exposed to a pool of 20 different 
recombineering oligonucleotides.  After only a single cycle with this oligo set, 48% of 
recombinants had five or more allele replacements and just 8% lacked any modified non-
selectable alleles.  Furthermore, in a given round of CoS-MAGE with ten oligos, nuc5
-
.dnaG.Q576A displayed on average 111% more alleles converted per clone, 527% more clones 
with five or more allele conversions, and 71% fewer clones with zero allele conversions, in 
comparison with EcNR2.  This improvement in MAGE performance will be highly valuable for 
increasing the diversity explored during the directed evolution of biosynthetic pathways,
6
 and for 
enabling the rapid generation of desired genotypes involving tens to hundreds of allele 
replacements.
14
 
 
Experimental 
Oligonucleotides used in this Study 
A full list of oligonucleotides used in this study is given in Table 5.4.  In this table, “wt-f” 
refers to a forward ascPCR/mascPCR primer used to detect a wild type allele, “mut-f” refers to a 
forward ascPCR/mascPCR primer used to detect a mutated allele, and “rev” refers to the reverse 
ascPCR/mascPCR primer used with both forward primers. Sizes of mascPCR bands 
corresponding to a given locus are denoted in the table as 100, 150, 200, 250, 300, 400, 500, 600, 
700, or 850.  Asterisks represent phosphorothioate bonds between the indicated nucleotides.  
Recombination and screening oligonucleotides for Sets 1-3 are given in Table 4.1, and are not 
reproduced here.  All oligonucleotides were ordered from Integrated DNA Technologies with 
standard purification and desalting. 
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Table 5.4: Oligonucleotides used in Chapter 5 
Name
 
Use
 
Sequence
 
ygfJ_AGR Set 3X.850 recombineering oligo 
C*C*ACTATGTCAGCCATCGACTGTATAATTACCG
CTGCCGGATTATCATCAAGGATGGGGCAATGGAA
AATGATGTTACCCTGGGAACA*G*G 
ygfT_AGR Set 3X.700 recombineering oligo 
G*A*TGCCTTCGTATCAAACAGAGTTAACATATCG
CGCGCCGCCTGTCTTCCTGCGGCCATTGCAGTGAC
AACCAGATCCGCGCCATGAA*C*T 
ubiH_AGR Set 3X.600 recombineering oligo 
G*T*GCAGAGTTTGCGCCGCATTGCCCACCAGCAC
GGTACGATGGGTAATAGACCTGGCGGCGTGGGTT
AACGCCAGCGGATAAGCACTG*C*G 
argO_AGR Set 3X.500 recombineering oligo 
G*G*ATTCAGCCAGGTCACTGCCAACATGGTGGCG
ATAATTTTCCACCTGCCTTGCTTCATGACTTCGGC
GCTGGCTAACTCAATATTAC*T*G 
yqgC_AGR Set 3X.400 recombineering oligo 
G*A*ATCCTGAGAAGCGCCGAGATGGGTATAACA
TCGGCAGGTATGCAAAGCAGGGATGCAGAGTGCG
GGGAACGAATCTTCACCAGAAC*G*G 
trmI_AGR Set 3X.300 recombineering oligo 
T*T*TTTTACGCAGACGACGGCTACGGTTCTTTGC
CATTATTTCACTCTCTCGAACATTAAGTCCCATAC
TCCGTGACCAAGACGATGAC*C*A 
glcC_AGR Set 3X.250 recombineering oligo 
A*C*GATCTGCTCGACGTTCGCGCATTACTGGAGG
GCGAATCGGCAAGACTGGCGGCAACGCTGGGAA
CGCAGGCTGATTTTGTTGTGAT*A*A 
yghT_AGR Set 3X.200 recombineering oligo 
G*T*GAACATCTTATTACCGTTGTCGAAAAATATG
GTGCTGCCGAAAGGGTTCATTTAGGAAAACAGGC
CGGAAATGTCGGTCGTGCAGT*G*A 
ygiZ_AGR Set 3X.150 recombineering oligo 
A*A*TACATATACCCAAAACTCGAACATTTCCCGC
ATAAAGAGTTTCCTTAAGATAAGAATAATAAGTG
GCGTAAGAAGAAAAAATGCTG*C*A 
cpdA_AGR Set 3X.100 recombineering oligo 
C*T*TCGTGCTTTTGTGCAAACAGGTGAGTGTCGG
TAATTTGTAAAATCCTGACCCTGGCCTCACCAGCC
AGAGGAAGGGTTAACAGGCT*T*T 
lacZ_KO1 Set lacZ TAG  TAA +61 
T*C*ACTGGCCGTCGTTTTACAACGTCGTGACTGG
GAAAACCCTTGAGTTACCCAACTTAATCGCCTTGC
AGCACATCCCCCTTTCGCCA*G*C 
lacZ_KO2 Set lacZ TAG  TAA +264 
G*C*TGGAGTGCGATCTTCCTGAGGCCGATACTGT
CGTCGTCCCCTCATAATGGCAGATGCACGGTTAC
GATGCGCCCATCTACACCAAC*G*T 
lacZ_KO3 Set lacZ TAG  TAA +420 
C*A*CATTTAATGTTGATGAAAGCTGGCTACAGGA
AGGCCAGACGTAAATTATTTTTGATGGCGTTAACT
CGGCGTTTCATCTGTGGTGC*A*A 
lacZ_KO4 Set lacZ TAG  TAA +602 
T*G*ATGGTGCTGCGCTGGAGTGACGGCAGTTATC
TGGAAGATCAGTAGATGTGGCGGATGAGCGGCAT
TTTCCGTGACGTCTCGTTGCT*G*C 
lacZ_KO5 Set lacZ TAG  TAA +693 
T*A*AACCGACTACACAAATCAGCGATTTCCATGT
TGCCACTCGCTAAAATGATGATTTCAGCCGCGCT
GTACTGGAGGCTGAAGTTCAG*A*T 
lacZ_KO6 Set lacZ TAG  TAA +1258 
T*A*CGGCCTGTATGTGGTGGATGAAGCCAATATT
GAAACCCACTGAATGGTGCCAATGAATCGTCTGA
CCGATGATCCGCGCTGGCTAC*C*G 
lacZ_KO7 Set lacZ TAG  TAA +1420 
G*G*GAATGAATCAGGCCACGGCGCTAATCACGA
CGCGCTGTATTGATGGATCAAATCTGTCGATCCTT
CCCGCCCGGTGCAGTATGAAG*G*C 
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Table 5.4 (Continued) 
lacZ_KO8 Set lacZ TAG  TAA +1599 
G*T*CCATCAAAAAATGGCTTTCGCTACCTGGAGA
GACGCGCCCGTAGATCCTTTGCGAATACGCCCAC
GCGATGGGTAACAGTCTTGGC*G*G 
lacZ_KO9 Set lacZ TAG  TAA +1710 
G*T*TTCGTCAGTATCCCCGTTTACAGGGCGGCTT
CGTCTGGGACTAAGTGGATCAGTCGCTGATTAAA
TATGATGAAAACGGCAACCCG*T*G 
lacZ_KO10 Set lacZ TAG  TAA +1890 
A*G*CGCTGACGGAAGCAAAACACCAGCAGCAGT
TTTTCCAGTTCTGATTATCCGGGCAAACCATCGAA
GTGACCAGCGAATACCTGTTC*C*G 
ygfJ_2*:2*_lead 
Set 3.850_lead TAG  TAA 
oligo 
G*C*CGGAAGGATTAAATATTTGAACGCAATCGTT
TAACTACGTTTTTTAAATTTCAGTATACCTTTCCTT
CGCTGTAATAAAGTCGTCC*G*G 
recJ_2*:2*_lead 
Set 3.700_lead TAG  TAA 
oligo 
C*A*ACCGCAGCCTGCAAATTATCATCGACAATAT
CTGGCCAATTTAACGTCATCTTCTCTATAAAAAAG
AGCGTGGATTGGGTACAATC*C*C 
argO_2*:2*_lead 
Set 3.600_lead TAG  TAA 
oligo 
G*A*GAGACGGTATTGCTCATGCACAAGCCTTGTT
CAGTTAAGCGCTATCTGATGGAAAAATAAAACAG
AGGCGCTAAGCTTGCCTCCAG*A*G 
yggU_2*:2*_lead 
Set 3.500_lead TAG  TAA 
oligo 
T*T*ACCGACATTGCCGGTTGCGAGGACAACTTTT
TGCATAGGATACTTAATTAATTAACGCCGCGATTT
CTGGCGGGATTTGTTGCGGA*T*T 
mutY_2*:2*_lead 
Set 3.400_lead TAG  TAA 
oligo 
A*A*AAATCGTTCTGCTCATAAATCATCCTCTTTAT
CGACTCACGCGTTAAACCGGCGCGCCAGTGCGTA
ACTGCTGTAACAAACGCTCC*A*C 
glcC_2*:2*_lead 
Set 3.300_lead TAG  TAA 
oligo 
C*A*AGCGTTACCGATTGTATGAAAAGCAGATTTA
ATACCAGTTAACTCAGGTTCATCTCCAGCGGCAC
CGCCGAGCGAATCAAATGGTG*G*C 
yghQ_2*:2*_lead 
Set 3.250_lead TAG  TAA 
oligo 
G*C*TGGTGTTTGGCGTTAAGTATCTCGAAGCGTA
TGACCTGATTTAAGGAAGGTGCGAATAAGCGGGG
AAATTCTTCTCGGCTGACTCA*G*T 
yghT_2*:2*_lead 
Set 3.200_lead TAG  TAA 
oligo 
C*C*CGGTCCTGGCGATCGGGCATTTCCATTTTTG
ATTAGTGATAACCACGCGCGGTCATAAAATCCGT
AATCGCTTTTTCTGCATCAAC*C*A 
ygiZ_2*:2*_lead 
Set 3.150_lead TAG  TAA 
oligo 
T*T*GTGGTTGGTGGCTTTTTTGGGGACGGTTTATA
TTTTGCTATTAATAAAATCTATGAGAGTCGTTTTA
ACGGCTCTCATAGACAGAG*A*A 
yqiB_2*:2*_lead 
Set 3.100_lead TAG  TAA 
oligo 
G*C*GATACTGTTTAGCACATGGAGCGATGGCGAT
TCCGGTTTATTAACGTCGTGAAACCTAAGGACAC
CATTTGGAAAGCCTGTTAACC*C*T 
dnaG_Q576A 
Oligo used to make DnaG 
Q576A mutation 
GCACGCATGGTTTAAGCAACGAAGAACGCCTGGA
GCTCTGGACATTAAACGCGGAACTGGCGAAAAAG
TGATTTAACGGCTTAAGTGCCG 
dnaG_K580A 
Oligo used to make DnaG 
K580A mutation 
CGCACGCATGGTTTAAGCAACGAAGAACGCCTGG
AGCTCTGGACATTAAACCAGGAACTGGCGGCAAA
GTGATTTAACGGCTTAAGTGCC 
tolC.90.del 
Oligo that deletes endogenous 
tolC 
GAATTTCAGCGACGTTTGACTGCCGTTTGAGCAGT
CATGTGTTAAAGCTTCGGCCCCGTCTGAACGTAA
GGCAACGTAAAGATACGGGTTAT 
galK_KO1.100 
Oligo used to delete 100 bp 
including a portion of galK 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAATCC
GGAGTGTAAGAAAACACACCGACTACAACGACG
GTTTCGTTCTGCCCTGCGCGAT*T*G 
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Table 5.4 (Continued) 
galK_KO1.1149 
Oligo used to delete 1149 bp 
including a portion of galK 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAATCC
GGAGTGTAAGAAACGAAACTCCCGCACTGGCACC
CGATGGTCAGCCGTACCGACT*G*T 
galK_KO1.7895 
Oligo used to delete 7895 bp 
including a portion of galK 
C*G*CGCAGTCAGCGATATCCATTTTCGCGAATCC
GGAGTGTAAGAACTTACCATCTCGTTTTACAGGCT
TAACGTTAAAACCGACATTA*G*C 
ygfJ_WT Set 3X.850_wt-f mascPCR GCTGCCGGATTATCATCAAGA 
ygfT_WT Set 3X.700_wt-f mascPCR GCAATGGCCGCAGGAAGG 
ubiH_WT Set 3X.600_wt-f mascPCR GCACGGTACGATGGGTAATAGAT 
argO_WT Set 3X.500_wt-f mascPCR GAAGTCATGAAGCAAGGCAGA 
yqgC_WT Set 3X.400_wt-f mascPCR CGGCAGGTATGCAAAGCAGA 
trmI_WT Set 3X.300_wt-f mascPCR AGTATGGGACTTAATGTTCGAGAGG 
glcC_WT Set 3X.250_wt-f mascPCR AGGGCGAATCGGCAAGG 
yghT_WT Set 3X.200_wt-f mascPCR GAAAAATATGGTGCTGCCGAAAGA 
ygiZ_WT Set 3X.150_wt-f mascPCR CTTCTTACGCCACTTATTATTCTTATCTTAAGA 
cpdA_WT Set 3X.100_wt-f mascPCR TGGCTGGTGAGGCCAGA 
dnaG_Q576A_wt-f 
dnaG_Q576A wt-f ascPCR 
primer 
TGGAGCTCTGGACATTAAACCA 
dnaG_K580A_wt-f 
dnaG_K580A wt-f ascPCR 
primer 
CATTAAACCAGGAACTGGCGAA 
ygfJ_MUT Set 3X.850_mut-f mascPCR GCTGCCGGATTATCATCAAGG 
ygfT_MUT Set 3X.700_mut-f mascPCR GCAATGGCCGCAGGAAGA 
ubiH_MUT Set 3X.600_mut-f mascPCR GCACGGTACGATGGGTAATAGAC 
argO_MUT Set 3X.500_mut-f mascPCR GAAGTCATGAAGCAAGGCAGG 
yqgC_MUT Set 3X.400_mut-f mascPCR GGCAGGTATGCAAAGCAGG 
trmI_MUT Set 3X.300_mut-f mascPCR GAGTATGGGACTTAATGTTCGAGAGA 
glcC_MUT Set 3X.250_mut-f mascPCR GAGGGCGAATCGGCAAGA 
yghT_MUT Set 3X.200_mut-f mascPCR AAAATATGGTGCTGCCGAAAGG 
ygiZ_MUT Set 3X.150_mut-f mascPCR CTTCTTACGCCACTTATTATTCTTATCTTAAGG 
cpdA_MUT Set 3X.100_mut-f mascPCR GGCTGGTGAGGCCAGG 
dnaG_Q576A_mut-f 
dnaG_Q576A mut-f ascPCR 
primer 
GGAGCTCTGGACATTAAACGC 
dnaG_K580A_mut-f 
dnaG_K580A mut-f ascPCR 
primer 
ACCAGGAACTGGCGGC 
ygfJ_rev Set 3X.850_rev mascPCR TCTGTTTGCACTGCGGGTAC 
ygfT_rev Set 3X.700_rev mascPCR TGGTTGGGCAATCTAATAGATTCTCC 
ubiH_rev Set 3X.600_rev mascPCR ATGAGCGTAATCATCGTCGGTG 
argO_rev Set 3X.500_rev mascPCR CCGTCTCTCGCCAGCTG 
yqgC_rev Set 3X.400_rev mascPCR AGCACACGACGTTTCTTTCG 
trmI_rev Set 3X.300_rev mascPCR ATCTGTTCTTCCGATGTACCTTCC 
glcC_rev Set 3X.250_rev mascPCR CTTCCAGCTCGATATCGTGGAG 
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Table 5.4 (Continued) 
yghT_rev Set 3X.200_rev mascPCR CACCACCAAAGGTTAACTGTGG 
ygiZ_rev Set 3X.150_rev mascPCR CACAAACCAGACAAATACCGAGC 
cpdA_rev Set 3X.100_rev mascPCR CGATGGTATCCAGCGTAAAGTTG 
dnaG_seq-r 
dnaG rev ascPCR primer for 
both Q576A and K580A 
GCTCCATAAGACGGTATCCACA 
Rx-P19 
forward screening primer for wt 
tolC deletion 
GTTTCTCGTGCAATAATTTCTACATC 
Rx-P20 
reverse screening primer for wt 
tolC deletion 
CGTATGGATTTTGTCCGTTTCA 
lacZ_jackpot_seq-f 
forward sequencing primer for 
lacZ alleles 
GAATTGTGAGCGGATAACAATTTC 
lacZ_jackpot_seq-r 
reverse sequencing primer for 
lacZ alleles 
CCAGCGGCTTACCATCC 
cat_mut* cat inactivation oligo 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTC
AGTTGCTTAATGTACCTATAACCAGACCGTTCAGC
TGGATATTACGGCCTTTTTA*A*A  
cat_restore* cat reactivation oligo 
G*C*ATCGTAAAGAACATTTTGAGGCATTTCAGTC
AGTTGCTCAATGTACCTATAACCAGACCGTTCAG
CTGGATATTACGGCCTTTTTA*A*A 
tolC-r_null_mut* tolC inactivation oligo 
A*G*CAAGCACGCCTTAGTAACCCGGAATTGCGTA
AGTCTGCCGCTAAATCGTGATGCTGCCTTTGAAA
AAATTAATGAAGCGCGCAGTCCA 
tolC-r_null_revert* tolC reactivation oligo 
C*A*GCAAGCACGCCTTAGTAACCCGGAATTGCGT
AAGTCTGCCGCCGATCGTGATGCTGCCTTTGAAA
AAATTAATGAAGCGCGCAGTCCA 
tolC_null_revert* 
tolC reactivation oligo (leading-
targeting) 
T*G*GACTGCGCGCTTCATTAATTTTTTCAAAGGC
AGCATCACGATCGGCGGCAGACTTACGCAATTCC
GGGTTACTAAGGCGTGCTTGCTG 
bla_mut* bla inactivation oligo 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTATTAGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAG 
bla_restore* bla reactivation oligo 
G*C*C*A*CATAGCAGAACTTTAAAAGTGCTCATC
ATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAA
GGATCTTACCGCTGTTGAGATCCAG 
313000.T.lacZ.coMA
GE-f 
Forward cassette primer for 
generating T.co-lacZ (inserted 
for lacZ co-selection) 
TGCTTCTCATGAACGATAACACAACTTGTTCATGA
ATTAACCATTCCGGATTGAGGCACATTAACGCC 
313001.T.lacZ.coMA
GE-r 
Reverse cassette primer for 
generating T.co-lacZ (inserted 
for lacZ co-selection) 
ACGGAAACCAGCCAGTTCCTTTCGATGCCTGAAT
TTGATCCCATAGTTTATCTAGGGCGGCGGATT 
312869.seq-f 
Forward screening primer for 
T.co-lacZ 
GAACTTGCACTACCCATCG 
313126.seq-r 
Reverse screening primer for 
T.co-lacZ 
AGTGACGGGTTAATTATCTGAAAG 
LacZ::KanR.full-f 
Forward cassette primer for 
generating lacZ::kanR 
TGACCATGATTACGGATTCACTGGCCGTCGTTTTA
CAACGTCGTGCCTGTGACGGAAGATCACTTCG 
LacZ::KanR.full-r 
Reverse cassette primer for 
generating lacZ::kanR 
GTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGG
GTTTTCCCAGTAACCAGCAATAGACATAAGCGG 
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Strain Creation 
Lambda Red recombination was used to generate all mutations, and was performed as 
described below and in previous chapters.  All of the strains used in this work were derived from 
EcNR2 (Escherichia coli MG1655 ∆mutS::cat ∆(ybhB-bioAB)::[λcI857 N(cro-ea59)::tetR-bla]).
6
  
Strain nuc5
-
.dnaG.Q576A was generated by recombining oligo dnaG_Q576A into nuc5
-
, an 
EcNR2-derived strain described in Chapter 4.
1
  EcNR2.DT was created by deleting the 
endogenous tolC gene using the tolC.90.del recombineering oligo.
14
  EcNR2.T.co-lacZ was 
created by recombining a tolC cassette (T.co-lacZ) into the genome of EcNR2.DT, upstream of 
the lac operon, as described below.  CoS-MAGE strains were prepared by inactivating a 
chromosomal selectable marker (cat, tolC, or bla) using an oligonucleotide.  Clones with 
sensitivity to the appropriate antibiotic or SDS
22
 were identified by replica plating.  The growth 
rates of strains EcNR2, EcNR2.dnaG.K580A, and EcNR2.dnaG.Q576A were approximately 
equivalent, while nuc5
-
.dnaG.Q576A had a doubling time that was roughly 7% longer than those 
of the other strains. 
 
Generating the T.co-lacZ dsDNA Recombineering Cassette 
 The T.co-lacZ dsDNA recombineering cassette (for inserting tolC in the vicinity of the 
lacZ gene) was generated by PCR, using primers 313000.T.lacZ.coMAGE-f and 
313001.T.lacZ.coMAGE-r (Table 5.4).  PCR was performed using Kapa HiFi HotStart 
ReadyMix, with primer concentrations of 0.5 µM, and T.5.6
14
 used as template (wherein a 
terminator was present downstream of the tolC stop codon).  The PCR (50 µL total) was heat 
activated at 95 °C for 5 min, then cycled 30 times at 98 °C (20 sec), 62 °C (15 sec), and 72 °C 
(45 sec).  The final extension was at 72 °C for 5 min.  The Qiagen PCR purification kit was used 
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to isolate the PCR product (with elution in 30 µL H2O).  Purified PCR product was quantitated 
on a NanoDrop ND1000 spectrophotometer, and analyzed on a 1% agarose gel with ethidium 
bromide staining. 
 
Performing Lambda Red Recombination 
 Lambda Red recombination was performed as described in Chapter 3.  Here, for 
recombination of dsDNA PCR products, 50 ng of PCR product was used.  For experiments in 
which a single oligo was recombined, 1 µM of oligo was used.  For experiments in which sets of 
ten or twenty recombineering oligos were recombined along with a co-selection oligo, 0.5 µM of 
each recombineering oligo and 0.2 µM of the co-selection oligo were used (5.2 µM total for 10-
plex sets and 10.2 µM total for the 20-plex set).  
Electroporated cells were allowed to recover in 3 mL LB Lennox media, in a rotator 
drum at 30 °C.  For MAGE and CoS-MAGE experiments, cultures were recovered to apparent 
saturation (5 or more hours) to minimize polyclonal colonies.  MAGE recovery cultures were 
diluted to ~5× 10
3
 cfu/mL, and 50 µL of this dilution was plated on non-selective LB Lennox 
agar plates.  To compensate for fewer recombinants surviving co-selection, CoS-MAGE 
recovery cultures were diluted only to 10
5
 cfu/mL, and 50 µL of this dilution was plated on 
appropriate selective media for the co-selected resistance marker (LB Lennox with 50 µg/mL 
carbenicillin for bla, 20 µg/mL chloramphenicol for cat, or 0.005% w/v SDS for tolC, with 20 
µg/mL chloramphenicol added to enhance the robustness of selection).  Leading-targeting CoS-
MAGE recovery cultures were diluted to ~5 × 10
6
 cfu/mL before plating. 
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Analyzing Recombination 
GalK activity was assayed by plating recovered recombination cultures onto MacConkey 
agar supplemented with 1% galactose as a carbon source.  Red colonies were scored as galK
+
, 
and white colonies were scored as galK
-
.  LacZ activity was assayed by plating recovery cultures 
onto LB Lennox + X-Gal/IPTG (Fisher ChromoMax).  Blue colonies were scored as lacZ
+
 and 
white colonies were scored as lacZ
-
. 
Kapa 2GFast ReadyMix was used in colony PCRs to screen for the correct insertion of 
the tolC selectable marker that was placed near lacZ.  PCRs had a total volume of 20 µL, with 
0.5 µM of each primer.  These PCRs were carried out with an initial activation step at 95 °C for 
2 min, then cycled 30 times at 95 °C (15 sec), 56 °C (15 sec), and 72 °C (40 sec), followed by a 
final extension at 72 °C (90 sec).  PCR products were analyzed on a 1% agarose gel with 
ethidium bromide, to confirm amplification of the expected band. 
Allele-specific colony PCR (ascPCR) was used to detect the DnaG K580A and Q576A 
mutations, and was performed as described in Chapter 3.  Multiplex allele-specific colony PCR 
(mascPCR)
15
 was used to detect the 1-2 bp mutations generated in the MAGE and CoS-MAGE 
experiments, and was performed as described in Chapter 4.  Annealing temperatures for ascPCR 
and mascPCR were optimized for each pair of reactions, and ranged between 63 °C and 67 °C. 
In CoS-MAGE experiments, all strains were recombined with all tested oligo sets at least 
twice.  All replicates for a given strain and oligo set were combined to generate a complete data 
set.  Polyclonal or ambiguous mascPCR results were discarded from our analysis.  The mean 
number of alleles replaced per clone was determined by scoring each allele as 1 for converted or 
0 for unmodified.  Data for EcNR2 and nuc5
-
 were as collected and described in Chapter 4.  
Given the sample sizes tested in the CoS-MAGE experiments (n > 47), we used parametric 
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statistical analyses, as these analyses are preferable to their non-parametric equivalents for large 
sample sizes.
23
   We used a one-way ANOVA to test for significant variance in the CoS-MAGE 
performance of the strains for a given oligo set.  Subsequently, we used a Student’s t-test to 
make pairwise comparisons, with significance defined as p < 0.05/n, where n is the number of 
pairwise comparisons.  Here, n = 15, as this data set was planned and collected as part of a larger 
set with 6 different strains, although only EcNR2, EcNR2.dnaG.K580A, EcNR2.dnaG.Q576A, 
and nuc5
-
.dnaG.Q576A are presented here (the others, EcNR2.xseA
-
 and nuc5
-
, are discussed in 
Chapter 4).  As such, significance was defined as p < 0.003 for the analyses presented in Figures 
5.3 and 5.5.  Statistical significance in these figures is denoted using a system where * denotes p 
< 0.003, ** denotes p < 0.001, and *** denotes p < 0.0001.   For the experiment comparing the 
CoS-MAGE performance of EcNR2 and EcNR2.dnaG.Q576A with leading-targeting oligos, we 
tested for statistical significance using a single t-test with significance defined as p < 0.05.  
For the experiment in which 10 loci were targeted within lacZ, recombinants were 
identified by blue/white screening.  The frequency of clones with 1 or more alleles replaced (# of 
white colonies / # of total colonies) was determined for every replicate.  For white colonies only, 
a portion of the lacZ gene was amplified with primers lacZ_jackpot_seq-f and lacZ_jackpot_seq-
r, using Kapa HiFi HotStart ReadyMix as described above.  Purified (Qiagen PCR purification 
kit) amplicons were submitted to Genewiz for Sanger sequencing in both directions using 
lacZ_jackpot_seq-f and lacZ_jackpot_seq-r.  Combined, the two sequencing reads interrogated 
all 10 targeted alleles.  Three replicates of recombinations and blue/white analyses were 
performed to ensure consistency, but only one replicate was sequenced (n = 39 for EcNR2 and n 
= 55 for EcNR2.dnaG.Q576A).  The mean number of alleles converted per clone was determined 
as above.  We tested for statistically significant differences in mean allele conversion between 
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the strains using a Student’s t-test with significance defined as p < 0.05.  Statistical significance 
in Figure 5.4C is denoted using a system where *** denotes p < 0.0001. 
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Chapter Six  
 
 
Conclusion: Lambda Red Recombination, 
 Today and Going Forward 
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 The work described in this thesis has substantially advanced our understanding of 
Lambda Red recombination.  In Chapter 2, we proposed a novel mechanism for Lambda Red 
dsDNA recombination in which Lambda Exo degrades the leading-targeting strand to generate a 
full-length ssDNA intermediate.
1
  This intermediate then anneals at the lagging strand of the 
replication fork, where it is incorporated into the newly-synthesized strand as an Okazaki 
Fragment; this final step is analogous to the accepted mechanism for Lambda Red ssDNA 
recombination.
2
  Thus, our mechanism unifies these two models and presents a parsimonious and 
logical explanation of how dsDNA recombination occurs.  Moreover, we supported our model 
with a large body of experimental evidence showing that a full-length ssDNA intermediate is 
much more likely than the intermediate proposed in prior mechanisms for dsDNA 
recombination.
1
 
 In Chapter 3, we further supported this mechanism through our recombineering 
experiments with phosphorothioated dsDNA cassettes.  These results also led us to discover that 
ExoVII degrades dsDNA cassette ends, and that this has a negative impact on recombination 
frequency.  Indeed, the variable dsDNA recombination frequencies of the nuclease knockout 
strains tested in this chapter indicated that endogenous nucleases routinely act on dsDNA 
cassettes, and that this can profoundly impact recombination.
3
  In Chapter 4, we went on to show 
that endogenous nucleases also degrade the ssDNA oligonucleotides used for MAGE and CoS-
MAGE.  By extension, this established that the concentration of oligonucleotides within the cell 
– and hence, oligo uptake – is a limiting factor for multiplex oligonucleotide recombination.  We 
also showed that oligonucleotide phosphorothioation has countervailing effects on recombination 
frequency.  While phosphorothioation can increase recombination frequency by protecting oligos 
from nuclease degradation, it can also hinder recombination, presumably by reducing the 
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strength of the annealing interaction between the oligo and the lagging strand of the replication 
fork.  The net effect of oligo phosphorothioation depends on the nuclease background of the 
strain used for recombineering.
3
  Finally, in Chapter 5, we showed that the amount of accessible 
ssDNA on the lagging strand limits multiplex oligonucleotide recombination frequency.  These 
results thereby established that intracellular oligo concentration and accessible lagging strand 
ssDNA are separate factors that both significantly influence MAGE and CoS-MAGE frequency.
4
 
 As a result of this advancement in our understanding of Lambda Red recombination, we 
were able to markedly improve the performance of both dsDNA and ssDNA recombineering.  
For dsDNA recombineering, we showed that recombination frequency could significantly be 
enhanced in two different ways – by protecting the 5′ end of the lagging-targeting strand with 
phosphorothioate (PT) bonds, and by inactivating the exonuclease ExoVII.
3
   By combining 
these two strategies, we were able to achieve a roughly six-fold improvement of gene insertion 
frequency.
3
  Moreover, removing ExoVII enabled mutations encoded near the ends of a dsDNA 
cassette to more reliably be conferred. 
In addition to its impact on dsDNA recombination, we found that ExoVII removal also 
improved the inheritance of mutations encoded near the 3′ ends of ssDNA oligonucleotides, and 
slightly increased CoS-MAGE frequencies.  Building upon these results, we discovered that 
CoS-MAGE performance could further be enhanced through the deletion of four additional 
nucleases (RecJ, ExoI, ExoX, and Lambda Exo).  In comparison with our standard 
recombineering strain EcNR2, the resulting “nuc5
-
” strain yielded 46% more alleles converted 
per average clone, 200% more clones with five or more allele conversions, and 35% fewer 
clones without any allele conversions in a cycle of 10-plex CoS-MAGE.
3
  Additionally, we 
found that CoS-MAGE allele conversion frequency could be improved by attenuating the 
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interaction between DnaG primase and replisome-associated DnaB helicase, which increases the 
amount of accessible ssDNA on the lagging strand.  The more attenuated of the two primase 
variants tested in our study displayed 62% more alleles converted per average clone, 239% more 
clones with five or more allele conversions, and 38% fewer clones without any allele 
conversions.
4
  Moreover, combining primase modification and nuclease removal had additive 
beneficial effects on CoS-MAGE performance.  In comparison with EcNR2, the resulting “nuc5
-
.dnaG.Q576A” strain demonstrated 111% more alleles converted per average clone, 527% more 
clones with five or more allele conversions, and 71% fewer clones without any allele 
conversions in a cycle of 10-plex CoS-MAGE.
4
  This strain also displayed improved 
performance for larger CoS-MAGE oligo sets; in a single cycle of 20-plex CoS-MAGE, nuc5
-
.dnaG.Q576A yielded 4.50 non-selectable alleles converted per average clone.
4
  This represents a 
nearly three-fold improvement over EcNR2, and significantly augments the power of CoS-
MAGE for diversity generation and genome engineering. 
These advancements represent a significant step forward in the development of Lambda 
Red technology; however, further work will be necessary in order to maximize the utility of 
recombineering.  While we have managed to increase Lambda Red dsDNA gene insertion 
frequency approximately six-fold,
3
 the resulting recombination frequency of ~0.3% is still such 
that hundreds or thousands of colonies would need to be screened by PCR in order to ensure the 
identification of a recombinant colony.  As a result, selectable markers are still necessary in 
order to identify recombinants in a practical fashion, complicating pathway transfer and 
preventing the multiplex and/or combinatorial insertion of exogenous genes.  Similarly, although 
we significantly increased both the average and top number of alleles converted in a given CoS-
MAGE cycle, the power of the technique is still limited by the number of mutations that it can 
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generate.  While our work will certainly facilitate novel CoS-MAGE applications, genome 
engineering efforts involving several thousand or more genetic changes probably remain beyond 
the reach of current recombineering capabilities.  Thus, the development of Lambda Red 
technology must continue.  Here, I briefly discuss what I believe to be the most fruitful avenue 
for the future improvement of dsDNA and ssDNA recombineering, respectively. 
 For several reasons, I believe that the performance of Lambda Red dsDNA-mediated 
gene insertion could significantly be improved through directed evolution.  For one, the 
recombination of antibiotic resistance genes provides for an extremely straightforward selection 
for gene insertion.  Successive rounds of recombination and selection should enrich for highly 
recombinogenic cells, and insertion cassettes can be designed so that they replace the cassette(s) 
used in prior rounds,
5
 thereby allowing those selectable markers to be reused.  It should therefore 
be fairly simple to carry out a directed evolution project using such a strategy.  Another reason 
for optimism regarding this approach is that a previous attempt at a similar experiment yielded 
positive results.  In this work,
6
 the authors mutagenized the Lambda Red genes, then performed 
two rounds of selection for the ability to recombine a dsDNA antibiotic resistance insertion 
cassette.  Despite performing only one round of diversification and two rounds of selection, the 
authors were nevertheless able to isolate mutants of Exo and Beta that together provided for a 
roughly four-fold increase in recombination frequency.
6
  Additional rounds of diversification and 
selection are likely to yield even more impressive results.  Finally, there are several promising 
targets for diversification.  First, the Lambda Red genes could themselves be altered (as in the 
above-described study), to isolate variants with improved recombineering properties.  
Additionally, the strong impact of nuclease activity on dsDNA recombination frequency
3
 
suggests that the inactivation, downregulation, and/or upregulation of endogenous nucleases 
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could significantly improve recombineering performance.  For either of these sets of targets, 
diversification could easily be facilitated by MAGE.  Lastly, genome-wide diversification could 
be accomplished through the use of untargeted mutagenesis (e.g., via mutS removal, chemical 
mutagens, and/or UV radiation).  Any recombination-enhanced variants arising from genome-
wide modification could then be characterized by next-generation sequencing.  Such an unbiased 
approach could reveal host factors that impact recombination, for example by interacting with 
Lambda Red proteins, altering replisome dynamics, or affecting DNA uptake.  Thus, directed 
evolution is likely to be a versatile and powerful platform for further improving Red-mediated 
dsDNA gene insertion; efforts to utilize this strategy are currently underway in our lab. 
 Directed evolution may also be useful for improving ssDNA recombineering; for 
example, cells could be selected for the ability to carry out the simultaneous oligo-mediated 
repair of several broken antibiotic resistance genes.  However, I believe that the most promising 
near-term avenue for improving ssDNA recombineering is through making CoS-MAGE 
amenable to cycling.  As discussed previously, CoS-MAGE involves the use of a co-selection 
oligonucleotide which repairs a chromosomally-located defective selectable marker.
7
  After 
selection for the repaired marker, that marker (or a newly placed one) must then be inactivated 
before the next round of CoS-MAGE can proceed.  This complication prevents CoS-MAGE 
from easily being applied in iterative cycles. 
The use of bidirectionally selectable markers presents a possible solution to this problem.  
Such markers could both be broken and repaired with concomitant selection, thereby facilitating 
the seamless cycling of CoS-MAGE.  Our lab typically uses tolC as a bidirectionally selectable 
marker, as alternative markers such as galK and thyA require selection on minimal media, which 
is time-consuming and inconvenient.
8
  SDS can be used to select for functional tolC (positive 
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selection), and colicin E1, a toxin that depends on tolC for cellular entry, can be used to select 
for non-functional tolC (negative selection).
8
  However, we have found that tolC
+
 cells can 
frequently survive negative selection, thereby limiting the usefulness of tolC as a bidirectionally 
selectable marker.  To determine the origin of this problem, members of our lab sequenced the 
full genomes of 96 tolC
+
 cells that survived colicin selection.  Subsequent analysis revealed that 
nearly all of these cells had spontaneous inactivating mutations in the tolQRA operon; it is likely 
that defective tolQ, tolR, or tolA proteins prevent colicin from entering the cell, even when 
functional tolC is present.
9
  We subsequently found that duplicating the tolQRA operon results in 
substantially fewer tolC
+
 escapees evading negative selection.  By duplicating this operon, using 
vancomycin along with colicin for negative selection, and making other minor adjustments to the 
selection protocol, we succeeded in decreasing the dysfunction rate of tolC negative selection by 
over 2000-fold.  This improvement enables the use of tolC for iterative CoS-MAGE.  We are 
currently in the process of fine-tuning this technique and demonstrating its utility in a proof of 
concept experiment involving the recoding of AGG and AGA codons.  When combined with the 
improvements described in Chapters 4 and 5, this iterative CoS-MAGE technology should 
facilitate a breakthrough in MAGE performance, enabling genome engineering of a heretofore 
unprecedented scope. 
 While future work will likely increase the power of recombineering, significant efforts 
are now achievable with current technology – due in part to the developments described in this 
thesis.  To illustrate, I will briefly discuss a recent project in which we utilized Lambda Red 
recombineering to assess the feasibility of radically altering the genetic code of E. coli – a 
longstanding goal of the Church lab.  Such a recoded organism would be immune to viruses 
(given that viral proteins would be mistranslated by recoded host cells), and unable to exchange 
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functional genetic material with the environment.  Furthermore, codon reassignment would allow 
for the creation of organisms with novel chemical functionalities, through the dedicated 
incorporation of one or more non-standard amino acids (NSAAs).  As discussed in Chapter 1, we 
have recently completed the creation of a strain with all instances of the UAG stop codon 
changed to UAA.  This enabled the subsequent deletion of Release Factor 1 (RF1), which would 
otherwise be necessary for terminating genes ending in a UAG stop codon.  Removing RF1 
allowed the UAG codon to serve as a dedicated channel for the site-specific incorporation of 
NSAAs.  Moreover, because RF1 was no longer present to terminate viral genes ending in UAG, 
this strain also demonstrated slight phage resistance.
10
  The UAG-reassigned strain therefore 
serves as a powerful proof of concept for the utility of recoding.  However, this work also 
confirmed that several additional codons will likely need to be reassigned in order to achieve 
complete virus resistance and genetic isolation, and to enable the dedicated incorporation of 
multiple NSAAs.  It was therefore imperative to assess the feasibility of more significantly 
altering the E. coli genetic code, and to test whether several additional codons could possibly be 
removed genome-wide. 
 To do this, we attempted to remove all instances of 13 rare codons (hereafter referred to 
as “forbidden” codons) from a panel of 42 essential genes, chosen to serve as a stringent test bed 
for codon essentiality.  This panel included prfB, which relies on a programmed frameshift for 
proper translation,
11
 as well as all 41 essential protein-coding ribosomal genes,
12
 which are both 
highly expressed and tightly regulated.  We first assessed the feasibility of radically recoding 
these genes: eliminating all instances of the 13 forbidden codons and shuffling all other possible 
codons to synonymous alternatives, changing all start codons to AUG, separating overlapping 
genes, removing frameshifts, and eliminating several restriction sites.
13
  Thus, our resulting 
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recoded gene designs had only 65.4% average nucleotide identity with the corresponding wild 
type genes, despite amino acid sequences being unchanged.
13
 
 We utilized Lambda Red dsDNA recombination to attempt to replace the 42 targeted 
wild type genes with their respective recoded genes.  To do so, we synthesized the recoded genes 
from chip-generated oligonucleotides,
14
 and attached kanR genes to their C-termini via 
isothermal assembly.
15
  We then PCR-amplified these constructs with primers containing 
homology regions flanking the corresponding wild type genes, and separately recombined the 
resulting cassettes into EcNR2.  Kanamycin-resistant recombinants were assayed by PCR and 
Sanger sequencing in order to determine whether the targeted gene had correctly and completely 
been replaced.  Somewhat surprisingly, we found that 26/42 tested genes could successfully be 
converted to their radically recoded analogs, with varying effects on strain fitness.
13
  Encouraged 
by this, we next set out to answer the question of whether all instances of the 13 forbidden 
codons could be removed from the panel of 42 genes.  Through recombination with the radically 
recoded dsDNA cassettes, we successfully removed 294 of the 405 targeted instances of 
forbidden codons; we next utilized CoS-MAGE to try to remove the remaining forbidden codons 
in small groups across several strains.  We performed these CoS-MAGE recombinations in an 
EcNR2.xseA
-
 background, taking advantage of the fact that the removal of ExoVII (xseA) 
provides for greater inheritance of mutations encoded near the 3′ end of an oligo, as discussed in 
Chapter 4.
3
  This allowed a greater number of codon changes to be conferred by a single 
oligonucleotide.  Ultimately, we were able to remove all 111 remaining forbidden codons using 
this CoS-MAGE strategy, although one forbidden codon in rplQ could not be converted to the 
first attempted synonymous replacement codon.  In subsequent attempts, this codon was 
successfully converted to a number of other synonymous and non-synonymous codons.
13
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 Taken together, these results indicate that the E. coli genome is surprisingly malleable, 
and that the genome-wide removal of the 13 forbidden codons appears feasible.  However, given 
the 16 failed recoded gene replacements and the case of the codon in rplQ, it is clear that many 
recoded genome designs will be non-viable for reasons that may not be apparent a priori.  This 
reinforces the importance of using a genome engineering strategy that rapidly prototypes and 
tests many designs in small pieces, such as our approaches based on MAGE and dsDNA 
recombineering.  As a result, it is highly likely that Lambda Red recombination will be a 
cornerstone technique for future efforts in genome engineering.  The advancements described in 
this thesis have significantly increased our understanding of Lambda Red recombination, and 
substantially broadened its power.  Thus, it is my hope that this work will enable new and 
exciting applications in synthetic biology and genome engineering. 
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Appendix 1: Strains Used in this Thesis 
 
Strain Name Genotype/Description Chapter(s) 
used in 
 
 
EcNR2
 
 
Escherichia coli MG1655 ∆mutS::cat ∆(ybhB-
bioAB)::[λcI857 ∆(cro-ea59)::tetR-bla] 
 
 
2-5
* 
SIMD90 Escherichia coli W3110 ∆mutS::cat lac∆U169 
galKTYR145UAG[λcI857 ∆(cro-bioA), (int-cIII)< >bet] 
 
2
§
 
EcNR2.endA
-
 N/A (see left) 
 
3 
nuc4
-
 EcNR2.xonA
-
,recJ
-
,xseA
-
,exoX
-
 3 
 
EcNR2. recJ
-
,xseA
-
,exoX
-
 N/A (see left) 
 
3 
EcNR2. xonA
-
,xseA
-
,exoX
-
 N/A (see left) 
 
3 
EcNR2. xonA
-
,recJ
-
,exoX
-
 N/A (see left) 
 
3 
EcNR2. xonA
-
,recJ
-
,xseA
-
 N/A (see left) 
 
3 
EcNR2.xseA
-
 N/A (see left) 
 
3, 4
*
 
nuc5
-
 
 
EcNR2.xonA
-
,recJ
-
,xseA
-
,exoX
-
,redα
-
 4, 5
*
 
EcNR2.dnaG.K580A N/A (see left) 
 
5
*
 
EcNR2.dnaG.Q576A N/A (see left) 
 
5
*
 
nuc5
-
.dnaG.Q576A 
 
N/A (see left) 
 
5
*
 
EcNR2.DT EcNR2 ∆tolC 
 
5
¶
 
EcNR2.T.co-lacZ 
 
EcNR2.DT with tolC reinserted at nucleotide 
position 313000, and subsequently inactivated 
 
5
¶
 
 
*
 Versions of these strains were also made with cat, bla, and tolC inactivated (separately). 
 
§
 Strain SIMD90 was a generous gift from Dr. Donald Court, and is described in the following 
paper: Datta, S., Costantino, N., Zhou, X. & Court, D.L. Identification and analysis of 
recombineering functions from Gram-negative and Gram-positive bacteria and their phages. 
Proc Natl Acad Sci U S A 105, 1626-31 (2008). 
 
¶
 Versions of these strains were also made with the DnaG Q576A mutation. 
